Pathology In Depth

Library › Endocrine and metabolic chemistry: diabetes, lipids, electrolytes and acid-base, cardiac markers, bone and mineral, and endocrine testing

Endocrine and metabolic chemistry: diabetes, lipids, electrolytes and acid-base, cardiac markers, bone and mineral, and endocrine testing

Last reviewed 2026-11-17 by a board-certified pathologist. 362 references.

Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup

Definition. Diabetes is diagnosed from venous plasma glucose or hemoglobin A1c (HbA1c), and glycemia is monitored with HbA1c, glucose meters, continuous glucose monitoring (CGM), fructosamine and glycated albumin (Sacks 2023; ADA 2026 section 6). The ADA 2026 Summary of Revisions lists no change to the diagnostic thresholds; the 2026 changes in section 2 concern type 1 diabetes staging, drug-associated hyperglycemia, cystic fibrosis-related diabetes and early-pregnancy screening (ADA 2026 Summary of Revisions). The 2024 ADA/EASD/JBDS/AACE/DTS consensus report replaced the 2009 ADA statement on diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state (HHS) (Umpierrez 2024).

Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (glycolysis, fluoride and citrate tubes, glucose meters and point-of-care HbA1c) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (hemoglobin variants, HbF quantitation and HPLC patterns) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (immunoassay interference, osmometry and the osmolal gap formula) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (CLIA proficiency testing limits for HbA1c and glucose) Related page: Liver, Kidney and Gastrointestinal Function Tests (albuminuria categories A1–A3 and eGFR) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (methods for GAD65, IA-2, ZnT8 and insulin autoantibodies) Related page: Water, Electrolytes, Osmolality and Acid-Base Disorders (anion gap, mixed acid-base disorders and corrected sodium) Related page: Lipids, Lipoproteins and Cardiovascular Risk Markers: LDL-C Equations, ApoB and Lp(a) (diabetic dyslipidemia) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (glycogen storage disease, galactosemia, hereditary fructose intolerance and fatty acid oxidation disorders) Related page: Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring (toxic alcohols in the differential of ketoacidosis)

Glucose measurement: enzymes, sample type and meters

  • Enzymatic chemistry. In the glucose oxidase-peroxidase (Trinder) reaction, hydrogen peroxide generated by glucose oxidase is coupled to a chromogen. Ascorbic acid interferes negatively by consuming peroxide (Martinello 2006). Hexokinase or glucose oxidase is used in virtually all US laboratories, and fewer than 1% use glucose dehydrogenase. Mean serum glucose by the two main methods is essentially the same, but 40.6% of peer groups showed significant bias of up to 13% against a reference measurement procedure (Sacks 2023).
  • Plasma and whole blood. Glucose molality is equal in plasma and red cell water, but plasma glucose concentration is higher because plasma contains more water. The IFCC recommends reporting glucose as the plasma concentration in mmol/L irrespective of sample type, with a constant factor of 1.11 to convert whole-blood to plasma-equivalent values (D'Orazio 2005).
  • Glycolysis. Delayed processing lowers glucose by up to 6 mg/dL (0.3 mmol/L) per hour (Thornton 2015). Plasma is separated immediately or the sample is kept on ice (ADA 2026 section 2). Glucose is not standardized across methods, and its within-person variability is high (ADA 2026 section 2).
  • Meters. Meter interferences, including maltose with glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) strips, are tabulated in Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry. A review of 82 adverse events with GDH-PQQ strips found 16 deaths, and the agents most often involved were icodextrin peritoneal dialysate and maltose-containing intravenous immune globulin (Frias 2010). Meter accuracy is about ±10–15 mg/dL (0.6–0.8 mmol/L) in the hypoglycemic range, so a low meter value is confirmed with a laboratory method (Thornton 2015).
  • Oral glucose tolerance test. At least 150 g of carbohydrate per day is ingested for 3 days before an OGTT, because antecedent carbohydrate restriction can falsely raise postload glucose (ADA 2026 section 2).

Diagnosis and classification of diabetes (ADA 2026)

Criteria for diabetes and prediabetes in nonpregnant individuals (ADA Standards of Care 2026, Tables 2.1 and 2.2; unchanged from 2025).

Test Diabetes Prediabetes Source
HbA1c ≥6.5% (≥48 mmol/mol), NGSP-certified method standardized to the DCCT assay 5.7–6.4% (39–47 mmol/mol) ADA 2026 section 2
Fasting plasma glucose (no caloric intake for ≥8 h) ≥126 mg/dL (≥7.0 mmol/L) 100–125 mg/dL (5.6–6.9 mmol/L), impaired fasting glucose ADA 2026 section 2
2-h plasma glucose, 75-g OGTT ≥200 mg/dL (≥11.1 mmol/L) 140–199 mg/dL (7.8–11.0 mmol/L), impaired glucose tolerance ADA 2026 section 2
Random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic symptoms or hyperglycemic crisis Not applicable ADA 2026 section 2
  • Confirmation. Without unequivocal hyperglycemia, diagnosis requires two abnormal results, from the same sample or from two samples. When two tests are discordant, the test above its cut point is repeated, and the diagnosis rests on the confirmatory result (ADA 2026 section 2).
  • Impaired fasting glucose limit. WHO and several organizations set the lower limit of impaired fasting glucose at 110 mg/dL (6.1 mmol/L). ADA used this limit in 1997 and adopted 100 mg/dL (5.6 mmol/L) in 2003 (ADA 2026 section 2).
  • Test characteristics. The 2-h OGTT diagnoses more people with prediabetes and diabetes than fasting glucose or HbA1c. OGTT is the preferred test for cystic fibrosis-related diabetes and posttransplantation diabetes. CGM is not used for screening or diagnosis (ADA 2026 section 2).
  • When HbA1c is not used for diagnosis. Plasma glucose criteria are used with some hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV and altered red cell turnover (ADA 2026 Recommendation 2.4). The X-linked G6PD G202A variant, carried by 11% of Black individuals in the US, lowers HbA1c by about 0.8% in homozygous males and 0.7% in homozygous females (ADA 2026 section 2).
  • Screening ages. Testing is considered at any age in adults with overweight or obesity and one or more risk factors. All other adults begin screening at age 35 years, with repeat testing at a minimum of 3-year intervals after normal results and yearly with prediabetes. Children and adolescents with overweight or obesity and a risk factor are screened after puberty or after age 10 years, whichever is earlier (ADA 2026 Recommendations 2.12a–2.12c and 2.15).
  • Medication- and condition-specific screening. People starting second-generation antipsychotics are screened at baseline, at 12–16 weeks and yearly. People with HIV have fasting glucose tested before and 3–6 months after starting or switching antiretroviral therapy. Screening follows acute pancreatitis at 3–6 months and yearly thereafter (ADA 2026 Recommendations 2.16b, 2.17 and 2.23).

Classification of diabetes and monogenic forms

  • Categories. Diabetes is classified as type 1 (autoimmune β-cell destruction, including latent autoimmune diabetes in adults), type 2 (nonautoimmune progressive loss of β-cell insulin secretion), specific types due to other causes (monogenic syndromes, exocrine pancreatic disease, drug- or chemical-induced) and gestational diabetes mellitus (GDM) (ADA 2026 section 2).
  • Features favoring type 1 diabetes in adults. Age <35 years at diagnosis, BMI <25 kg/m², unintentional weight loss, ketoacidosis and glucose >360 mg/dL (>20 mmol/L) at presentation (ADA 2026 section 2).
  • Immune checkpoint inhibitor diabetes. Fulminant autoimmune diabetes with DKA and low or undetectable C-peptide occurs in 0.6–1.4% of treated individuals, and fewer than half have islet autoantibodies (ADA 2026 section 2).
  • MODY. Maturity-onset diabetes of the young is autosomal dominant, involves at least 14 genes and is characterized by impaired insulin secretion with minimal defects in insulin action. Genetic testing is recommended for diabetes in the first 6 months of life and for atypical diabetes with a family history in successive generations (ADA 2026 Recommendations 2.29a and 2.29b). Monogenic diabetes is suggested by HbA1c <7.5% (<58 mmol/mol) at diagnosis, one affected parent and a prediction model probability >5% (ADA 2026 Figure 2.1).

Common MODY subtypes (ADA 2026, Table 2.7).

Subtype Laboratory and clinical pattern Treatment implication
GCK-MODY (MODY2) Stable, nonprogressive fasting hyperglycemia; small 2-h OGTT rise (<54 mg/dL [<3 mmol/L]) Usually no treatment outside pregnancy
HNF1A-MODY (MODY3) Progressive secretory defect; lowered renal threshold for glucosuria; large 2-h OGTT rise (>90 mg/dL [>5 mmol/L]); low hs-CRP Sulfonylurea-sensitive
HNF4A-MODY (MODY1) Progressive secretory defect; macrosomia and transient neonatal hypoglycemia Sulfonylurea-sensitive

ADA 2026 changes to diabetes diagnosis and screening, with the previous rules

  • Recommendation 2.8 (changed). In 2026, Recommendation 2.8 was split. Recommendation 2.8a calls for prompt evaluation for stage 3 type 1 diabetes, with HbA1c, urinalysis or plasma glucose, in anyone with one or more islet autoantibodies. Recommendation 2.8b keeps the previous rule that people with multiple confirmed autoantibodies are referred to a specialized center (ADA 2026 Summary of Revisions).
  • Recommendation 2.9 (new). A single confirmed IA-2 autoantibody is monitored like multiple autoantibodies, because IA-2 positivity is an independent risk factor for progression. Other single confirmed autoantibodies are retested every 6 months to 3 years depending on age (ADA 2026 section 2).
  • Recommendations 2.18–2.22 (new). Postprandial or random glucose is monitored with recurrent or long-term glucocorticoids. Glucose is tested before and during treatment with immune checkpoint inhibitors and mTOR inhibitors. With PI3Kα inhibitors, fasting or random glucose and HbA1c are tested before treatment, random glucose weekly for 2 weeks and then every 4 weeks (ADA 2026 section 2).
  • Recommendations 2.24a and 2.24b (changed). Annual screening for cystic fibrosis-related diabetes begins by age 10 years, preferably with an OGTT. When an OGTT is not feasible, HbA1c 5.5–6.4% (37–47 mmol/mol) leads to an OGTT within 3 months, and HbA1c ≥6.5% is consistent with cystic fibrosis-related diabetes (ADA 2026 section 2).

Type 1 diabetes staging, islet autoantibodies and C-peptide

Staging of type 1 diabetes (ADA 2026, Table 2.4, adapted from the JDRF/Endocrine Society/ADA statement).

Stage Autoimmunity Glycemia Symptoms Source
1 Multiple islet autoantibodies Normal; no impaired fasting glucose or impaired glucose tolerance; normal HbA1c Presymptomatic ADA 2026 section 2; Insel 2015
2 Islet autoantibodies, usually multiple Dysglycemia: fasting glucose 100–125 mg/dL, 2-h glucose 140–199 mg/dL, HbA1c 5.7–6.4% or a ≥10% rise in HbA1c Presymptomatic ADA 2026 section 2
3 Autoantibodies may become absent Diabetes by standard criteria Symptomatic ADA 2026 section 2
  • Autoantibody screening. Screening for presymptomatic type 1 diabetes uses autoantibodies to insulin, glutamic acid decarboxylase (GAD), IA-2 or zinc transporter 8 (ZnT8), offered to people with a family history or known genetic risk (ADA 2026 Recommendations 2.6 and 2.7). About 90% of people who develop type 1 diabetes have no affected relative (ADA 2026 section 2).
  • Confirmation. Up to 50% of children with a single autoantibody revert to negative. A first positive test is confirmed within 3 months, preferably in a laboratory that meets Islet Autoantibody Standardization Program performance standards (ADA 2026 section 2).
  • Progression. Of 585 children with two or more autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (ADA 2026 section 2).
  • Testing order in adults. GAD antibody is measured first, followed by IA-2 or ZnT8 if negative. Insulin autoantibodies are informative only before insulin treatment, and 5–10% of people with type 1 diabetes lack autoantibodies (ADA 2026 Figure 2.1).
  • C-peptide thresholds. C-peptide is measured only in insulin-treated people, and a random sample with concurrent glucose within 5 h of eating can replace a stimulation test. A value ≥600 pmol/L (≥1.8 ng/mL) is not consistent with type 1 diabetes; 200–600 pmol/L (0.6–1.8 ng/mL) is usually consistent with type 1 diabetes or MODY; <80 pmol/L (<0.24 ng/mL) indicates severe insulin deficiency. A value <600 pmol/L with glucose <70 mg/dL (<4 mmol/L) is repeated, and C-peptide is not tested within 2 weeks of a hyperglycemic emergency (ADA 2026 Figure 2.1).
  • C-peptide specimen stability and urine C-peptide. C-peptide in EDTA whole blood is stable at room temperature for at least 24 h on modern immunoassay analyzers. A postmeal urine C-peptide:creatinine ratio <0.2 nmol/mmol was 96% sensitive and 98% specific for type 1 diabetes of more than 5 years' duration against type 2 diabetes or HNF1A/HNF4A MODY (Jones 2013).

Gestational diabetes testing

  • Early pregnancy. Before 15 weeks of gestation, people with risk factors are tested for undiagnosed diabetes with standard nonpregnancy criteria (ADA 2026 Recommendation 2.31a). Early abnormal glucose metabolism, defined as HbA1c 5.9–6.4% (41–47 mmol/mol) or fasting glucose 110–125 mg/dL (6.1–6.9 mmol/L), identifies people at higher risk of adverse outcomes and later GDM (ADA 2026 Recommendation 2.31b).
  • Early-pregnancy limits of GDM criteria. The IADPSG 75-g criteria and the two-step criteria were not derived from data in the first half of pregnancy and are not used for early screening (ADA 2026 section 2).
  • Timing. People without diabetes or early abnormal glucose metabolism are screened for GDM at 24–28 weeks. People with GDM are tested at 4–12 weeks postpartum with a 75-g OGTT and nonpregnancy criteria, and every 1–3 years for life (ADA 2026 Recommendations 2.32–2.34).
  • ACOG. The 2024 ACOG Clinical Practice Update on screening for gestational and pregestational diabetes updates Practice Bulletins 190 and 201 (ACOG 2024).
  • One-step against two-step. A 2021 USPSTF systematic review found GDM in 11.5% with one-step and 4.9% with two-step screening, without improved health outcomes. HbA1c at 24–28 weeks does not perform as well as the 50-g glucose load test as a GDM screen (ADA 2026 section 2).
  • Evidence base. In HAPO, 25,505 pregnant participants underwent a 75-g OGTT at 24–32 weeks (HAPO 2008). The IADPSG one-step thresholds are the mean values at which the odds of adverse outcomes reached 1.75 times the estimated odds, and one-step testing raised GDM incidence from 5–6% to 15–20% (ADA 2026 section 2).
  • Origin of the 50-g threshold. Carpenter and Coustan proposed lowering the 50-g screen threshold from 143 to 135 mg/dL of plasma glucose, below which the probability of GDM was <1% (Carpenter 1982).

GDM one-step and two-step strategies at 24–28 weeks (ADA Standards of Care 2026, Table 2.8).

Strategy Load and timing Diagnostic thresholds (plasma glucose) Values required
One-step (IADPSG) 75-g OGTT after an overnight fast of ≥8 h Fasting 92 mg/dL (5.1 mmol/L); 1 h 180 mg/dL (10.0 mmol/L); 2 h 153 mg/dL (8.5 mmol/L) Any one value met or exceeded
Two-step, step 1 50-g nonfasting load, 1-h glucose ≥130, 135 or 140 mg/dL (7.2, 7.5 or 7.8 mmol/L) leads to step 2 Screen
Two-step, step 2 (Carpenter-Coustan) 100-g OGTT, fasting Fasting 95 mg/dL (5.3 mmol/L); 1 h 180 mg/dL (10.0 mmol/L); 2 h 155 mg/dL (8.6 mmol/L); 3 h 140 mg/dL (7.8 mmol/L) At least two values met or exceeded (ACOG accepts one)

Hemoglobin A1c: glycation, methods and standardization

  • Biology. HbA1c reflects glucose bound to hemoglobin over the erythrocyte life span of about 120 days. It is a weighted average in which recent glucose exposure counts more, so meaningful changes appear in less than 120 days (ADA 2026 section 2).
  • Standardization. The IFCC reference method is the basis for international standardization, and its relationship with each national designated comparison method is linear. The master equation is NGSP HbA1c (%) = 0.915 × IFCC HbA1c (%) + 2.15 (Hoelzel 2004). IFCC results expressed in percent are 1.5–2% HbA1c lower than NGSP values across the range (NGSP IFCC page). The US reports NGSP %HbA1c, and ADA and AACC recommend reporting estimated average glucose (eAG) with it (NGSP IFCC page).
  • Certification and point-of-care use. HbA1c is measured by an NGSP-certified method traceable to the DCCT reference assay. Point-of-care HbA1c is used for diagnosis only with FDA-approved devices in CLIA-certified laboratories performing tests of moderate complexity or higher (ADA 2026 Recommendations 2.2a and 2.2b).
  • Method classes. HbA1c methods are grouped as immunoassay, ion-exchange HPLC, boronate affinity and others, and each variant's effect is examined method by method (Little 2009). NGSP lists the interference status of the 20 most used methods, which include enzymatic, HPLC, capillary electrophoresis and point-of-care systems (NGSP interference table).
  • Advantages and diagnostic sensitivity of HbA1c. HbA1c needs no fasting, is stable before analysis, has low within-person variability and is well standardized. Its sensitivity at the diagnostic cut point is lower than that of the 2-h OGTT glucose (ADA 2026 section 2).

HbA1c conversions and estimated average glucose (ADAG study and NGSP).

Quantity Equation Source
IFCC HbA1c from NGSP IFCC (mmol/mol) = 10.93 × NGSP (%) − 23.50 NGSP IFCC page
NGSP HbA1c from IFCC NGSP (%) = 0.09148 × IFCC (mmol/mol) + 2.152 NGSP IFCC page
eAG, conventional units eAG (mg/dL) = 28.7 × HbA1c (%) − 46.7; R² = 0.84 Nathan 2008
eAG, SI units eAG (mmol/L) = 1.59 × HbA1c (%) − 2.59 Nathan 2008

Selected HbA1c equivalents (ADA 2026 Table 6.1; NGSP).

HbA1c (%) HbA1c (mmol/mol) eAG mg/dL (95% CI) eAG mmol/L
5 31 97 (76–120) 5.4
6 42 126 (100–152) 7.0
7 53 154 (123–185) 8.6
8 64 183 (147–217) 10.2
9 75 212 (170–249) 11.8
10 86 240 (193–282) 13.4
  • ADAG study. The ADAG study related HbA1c to about 2,700 glucose values per participant over 3 months in 507 adults with type 1, type 2 or no diabetes (Nathan 2008; ADA 2026 section 6).

Hemoglobin variants, HbF and carbamylated hemoglobin

  • Interference criterion. NGSP classifies interference as clinically significant when the bias exceeds ±6% at HbA1c 6% and/or 9% (NGSP interference table).
  • Common variants. HbS, HbE, HbC and HbD are the most common variants, each a single β-chain substitution, and each interferes with some methods (Little 2009). Without method-specific data, immunoassays are assumed free of HbE and HbD interference, because these substitutions are distant from the β-chain N-terminus (NGSP interference table). An assay free of variant interference is used in sickle cell trait (ADA 2026 section 2).
  • HbF. Without method-specific data, immunoassay, boronate affinity and enzymatic methods are assumed to show interference from elevated HbF (NGSP interference table). Compared with the IFCC reference method, HbF above 20% lowered HbA1c on three of five common methods, including a boronate affinity method (Rohlfing 2008). Methods without HbF interference in the NGSP table carry upper HbF limits from <9.2% to <32.2% (NGSP interference table).
  • Carbamylated hemoglobin. Carbamylated hemoglobin in renal failure is a chemically modified derivative listed among HbA1c interferences (NGSP factors page).
  • Homozygous and compound states. HbA1c in HbSS, HbCC and HbSC is interpreted with caution because of anemia, increased red cell turnover and transfusion. Glycated serum protein or glycated albumin is considered in these patients (NGSP factors page).

Red cell turnover and other nonanalytic effects on HbA1c

Conditions that alter HbA1c independent of assay (ADA 2026; NGSP; English 2015; Radin 2014; Ng 2010; Sacks 2023).

Condition Direction of HbA1c Source
Hemolysis, recovery from acute blood loss, any shortened red cell survival Falsely low with all methods NGSP factors page
Chronic blood loss and splenomegaly Falsely low (increased red cell turnover) Radin 2014
Asplenia Falsely high (longer erythrocyte life span) Radin 2014
Iron deficiency, with or without anemia Falsely high, without a rise in glucose; iron replacement lowers HbA1c English 2015; NGSP factors page
Anemia not due to iron deficiency Possibly low (limited data) English 2015
Late pregnancy HbA1c rises from iron deficiency; glycated albumin does not NGSP factors page
Normal pregnancy Falls with increased red cell turnover Sacks 2023
Dialysis and kidney failure HbA1c underestimates glycemia; glycated albumin is the more reliable index NGSP factors page
Recent red cell transfusion Conflicting reports of falsely high (storage-medium glucose) and falsely low (dilution with donor cells) results; uninterpretable after recent transfusion Radin 2014
Intravenous iron or erythropoiesis-stimulating agents in CKD Falls (7.40% to 6.96% with iron; 7.31% to 6.63% with ESA) with no change in mean glucose Ng 2010
HIV HbA1c may underestimate glycemia; plasma glucose criteria are preferred ADA 2026 section 2
Cirrhosis Listed as a factor that alters HbA1c ADA 2026 Table 2.3
Severe hypertriglyceridemia or hyperbilirubinemia Assay-dependent interference ADA 2026 Table 2.3
  • Population differences. Black individuals have HbA1c values about 0.3% higher than non-Hispanic White or Hispanic people. The association of HbA1c with complications appears similar in both groups (ADA 2026 section 2).
  • Discordance. Consistent discordance between glucose and HbA1c prompts evaluation for assay interference, and fructosamine or glycated albumin is considered for monitoring (ADA 2026 Recommendation 2.3).

Fructosamine, glycated albumin, 1,5-anhydroglucitol and CGM-derived metrics

  • Fructosamine and glycated albumin. Fructosamine reflects total glycated serum proteins, mostly albumin. Glycated albumin is the glycated proportion of total albumin. Both reflect glycemia over the previous 2–4 weeks and are used when HbA1c is unreliable or cannot be measured, as with homozygous variants (ADA 2026 section 6). Fructosamine or CGM is an accepted alternative to HbA1c for monitoring (ADA 2026 Recommendation 6.1).
  • Glycated albumin method. The enzymatic assay releases glycated amino acids with an albumin-specific proteinase, oxidizes them with ketoamine oxidase and measures albumin with bromocresol green to calculate percent glycated albumin. Because the result is a ratio to albumin, it is independent of other serum proteins (Freitas 2017).
  • Glycated albumin interferences. Low albumin increases glycation rates, and increased protein turnover lowers glycated albumin. Glycated albumin is misleading in hyperthyroidism, hypothyroidism, cirrhosis and nephrotic syndrome with massive proteinuria (Freitas 2017). Reference intervals reported from Japan are 12.3–16.9% and 12.2–16.5% (Freitas 2017). In CKD, glycated albumin has a half-life of about 2–3 weeks and is proposed as a more reliable index than HbA1c (Gan 2018).
  • Fructosamine and iron. Iron deficiency anemia is associated with higher fructosamine as well as higher HbA1c (NGSP factors page).
  • 1,5-Anhydroglucitol (1,5-AG). 1,5-AG is a dietary polyol that is filtered and almost completely reabsorbed by the renal tubule, and glucose competitively inhibits its reabsorption (Radin 2014; Stettler 2008). When glucose exceeds the renal threshold of 8.9–10.0 mmol/L, 1,5-AG is lost in the urine and serum 1,5-AG falls (Xu 2026). Serum 1,5-AG therefore moves inversely with glycemia and reflects hyperglycemic excursions over the preceding 48 hours to 2 weeks (Radin 2014; Xu 2026). It correlated best with 2-hour postprandial glucose over the previous 2 weeks (Stettler 2008). The FDA approved an automated assay (GlycoMark) in 2003 (Radin 2014).
  • 1,5-AG limitations. 1,5-AG remained a reliable glycemic marker in type 2 diabetes with CKD stages 1–3. In stages 4–5, eGFR was its only independent determinant (Kim 2012). Results are unreliable in renal failure (falsely high), pregnancy (falsely low) and chronic severe liver disease (Radin 2014). SGLT2 inhibitors lower serum 1,5-AG regardless of glycemic control: 92% of treated patients had 1,5-AG ≤2 µg/mL against 12% of untreated patients. α-Glucosidase inhibitors lower it by reducing intestinal absorption (Xu 2026).
  • Glucose management indicator. The glucose management indicator (GMI) estimates HbA1c from CGM mean glucose over at least 10, and preferably 14 or more, days (Bergenstal 2018). A goal time in range of 70–180 mg/dL above 70% aligns with HbA1c of about 7%. Goals for time below range are <4% below 70 mg/dL (3.9 mmol/L) and <1% below 54 mg/dL (3.0 mmol/L) (ADA 2026 section 6).

Glucose management indicator equations (Bergenstal 2018).

Units Equation
Conventional GMI (%) = 3.31 + 0.02392 × mean glucose (mg/dL)
SI GMI (mmol/mol) = 12.71 + 4.70587 × mean glucose (mmol/L)

Ketone bodies and diabetic ketoacidosis

  • Ketone bodies. β-Hydroxybutyrate is the main ketoacid in DKA. Acetone, a breakdown product of acetoacetate, gives the breath its fruity odor (Umpierrez 2024).
  • Nitroprusside testing. The nitroprusside reaction in urine or serum measures acetoacetate and does not detect β-hydroxybutyrate. It underestimates ketonemia early in DKA and overestimates it during treatment, when β-hydroxybutyrate is converted to acetoacetate. Sulfhydryl drugs such as captopril and valproate give false-positive nitroprusside tests (Umpierrez 2024).
  • β-Hydroxybutyrate. Direct venous or capillary β-hydroxybutyrate is recommended for diagnosis and monitoring. A concentration ≥3.0 mmol/L correlates with acid-base changes with >90% sensitivity and specificity for DKA (Umpierrez 2024). Capillary β-hydroxybutyrate had high sensitivity, specificity and predictive values compared with urine ketone testing in a systematic review of nine studies (Brooke 2016).
  • Anion gap and mixed disorders. Most DKA presents with a high anion gap acidosis (>12 mmol/L). About one-third of patients have mixed acid-base disorders from vomiting, osmotic diuresis and respiratory compensation. A hyperchloremic non-anion gap acidosis can appear during recovery from keto-anion loss and chloride-containing fluids (Umpierrez 2024).

DKA diagnostic criteria: 2024 consensus with the 2009 ADA statement (Umpierrez 2024; Kitabchi 2009).

Component 2024 ADA/EASD/JBDS/AACE/DTS consensus (current) 2009 ADA statement (previous)
Glycemia Glucose ≥200 mg/dL (11.1 mmol/L) or a prior history of diabetes Plasma glucose >250 mg/dL
Ketosis β-Hydroxybutyrate ≥3.0 mmol/L or urine ketone strip 2+ or greater Urine and serum ketones positive by nitroprusside
Acidosis pH <7.3 and/or bicarbonate <18 mmol/L Arterial pH 7.25–7.30 or lower and bicarbonate 15–18 mEq/L or lower, graded by severity
Anion gap Not a diagnostic criterion >10 (mild) or >12 mEq/L (moderate, severe)

DKA severity: 2024 consensus with the 2009 ADA statement (Umpierrez 2024; Kitabchi 2009).

Severity 2024: pH or bicarbonate 2024: β-hydroxybutyrate 2009: arterial pH 2009: bicarbonate (mEq/L) Mental status
Mild pH >7.25 to <7.30 or bicarbonate 15–18 mmol/L 3.0–6.0 mmol/L 7.25–7.30 15–18 Alert
Moderate pH 7.0–7.25; bicarbonate 10 to <15 mmol/L 3.0–6.0 mmol/L 7.00 to <7.24 10 to <15 Alert or drowsy
Severe pH <7.0; bicarbonate <10 mmol/L >6.0 mmol/L <7.00 <10 Stupor or coma
  • Partial criteria. In the 2024 classification, a severity grade can be assigned when only some of its variables are met (Umpierrez 2024).
  • Resolution (2024). DKA resolves when plasma ketones are <0.6 mmol/L and venous pH is ≥7.3 or bicarbonate is ≥18 mmol/L. The anion gap and urine ketones are not used as resolution criteria (Umpierrez 2024).
  • Euglycemic DKA. About 10% of patients with DKA have glucose <200 mg/dL (11.1 mmol/L). Causes include exogenous insulin, reduced food intake, pregnancy, alcohol, liver failure and SGLT2 inhibitors, which now account for most cases (Umpierrez 2024). SGLT2 inhibitor-associated DKA occurs in about 4% of people with type 1 diabetes and 0.6–4.9 events per 1,000 patient-years in type 2 diabetes (Umpierrez 2024). Absence of marked hyperglycemia delayed recognition in the first reported SGLT2 inhibitor case series (Peters 2015).
  • Other ketoacidoses. Starvation ketosis follows intake below 500 kcal/day (2,090 kJ/day), and hyperemesis gravidarum also predisposes to ketosis (Umpierrez 2024). Alcoholic ketoacidosis presents with alcohol use, poor oral intake, an anion gap acidosis with elevated β-hydroxybutyrate and low, normal or mildly elevated glucose (Long 2021).

Hyperglycemic hyperosmolar state

HHS diagnostic criteria: 2024 consensus with the 2009 ADA statement (Umpierrez 2024, Figure 2; Kitabchi 2009).

Component 2024 consensus (current) 2009 ADA statement (previous)
Glucose Plasma glucose ≥600 mg/dL (33.3 mmol/L) Plasma glucose >600 mg/dL
Osmolality Calculated effective osmolality >300 mOsm/kg, or total serum osmolality >320 mOsm/kg Effective serum osmolality >320 mOsm/kg
Ketones β-Hydroxybutyrate <3.0 mmol/L or urine ketone strip less than 2+ Small urine and serum ketones by nitroprusside
Acid-base pH ≥7.3 and bicarbonate ≥15 mmol/L Arterial pH >7.30 and bicarbonate >18 mEq/L

Osmolality equations used in HHS criteria.

Quantity Equation Source
Effective osmolality, SI 2 × Na (mmol/L) + glucose (mmol/L) Umpierrez 2024
Total osmolality, SI 2 × Na (mmol/L) + glucose (mmol/L) + urea (mmol/L) Umpierrez 2024
Effective osmolality, conventional (2009) 2 × measured Na (mEq/L) + glucose (mg/dL) ÷ 18 Kitabchi 2009
  • Overlap. More than one-third of hyperglycemic crises show overlap between DKA and HHS. Ketonemia with β-hydroxybutyrate ≥3.0 mmol/L, ketonuria ≥2+, pH <7.30 or bicarbonate <18 mmol/L in HHS defines mixed DKA/HHS (Umpierrez 2024).
  • Sodium and osmolality during treatment. Sodium corrected for glucose is taught in Water, Electrolytes, Osmolality and Acid-Base Disorders. During treatment, osmolality falls by no more than 3.0–8.0 mOsm/kg/h and sodium by no more than 10 mmol/L in 24 h (Umpierrez 2024).
  • Resolution. HHS is considered resolved when measured or calculated osmolality is <300 mOsm/kg, glucose is <250 mg/dL (13.9 mmol/L), urine output is >0.5 mL/kg/h and cognition has improved (Umpierrez 2024).

Urine albumin screening in diabetes

  • Interval. ADA and KDIGO recommend annual CKD screening with urine albumin-to-creatinine ratio and eGFR. Screening starts at diagnosis of type 2 diabetes and 5 years after diagnosis of type 1 diabetes. Persistence for at least 3 months is required for a CKD diagnosis (de Boer 2022).
  • Categories. Albuminuria categories A1–A3 and eGFR categories are taught in Liver, Kidney and Gastrointestinal Function Tests.

Hypoglycemia in adults: definitions, workup and causes

  • Whipple triad. Hypoglycemia is evaluated in people without diabetes only when symptoms or signs, a low plasma glucose and relief after glucose is raised are documented (Cryer 2009).
  • Hypoglycemia levels in diabetes. Level 1 is glucose <70 mg/dL (<3.9 mmol/L) and ≥54 mg/dL (≥3.0 mmol/L). Level 2 is glucose <54 mg/dL (<3.0 mmol/L). Level 3 is a severe event with altered mental or physical status requiring assistance, irrespective of glucose (ADA 2026 section 6).
  • Sequence of evaluation. Drugs, critical illness, hormone deficiency and non-islet cell tumors are pursued first. Without these, the differential diagnosis is accidental, surreptitious or malicious hypoglycemia or endogenous hyperinsulinism. Glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate and oral hypoglycemic agents are measured during an episode, with insulin antibodies (Cryer 2009). The 72-h supervised fast is the classical test for insulinoma (Jensen 2012).

Biochemical criteria for endogenous hyperinsulinism during hypoglycemia (Endocrine Society criteria as restated in 2024, primary studies and ENETS 2012).

Analyte Threshold during hypoglycemia Source
Endocrine Society diagnostic set Glucose <55 mg/dL (3.0 mmol/L), preferably <45 mg/dL (2.5 mmol/L); insulin ≥3 µU/mL (18 pmol/L); C-peptide ≥0.6 ng/mL (0.2 nmol/L); proinsulin ≥5.0 pmol/L Hofland 2024, as corrected in 2026
β-Hydroxybutyrate ≤2.7 mmol/L at the end of the prolonged fast, with glucose ≤3.3 mmol/L (60 mg/dL) O'Brien 1993
Glucose response to intravenous glucagon ≥1.4 mmol/L (≥25 mg/dL) at the end of the fast O'Brien 1993
Proinsulin >5 pmol/L with glucose <2.5 mmol/L (45 mg/dL): 100% sensitivity and specificity for endogenous hyperinsulinism Vezzosi 2007
C-peptide >0.2 nmol/L with glucose <2.5 mmol/L in every insulinoma, but not in nesidioblastosis or controls Vezzosi 2007
ENETS diagnostic set Glucose ≤40 mg/dL (≤2.2 mmol/L); insulin ≥6 µU/mL (≥36 pmol/L); C-peptide ≥200 pmol/L; proinsulin ≥5 pmol/L; β-hydroxybutyrate ≤2.7 mmol/L; no sulfonylurea in plasma or urine Jensen 2012
  • Insulin assay specificity. Insulin-specific immunometric assays do not cross-react with proinsulin and give lower values, so up to 60% of insulinoma patients have insulin ≤6 µU/mL with these assays (Jensen 2012). In one study, insulin was <21 pmol/L in 8–35% of patients with endogenous hyperinsulinism at glucose <2.5 mmol/L (Vezzosi 2007).
  • Insulin surrogates. In 40 insulinomas and 25 controls, median β-hydroxybutyrate at the end of the fast was 0.3 mmol/L against 4.5 mmol/L. When insulin and C-peptide were in the normal fasting range, the glucagon response and β-hydroxybutyrate separated the groups better than insulin or C-peptide (O'Brien 1993).

Insulin-to-C-peptide molar ratio (unit factors from ENETS 2012 and ADA 2026).

Step Calculation Source
Insulin to pmol/L Insulin (µU/mL) × 6 Jensen 2012
C-peptide to pmol/L C-peptide (ng/mL) × 333 ADA 2026 Figure 2.1 (600 pmol/L = 1.8 ng/mL)
Molar ratio Insulin (pmol/L) ÷ C-peptide (pmol/L); physiologic ratio <1; ratio >1 in exogenous insulin and in insulin autoimmune syndrome Cappellani 2020

Laboratory patterns in adult hypoglycemia (Soliman 2025; Cappellani 2020; Dynkevich 2013).

Cause Insulin C-peptide Other findings Source
Insulinoma High High High proinsulin; low β-hydroxybutyrate; negative sulfonylurea screen; insulin/C-peptide ratio <1 Soliman 2025
Sulfonylurea or meglitinide High High Positive urine or blood sulfonylurea test Soliman 2025
Exogenous insulin High (analog detection assay-dependent) Low Negative sulfonylurea screen Soliman 2025
Insulin autoimmune syndrome (Hirata disease) Very high, often >1000 pmol/L Variable Postprandial episodes; insulin autoantibodies; low insulin recovery after PEG precipitation Cappellani 2020
Non-islet cell tumor hypoglycemia Low Low Low β-hydroxybutyrate; glucagon response >25 mg/dL; elevated IGF-2/IGF-1 ratio; hypokalemia possible Soliman 2025; Dynkevich 2013
  • Insulin autoimmune syndrome. Insulin-autoantibody complexes bind insulin after meals and release it later, causing postprandial hypoglycemia. Triggers include methimazole, carbimazole, propylthiouracil, captopril and some autoimmune diseases (Soliman 2025). Insulin values vary widely between kits, and IRMA measures unbound insulin more accurately than ICMA. Insulin autoantibody measurement is required for diagnosis, and most commercial assays detect only IgG autoantibodies (Cappellani 2020). Type B insulin resistance from insulin receptor-agonizing antibodies also causes postprandial hypoglycemia, with acanthosis nigricans (Soliman 2025).
  • Insulin analogs. Commercial insulin immunoassays fall into three groups: those detecting all insulins, those detecting only human insulin and those detecting analogs in variable proportions (Violin 2023). One automated immunoassay recovered 92–121% of five analogs, while an LC-MS/MS method designed for human insulin detected only glargine (Li 2025). A liquid chromatography high-resolution accurate mass immunoassay identified lispro, glulisine, aspart, a glargine metabolite and detemir in suspected factitious hypoglycemia (Egan 2022).
  • Non-islet cell tumor hypoglycemia. Hepatomas, fibromas and fibrosarcomas are the most common sources of IGF-2-related peptides. Insulin, IGF-1 and growth hormone are suppressed (Dynkevich 2013). Hepatocellular carcinoma is the most frequent associated tumor, and pro-IGF-2 is incompletely processed. IGF-1, IGF-2, pro-IGF-2 and the IGF-2/IGF-1 ratio are measured if the diagnosis remains unconfirmed (Soliman 2025).
  • Post-bariatric hypoglycemia. Post-bariatric hypoglycemia is most common after Roux-en-Y gastric bypass and usually begins 1–3 years after surgery, with symptoms 1–3 h after meals. Glucose <60 mg/dL during an OGTT or mixed-meal test is commonly used, and no gold-standard test exists (Soliman 2025; Salehi 2018). Early dumping syndrome occurs 10–30 min after meals without hypoglycemia (Soliman 2025).
  • Pseudohypoglycemia. Marked leukocytosis consumes glucose in vitro and produces low plasma glucose without symptoms, with normal simultaneous capillary glucose and a time-dependent fall in delayed samples (Drummond 2025). Raynaud phenomenon produces falsely low finger-stick glucose, corrected by sampling from the earlobe (Nishioka 2025).

Neonatal and pediatric hypoglycemia

  • Thresholds. In infants and young children who cannot report symptoms, evaluation and management are limited to laboratory-confirmed plasma glucose <60 mg/dL (3.3 mmol/L) (Thornton 2015 Recommendation 1.2). Evaluation of high-risk neonates is deferred until ≥48 hours of age, after transitional glucose regulation (Thornton 2015 Recommendation 1.3).
  • Transitional neonatal glucose regulation. Mean plasma glucose in the first hours of life is about 55–60 mg/dL (about 3 mmol/L). Transitional hypoglycemia is hypoketonemic with large glycemic responses to glucagon, consistent with a lowered insulin suppression threshold of about 55–65 mg/dL. Newborn standards are not applied beyond 2–3 days of age (Thornton 2015).
  • Targets. In high-risk neonates without a suspected congenital disorder, the target is >50 mg/dL (2.8 mmol/L) before 48 hours and >60 mg/dL (3.3 mmol/L) after 48 hours. With a suspected congenital hypoglycemia disorder, the target is >70 mg/dL (3.9 mmol/L) (Thornton 2015 Recommendations 3.1 and 3.2).
  • Critical sample. Blood is drawn at spontaneous hypoglycemia and before treatment for glucose, bicarbonate, β-hydroxybutyrate and lactate, with plasma held for insulin, free fatty acids, C-peptide, carnitine and acylcarnitine profile (Thornton 2015).
  • Hyperinsulinism pattern. A fasting test for hyperinsulinism is ended at glucose <50 mg/dL (<2.8 mmol/L), and glucagon is given. A glycemic response >30 mg/dL (>1.7 mmol/L) is nearly pathognomonic of hyperinsulinism. β-Hydroxybutyrate <1.5 mmol/L and free fatty acids <1.0–1.5 mmol/L are inappropriately low (Thornton 2015).
  • Discharge testing. A 6–8-hour safety fast before discharge confirms that glucose can be maintained, above 60 mg/dL in neonates expected to recover and above 70 mg/dL in those with a known persistent disorder (Thornton 2015).
  • Ketotic hypoglycemia. Children under 4 years may have glucose <70 mg/dL (3.9 mmol/L) with hyperketonemia after an overnight fast because of limited fasting tolerance (Thornton 2015).
  • Earlier neonatal guidance. The AAP 2011 report found no glucose concentration that discriminates normal from abnormal and recommended early identification of at-risk infants (Adamkin 2011).

Lipids, Lipoproteins and Cardiovascular Risk Markers: LDL-C Equations, ApoB and Lp(a)

Definition. The primary lipid panel comprises total cholesterol, triglycerides, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C) and calculated non-HDL cholesterol (non-HDL-C, total cholesterol minus HDL-C). It estimates the risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state (Nordestgaard 2020). Apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)] extend the panel. The 2026 ACC/AHA multisociety dyslipidemia guideline retires and replaces the 2018 AHA/ACC cholesterol guideline, and its scope includes high blood cholesterol, hypertriglyceridemia and elevated Lp(a) (Blumenthal 2026).

Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (lipemia interference and specimen handling) Related page: Water, Electrolytes, Osmolality and Acid-Base Disorders (pseudohyponatremia from severe hyperlipidemia) Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (diabetic dyslipidemia and glycemic markers) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (immunoturbidimetry, nephelometry and mass spectrometry) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (C-reactive protein and paraprotein interference) Related page: Liver, Kidney and Gastrointestinal Function Tests (cholestasis and nephrotic syndrome) Related page: Macrocytic Anemias and Vitamin B12 and Folate Testing (homocysteine in vitamin B12 and folate deficiency) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (homocysteine in thrombosis) Related page: Cardiac Biomarkers: High-Sensitivity Troponin, the Fourth Universal Definition of Myocardial Infarction and Natriuretic Peptides (troponin and natriuretic peptides) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (full CLIA PT tables, reference intervals and biological variation)

Lipoprotein classes and their apolipoproteins

  • Assembly. Microsomal triglyceride transfer protein combines triglyceride, cholesterol and phospholipid with apoB-48 in the intestine to form chylomicrons and with apoB-100 in the liver to form very-low-density lipoprotein (VLDL) (Dron 2020).
  • Lipolysis. Lipoprotein lipase (LPL) hydrolyzes chylomicrons and VLDL to chylomicron remnants and intermediate-density lipoprotein (IDL). Apolipoprotein C-II activates LPL, apolipoprotein A-V stabilizes it, and apolipoprotein C-III and angiopoietin-like protein 3 inhibit lipolysis. Apolipoprotein E mediates hepatic clearance of remnants and IDL. Hepatic lipase converts IDL to LDL, which the LDL receptor clears under regulation by PCSK9 (Dron 2020).
  • Particle count. Each LDL, VLDL remnant, IDL and Lp(a) particle carries one apoB molecule, so apoB estimates the number of atherogenic particles (Sabouret 2026).

Lipoprotein classes and defining apolipoproteins (Dron 2020; Kronenberg 2022; Liang 2026).

Particle Source Defining protein Fate or feature
Chylomicron Intestine ApoB-48 Hydrolyzed by LPL to chylomicron remnants
VLDL Liver ApoB-100 Hydrolyzed by LPL to IDL
IDL VLDL lipolysis ApoB-100 Converted to LDL by hepatic lipase; cleared by apoE-mediated uptake
LDL IDL ApoB-100 Cleared by the LDL receptor
Lp(a) Liver ApoB-100 covalently linked to apolipoprotein(a) Concentration >90% genetically determined
Lipoprotein X Cholestasis, LCAT deficiency, some parenteral lipid settings Usually lacks apoB Rich in phospholipid and unesterified cholesterol

Lipid panel measurement methods

  • Total cholesterol. Cholesterol esterase and cholesterol oxidase generate hydrogen peroxide, which is quantified by a Trinder endpoint (Hashmi 2024).
  • Direct (homogeneous) LDL-C. A selective surfactant releases cholesterol from non-LDL particles, and the hydrogen peroxide formed is removed by catalase. A second surfactant then releases LDL cholesterol for measurement (Hashmi 2024).
  • Direct HDL-C. Precipitation methods remove apoB-containing lipoproteins with polyanions and divalent cations before enzymatic measurement of the supernatant (Miida 2024). Homogeneous HDL-C assays generally meet NCEP precision, accuracy and total error criteria, but discrepancies against reference methods have been observed with some reagents (Warnick 2001).
  • Direct assay specificity. In 175 sera, 6 of 8 direct HDL-C and 5 of 8 direct LDL-C methods met NCEP total error goals in nondiseased individuals (≤13% for HDL-C and ≤12% for LDL-C). All methods failed the goals in individuals with disease because of nonspecificity toward abnormal lipoproteins (Miller 2010).
  • Triglycerides and direct assays. Higher triglycerides raised direct LDL-C results against the reference method for 7 of 8 methods. In one patient with 37.7 g/L IgG, HDL-C was 16–58% lower and LDL-C 22–63% lower than the reference method in all but one manufacturer's assays (Miller 2010).
  • Glycerol blank. Most laboratories measure triglycerides without subtracting endogenous glycerol. In outpatients the glycerol blank rarely changes triglycerides by >0.1 mmol/L, but high endogenous glycerol during intravenous lipid or heparin infusion falsely raises the result (Nordestgaard 2016).
  • Reference measurement procedures. CDC uses β-quantification, which combines ultracentrifugation with polyanion precipitation and Abell-Kendall cholesterol measurement, as the reference procedure for LDL-C (Miida 2024). Abell-Kendall results are about 2% higher than isotope-dilution mass spectrometry because of phytosterols and cholesterol precursors (Miida 2024).
  • Standardization network. CDC created the Cholesterol Reference Method Laboratory Network to validate manufacturer traceability to the National Reference System for Cholesterol. Member laboratories agree with CDC within ±1.0% and maintain a CV ≤2.0% (Myers 2000).
  • Consistency of method. On-treatment LDL-C is measured or calculated by the same method each time because between-method variation can alter treatment decisions (Nordestgaard 2020).

CLIA proficiency testing acceptance limits for lipids (42 CFR 493.931; current rule effective July 11, 2024).

Analyte From July 11, 2024 Before July 11, 2024
Total cholesterol Target value ±10% Target value ±10% (unchanged)
HDL cholesterol Target value ±20% or ±6 mg/dL (greater) Target value ±30%
LDL cholesterol, direct measurement Target value ±20% Not a regulated analyte
Triglycerides Target value ±15% Target value ±25%
  • Source of the change. The 2022 CMS final rule revised the regulated analytes and acceptance limits, and its amendments to the proficiency testing sections took effect on July 11, 2024 (eCFR 2026; eCFR 2024; CMS 2022).

Fasting and nonfasting lipid sampling

  • Current consensus. The EAS/EFLM consensus recommends nonfasting lipid profiles for most patients and fasting sampling when nonfasting triglycerides exceed 5 mmol/L (440 mg/dL) (Nordestgaard 2016). The 2018 AHA/ACC guideline allows screening with fasting or nonfasting lipid measurement (Grundy 2018).
  • Size of postprandial changes. At 1–6 hours after habitual meals, mean maximal changes were +0.3 mmol/L (26 mg/dL) for triglycerides, −0.2 mmol/L (8 mg/dL) for total cholesterol, LDL-C and non-HDL-C, and +0.2 mmol/L (8 mg/dL) for remnant cholesterol. HDL-C, apolipoprotein A1, apoB and Lp(a) were unaffected (Nordestgaard 2016).
  • LDL-C fall after meals. A 0.6 mmol/L (23 mg/dL) LDL-C decrease at 1–3 hours occurred in people with diabetes. Fluid intake and hemodilution are the likely explanation (Nordestgaard 2016).

Indications for fasting and nonfasting lipid profiles (Nordestgaard 2016, EAS/EFLM).

Sampling Settings
Nonfasting Most patients; initial assessment; acute coronary syndrome (repeat later because the syndrome lowers lipids); children; patients with diabetes; older adults; patients on stable drug therapy
Fasting sometimes required Nonfasting triglycerides >5 mmol/L (440 mg/dL); known hypertriglyceridemia in a lipid clinic; recovery from hypertriglyceridemic pancreatitis; start of drugs that cause severe hypertriglyceridemia; other tests that need fasting or morning samples

Nonfasting flagging cut-points and critical lipid values (Nordestgaard 2016, EAS/EFLM).

Analyte Flag as abnormal Extreme value and implication
Triglycerides ≥2 mmol/L (175 mg/dL) >10 mmol/L (880 mg/dL): chylomicronemia with high risk of acute pancreatitis
Total cholesterol ≥5 mmol/L (190 mg/dL) Not applicable
LDL-C ≥3 mmol/L (115 mg/dL) >5 mmol/L (190 mg/dL) in adults or >4 mmol/L (155 mg/dL) in children: heterozygous familial hypercholesterolemia; >13 mmol/L (500 mg/dL): homozygous familial hypercholesterolemia
Remnant cholesterol ≥0.9 mmol/L (35 mg/dL) Not applicable
Non-HDL-C ≥3.9 mmol/L (150 mg/dL) Not applicable
HDL-C ≤1 mmol/L (40 mg/dL) <0.2 mmol/L (<10 mg/dL): genetic hypoalphalipoproteinemia such as LCAT deficiency
ApoB ≥1.0 g/L (100 mg/dL) LDL-C <0.3 mmol/L or apoB <10 mg/dL: genetic abetalipoproteinemia
Lp(a) ≥50 mg/dL (80th percentile) >150 mg/dL (99th percentile): very high risk of myocardial infarction and aortic valve stenosis

LDL cholesterol equations

  • Friedewald (1972). LDL-C is total cholesterol minus HDL-C minus triglycerides ÷ 5 in mg/dL, or minus triglycerides ÷ 2.2 in mmol/L. The equation assumes a fixed triglyceride:VLDL-C ratio of 5 (Martin 2013a). It is applied when triglycerides are <4.5 mmol/L (<400 mg/dL), and LDL-C is measured directly above that concentration (Nordestgaard 2016).
  • Friedewald underestimation at low LDL-C. In 1,310,440 profiles, directly measured LDL-C exceeded a Friedewald LDL-C <70 mg/dL by a median of 9.0 mg/dL at triglycerides 150–199 mg/dL and 18.4 mg/dL at 200–399 mg/dL. Of patients with Friedewald LDL-C <70 mg/dL, 23% had directly measured LDL-C ≥70 mg/dL, rising to 39% and 59% in those triglyceride bands (Martin 2013b).
  • Martin-Hopkins (2013). The method replaces the fixed factor with the strata-specific median triglyceride:VLDL-C ratio from a 180-cell table indexed by triglyceride and non-HDL-C. The overall median ratio was 5.2 (IQR 4.5–6.0). It was derived from 1,350,908 profiles measured by vertical spin density-gradient ultracentrifugation (Martin 2013a). Guideline classification concordance at triglycerides <400 mg/dL was 91.7% versus 85.4% for Friedewald (Martin 2013a).
  • Martin-Hopkins at low LDL-C. For LDL-C <70 mg/dL with triglycerides 150–199 mg/dL, concordance was 92.4% versus 61.3% for Friedewald. At triglycerides 200–399 mg/dL it was 84.0% versus 40.3% (Martin 2013a).
  • Sampson/NIH equation 2 (2020). The equation was derived against β-quantification in 8656 patients (18,715 LDL-C results). It had a root mean square error of 15.2 mg/dL, compared with 32 mg/dL for Friedewald and 25.7 mg/dL for Martin. In hypertriglyceridemia, its mean absolute difference was 24.9 mg/dL, compared with 56.4 and 44.8 mg/dL. It estimates LDL-C at triglycerides up to 800 mg/dL as accurately as Friedewald does below 400 mg/dL (Sampson 2020).
  • Calculated LDL-C includes other particles. Cholesterol in Lp(a) cannot be separated from LDL cholesterol and is reported within LDL-C (Kronenberg 2022). Calculated LDL-C equations cannot identify lipoprotein X and may retain its cholesterol in the LDL-C result (Liang 2026).
  • Dysbetalipoproteinemia. The largest discordance of both Friedewald and Martin-Hopkins estimates against direct LDL-C occurred in the Fredrickson type III phenotype (Martin 2013a).

LDL-C, non-HDL-C and remnant cholesterol calculations (all values in mg/dL unless stated).

Quantity Formula Validity limit Source
Friedewald LDL-C TC − HDL-C − TG ÷ 5 (mmol/L: TC − HDL-C − TG ÷ 2.2) TG <400 mg/dL (<4.5 mmol/L) Friedewald 1972; Nordestgaard 2016
Martin-Hopkins LDL-C Non-HDL-C − TG ÷ adjustable factor; factor = median TG:VLDL-C ratio of the cell matching TG and non-HDL-C in a 180-cell table Derived and validated mainly at TG <400 mg/dL Martin 2013a
Sampson/NIH equation 2 LDL-C TC ÷ 0.948 − HDL-C ÷ 0.971 − (TG ÷ 8.56 + TG × non-HDL-C ÷ 2140 − TG² ÷ 16,100) − 9.44 TG ≤800 mg/dL Sampson 2020; Hashmi 2024
Non-HDL-C TC − HDL-C Any TG; fasting or nonfasting Nordestgaard 2016
Remnant cholesterol TC − LDL-C − HDL-C (equals TG ÷ 5 in mg/dL when LDL-C is Friedewald-calculated) Fasting or nonfasting Nordestgaard 2016
  • Laboratory reporting. Non-HDL-C includes remnant lipoprotein cholesterol and is reported in all standard lipid panels (Nordestgaard 2020).
  • Remnant cholesterol and risk. High remnant cholesterol is consistently associated with myocardial infarction and ischemic heart disease whether it is calculated or measured by ultracentrifugation, automated assays or nuclear magnetic resonance. Cholesterol in remnants, more than their triglyceride, carries this risk (Balling 2025).

Lipoprotein(a) structure and measurement

  • Structure. Lp(a) consists of an LDL-like particle whose apoB is covalently linked to apolipoprotein(a) [apo(a)]. Apo(a) isoforms vary in size with the number of kringle IV type 2 repeats (Miida 2024).
  • Genetics. Lp(a) ranges from <0.1 to >300 mg/dL (<0.2–750 nmol/L) and is >90% determined by variation at the LPA locus. The kringle IV repeat polymorphism explains about 30–70% of the variation. Small isoforms (<23 kringle IV repeats) are associated with higher Lp(a) concentrations (Kronenberg 2022).
  • Developmental and demographic variation. The LPA gene is fully expressed by age 2 years, and adult concentrations are usually reached by about age 5 years. In the UK Biobank, median Lp(a) was 16, 19, 31 and 75 nmol/L in Chinese, White, South Asian and Black participants. Concentrations are about 5–10% higher in women and tend to rise at menopause (Kronenberg 2022).
  • Nongenetic modifiers. Kidney impairment and nephrotic syndrome may raise Lp(a), and hepatic impairment may lower it. Lifestyle interventions have minimal effect. Statins may raise Lp(a) slightly, and PCSK9 inhibitors lower it by 15–30% (Kronenberg 2022).
  • Assay principle. The ideal assay uses an antibody to a unique non-repetitive apo(a) epitope and reports nmol/L. Most assays use polyclonal antibodies and therefore underestimate Lp(a) with small isoforms and overestimate it with large isoforms. Multiple calibrators spanning isoform sizes partly address this bias (Kronenberg 2022).
  • Units. The EAS panel does not recommend a standard factor for converting mg/dL to nmol/L because assays vary. A factor of 2–2.5 is an approximation only. Laboratories use an isoform-insensitive assay traceable to official reference materials and report molar units when available (Kronenberg 2022).
  • Standardization. A WHO-IFCC working group produced the serum reference material SRM2B, but global Lp(a) standardization was not achieved. IFCC has endorsed an isoform-independent mass spectrometry reference measurement procedure that reports nmol/L (Miida 2024).
  • Lp(a) cholesterol correction. Cholesterol was estimated as 30% of Lp(a) mass to correct LDL-C. Measured Lp(a) cholesterol varies from 6% to 60% of Lp(a) mass, so routine correction is not recommended. A possible exception is suspected familial hypercholesterolemia with elevated Lp(a), where correction reclassified 15–25% of probable or definite cases (Kronenberg 2022).
  • No genotyping needed. Measured Lp(a) concentration is sufficient for risk estimation without genotyping, polygenic scores or apo(a) isoform sizing (Kronenberg 2022).

Lp(a) testing recommendations by guideline

  • 2026 ACC/AHA (current US rule). Lp(a) is measured at least once in adulthood. A level ≥125 nmol/L or ≥50 mg/dL is associated with about a 1.4-fold increased long-term risk, and 250 nmol/L with at least a 2-fold risk. Repeat testing is generally not needed because lifestyle changes minimally affect Lp(a) (ACC 2026). The guideline links about 4-fold relative risk to 430 nmol/L (Sabouret 2026).
  • NLA 2024 focused update. Cascade screening of first-degree relatives identifies additional individuals at risk (Koschinsky 2024). The 2019 NLA statement estimated elevated Lp(a) in about 20% of the population (Wilson 2019).
  • EAS 2022 consensus. Values between the rule-out and rule-in cut-offs form a grey zone. Levels >180 mg/dL (>430 nmol/L) confer lifetime ASCVD risk equivalent to untreated heterozygous familial hypercholesterolemia (Kronenberg 2022).

Lp(a) thresholds by guideline.

Guideline Testing Risk threshold Source
2026 ACC/AHA (current) At least once in adulthood ≥125 nmol/L or ≥50 mg/dL ACC 2026
2018 AHA/ACC (previous) Relative indication: family history of premature ASCVD ≥50 mg/dL or ≥125 nmol/L Grundy 2018
NLA 2024 At least once in every adult <75 nmol/L low; 75–125 intermediate; ≥125 high Koschinsky 2024
EAS 2022 At least once in adults <30 mg/dL (<75 nmol/L) rule-out; >50 mg/dL (>125 nmol/L) rule-in Kronenberg 2022
ESC/EAS 2025 Should be considered once in adulthood >50 mg/dL or ≥105 nmol/L Sabouret 2026

Apolipoprotein B measurement and indications

  • Standardization. The WHO endorsed the liquid-stabilized material SP3-07 as the International Reference Material for apoB, with an accuracy-based value of 1.22 g/L. With SP3-07 calibration, the among-laboratory CV across 25 immunochemical systems was 3.1–6.7% (Marcovina 1994).
  • Use in residual risk. Residual ASCVD risk under optimal LDL-lowering treatment is assessed by non-HDL-C or apoB, especially in mild-to-moderate hypertriglyceridemia (2–10 mmol/L). ApoB detects elevated LDL particle numbers that LDL-C does not identify (Nordestgaard 2020).
  • 2026 ACC/AHA. ApoB may be measured to assess residual ASCVD risk and guide treatment (ACC 2026). Selective measurement applies particularly with triglycerides >200 mg/dL, diabetes or achieved LDL-C <70 mg/dL, and universal apoB testing is not recommended (Sabouret 2026).
  • 2018 AHA/ACC (previous rule). ApoB ≥130 mg/dL was a risk-enhancing factor, with triglycerides ≥200 mg/dL as a relative indication for measurement. An apoB of 130 mg/dL corresponds to an LDL-C of 160 mg/dL (Grundy 2018).

LDL-C and non-HDL-C goals in the 2026 and 2018 guidelines

  • 2026 ACC/AHA (current). The guideline reinstates explicit LDL-C and non-HDL-C goals. LDL-C goals are <100 mg/dL at borderline or intermediate 10-year risk, <70 mg/dL at high risk and <55 mg/dL in very-high-risk secondary prevention (ACC 2026). Non-HDL-C goals are generally 30 mg/dL above the corresponding LDL-C goal (<130, <100 and <85 mg/dL); <85 mg/dL is stated for very-high-risk secondary prevention (Sabouret 2026). Any coronary artery calcium supports an LDL-C goal <100 mg/dL (ACC 2026).
  • Risk estimation. The PREVENT-ASCVD equations are used for adults aged 30–79 years without known ASCVD (ACC 2026).
  • 2018 AHA/ACC (previous rule). The 2013 and 2018 US recommendations emphasized statin intensity, percentage LDL-C reduction and LDL-C thresholds for adding nonstatin therapy without treat-to-target goals (Sabouret 2026). LDL-C ≥190 mg/dL (≥4.9 mmol/L) defined severe hypercholesterolemia treated with high-intensity statin without risk calculation (Grundy 2018).
  • ESC/EAS. The 2019 LDL-C goals remain unchanged by the 2025 update: <116 mg/dL at low risk, <100 mg/dL at moderate risk, <70 mg/dL with ≥50% reduction at high risk and <55 mg/dL with ≥50% reduction at very high risk (Sabouret 2026, summarizing Mach 2019 and Mach 2025).

Familial hypercholesterolemia

  • Prevalence and risk. In the Copenhagen General Population Study, definite or probable familial hypercholesterolemia (Dutch Lipid Clinic Network score >5) occurred in about 1 in 200 people. Coronary heart disease risk was increased 13-fold in those not receiving statins (Nordestgaard 2013).
  • Children. In a child with one affected parent, LDL-C >3.5 mmol/L (>135 mg/dL) strongly suggests familial hypercholesterolemia (Nordestgaard 2013).
  • Genetic testing. An expert panel recommends genetic testing as the standard of care for definite or probable familial hypercholesterolemia and at-risk relatives, including LDLR, APOB and PCSK9 (Sturm 2018).
  • Cascade testing. Cascade testing begins with first-degree relatives, and a genetic test is offered to all first-degree relatives once a causative variant is found (Nordestgaard 2013).

Dutch Lipid Clinic Network criteria for heterozygous familial hypercholesterolemia in adults (Nordestgaard 2013, EAS). Only the highest-scoring item in each group counts.

Group Criterion Points
Family history First-degree relative with premature coronary heart disease (<55 years men; <60 years women) or LDL-C >95th percentile 1
Family history First-degree relative with tendon xanthoma or corneal arcus, or child <18 years with LDL-C >95th percentile 2
Clinical history Premature coronary heart disease 2
Clinical history Premature cerebral or peripheral vascular disease 1
Physical examination Tendon xanthoma 6
Physical examination Corneal arcus before age 45 years 4
LDL-C >8.5 mmol/L (>325 mg/dL) 8
LDL-C 6.5–8.4 mmol/L (251–325 mg/dL) 5
LDL-C 5.0–6.4 mmol/L (191–250 mg/dL) 3
LDL-C 4.0–4.9 mmol/L (155–190 mg/dL) 1
DNA analysis Causative variant in LDLR, APOB or PCSK9 8
Interpretation >8 definite; 6–8 probable; 3–5 possible; 0–2 unlikely Not applicable

Familial combined hyperlipidemia

  • Phenotype. Familial combined hyperlipidemia corresponds to the former Fredrickson type IIb pattern with raised LDL and VLDL (Bararu-Bojan 2026). Reported metabolic features include hepatic VLDL overproduction, elevated fasting apoB, delayed chylomicron remnant clearance, small dense LDL, insulin resistance and steatotic liver disease (Brouwers 2025).
  • Genetics. No single causative gene has been identified, and current evidence supports a polygenic model. About 25% of affected individuals carry an excess of triglyceride-raising single-nucleotide variants (Bararu-Bojan 2026).

Familial dysbetalipoproteinemia

  • Definition. Dysbetalipoproteinemia (Fredrickson type III, broad-β disease) is an accumulation of cholesterol-enriched remnant particles caused by apoE variants that impair remnant clearance (Sampson 2022; Heidemann 2022).
  • Genetics. About 90% of familial dysbetalipoproteinemia results from homozygosity for the ε2 allele (ε2ε2). The other 10% involves other APOE variants, often with dominant inheritance. The ε2ε2 genotype alone does not establish the diagnosis because the phenotype requires a metabolic second hit (Heidemann 2022).
  • Heterogeneity. Only 38% of patients with an ultracentrifugation-proven dysbetalipoproteinemia phenotype had the ε2ε2 genotype. Diagnosis requires both the genotype and a dysbetalipoproteinemia phenotype shown by ultracentrifugation, polyacrylamide gradient gel electrophoresis or apoB-based ratios (Heidemann 2022).
  • Electrophoresis. The β-VLDL band on agarose gel electrophoresis is the traditional gold standard (Sampson 2022). The broad-β band is highly specific for dysbetalipoproteinemia but has low sensitivity compared with polyacrylamide gradient gel electrophoresis (Heidemann 2022).
  • Prevalence in a reference laboratory. In 24,713 dyslipidemic patients tested by β-quantification, about 0.5% (115 patients) met the criteria of VLDL-C/plasma TG >0.3 with TG 150–1000 mg/dL (Sampson 2022).

Laboratory criteria for the dysbetalipoproteinemia phenotype (Heidemann 2022).

Method Criterion Sensitivity Specificity
Ultracentrifugation VLDL-C/VLDL-TG >0.42 by mass (>0.97 molar) or VLDL-C/plasma TG >0.30 by mass (>0.69 molar); >0.25 by mass (>0.57 molar) is suggestive Reference Reference
Non-HDL-C/apoB ratio >4.91 mmol/g 96.8% 95.0%
ApoB/total cholesterol ratio <0.15 g/mmol 89% 97%
Three-step algorithm TG >75th percentile, total cholesterol/apoB ≥6.2 mmol/g and TG/apoB <10.0 mmol/g AUC-ROC 0.988 for the combination; sensitivity not reported separately Specificity not reported separately
  • Distinction from familial combined hyperlipidemia. ApoB measurement separates familial dysbetalipoproteinemia from familial combined hyperlipidemia when ultracentrifugation is unavailable (Heidemann 2022).

Familial chylomicronemia syndrome and multifactorial chylomicronemia

  • Genetics. Familial chylomicronemia syndrome is the only true monogenic hypertriglyceridemia (former Fredrickson type I). It results from biallelic loss-of-function variants in LPL, APOC2, APOA5, LMF1 or GPIHBP1. About 80% of patients carry biallelic LPL variants, and almost half of the rest carry GPIHBP1 variants (Dron 2020).
  • Prevalence. Familial chylomicronemia syndrome affects about 1 in 200,000–300,000 people. Multifactorial chylomicronemia affects about 1 in 600 (Dron 2020).
  • Presentation. Triglycerides are ≥10 mmol/L (≥885 mg/dL), and plasma is lipemic or milky after centrifugation or overnight standing. Features include lipemia retinalis, eruptive xanthomas, hepatosplenomegaly and failure to thrive in infancy (Dron 2020).
  • Pancreatitis. Lifetime pancreatitis risk is about 60–80% in familial chylomicronemia syndrome and 10–20% in multifactorial chylomicronemia (Dron 2020).
  • Heterozygous variants. Rare heterozygous variants in the five genes occurred in 14.4% of 563 patients with severe hypertriglyceridemia and in 3.8% of normolipidemic controls. A heterozygous loss-of-function variant does not establish familial chylomicronemia syndrome (Dron 2020).
  • FCS score. The European expert score includes fasting triglycerides >10 mmol/L (885 mg/dL) on multiple occasions, resistance to triglyceride-lowering therapy, young age at onset, absence of secondary factors except pregnancy and oral estrogens, and acute pancreatitis. A score ≥10 had a sensitivity of 88% and specificity of 85% (Moulin 2018).

Fredrickson phenotypes

The Fredrickson (WHO) classification groups hyperlipoproteinemias by the lipoprotein pattern on electrophoresis or ultracentrifugation (Bararu-Bojan 2026). Current genetic terminology refers to familial chylomicronemia syndrome as former type I, combined hyperlipidemia as former type IIb and dysbetalipoproteinemia as former type III (Dron 2020).

Fredrickson phenotypes (historical classification; Bararu-Bojan 2026).

Type Elevated lipoprotein Lipid pattern Typical association
I Chylomicrons Severe hypertriglyceridemia Recurrent pancreatitis; LPL or apoC-II deficiency
IIa LDL Isolated hypercholesterolemia Familial hypercholesterolemia
IIb LDL and VLDL Combined hyperlipidemia Familial combined hyperlipidemia
III IDL (remnants) Raised cholesterol and triglycerides Dysbetalipoproteinemia; palmar xanthomas
IV VLDL Hypertriglyceridemia Insulin resistance, obesity, type 2 diabetes
V Chylomicrons and VLDL Severe mixed hypertriglyceridemia High pancreatitis risk

Secondary dyslipidemias

  • Hypothyroidism. Hypothyroidism raises LDL-C and sometimes triglycerides. Thyroid hormone induces hepatic LDL receptor expression. Patients with unexplained high LDL-C are screened with TSH and free T4, and hormone replacement usually improves the hypercholesterolemia (Won 2024).
  • Nephrotic syndrome. Cholesterol, triglycerides, VLDL, IDL and Lp(a) rise, mainly from increased VLDL production (Won 2024).
  • Cholestasis and lipoprotein X. In cholestasis, free cholesterol bound to phospholipid circulates as lipoprotein X, which contains little apoB (Won 2024). Primary biliary cholangitis shows elevated lipoprotein X and HDL with low LDL-C, without high cardiovascular risk (Won 2024).
  • Lipoprotein X laboratory clues. Proposed screening triggers are indicative only. In a compatible setting, total cholesterol ≥500 mg/dL (12.9 mmol/L) is considered marked and ≥1000 mg/dL (25.9 mmol/L) extreme. ApoB within or slightly above the adult range, with total cholesterol/apoB ≥8 mmol/g or non-HDL-C/apoB ≥7.5 mmol/g, prompts verification (Liang 2026). Confirmation uses free and esterified cholesterol, lipoprotein electrophoresis with filipin staining, apoB depletion, nuclear magnetic resonance or ultracentrifugation (Liang 2026). Lipoprotein X can also cause pseudoelectrolyte disorders (Liang 2026).
  • Pregnancy. Triglycerides can rise up to 4-fold in the third trimester and usually remain <250 mg/dL (Won 2024).

Drugs that raise LDL-C or triglycerides (Won 2024, KSoLA). Bands as published (% elevation); the moderate and mild bands overlap in the source.

Effect size LDL-C Triglycerides
Severe (≥50%) None listed Oral contraceptives with second- or third-generation progestogens; isotretinoin, acitretin; ritonavir (200–300%); L-asparaginase
Moderate (10–50%) Danazol; glucocorticoids (variable); ritonavir, indinavir, nelfinavir; cyclosporine, rapamycin Indinavir, nelfinavir; β-blockers; unopposed estrogens, tamoxifen, glucocorticoids; clozapine, olanzapine, haloperidol; cyclosporine, rapamycin
Mild (<15%) Thiazide and loop diuretics; testosterone-derived progestogens; isotretinoin; carbamazepine, phenytoin, phenobarbital Thiazide and loop diuretics

Hypertriglyceridemia and pancreatitis risk

  • Endocrine Society 2012. Mild and moderate hypertriglyceridemia (150–999 mg/dL) is diagnosed to evaluate cardiovascular risk, and severe and very severe hypertriglyceridemia (>1000 mg/dL) is a risk for pancreatitis. The guideline bases the diagnosis on fasting levels and recommends evaluation for secondary causes (Berglund 2012).
  • 2026 ACC/AHA. Management targets pancreatitis prevention when fasting triglycerides reach ≥500 mg/dL, and especially when they exceed 1000 mg/dL. Persistent triglycerides >1000 mg/dL after correction of secondary causes raise suspicion of a chylomicronemia syndrome (Sabouret 2026).
  • Graded risk below the severe range. Compared with nonfasting triglycerides <89 mg/dL, the adjusted hazard ratio for acute pancreatitis rose from 1.6 at 89–176 mg/dL to 8.7 at ≥443 mg/dL in 116,550 individuals (Pedersen 2016).

Triglyceride categories by source.

Source Normal or desirable Mild to moderate Severe
Endocrine Society 2012 (fasting) <150 mg/dL (<1.7 mmol/L) Mild 150–199 mg/dL (1.7–2.3 mmol/L); moderate 200–999 mg/dL (2.3–11.2 mmol/L) Severe 1000–1999 mg/dL (11.2–22.4 mmol/L); very severe ≥2000 mg/dL (≥22.4 mmol/L)
EAS/EFLM 2016 (nonfasting) <175 mg/dL (<2 mmol/L) 2–10 mmol/L (175–880 mg/dL) >10 mmol/L (>880 mg/dL)
Dron 2020 <175 mg/dL (<2.0 mmol/L) 175–885 mg/dL (2.0–9.9 mmol/L) ≥885 mg/dL (≥10 mmol/L)

Cardiovascular risk markers beyond the lipid panel

  • High-sensitivity C-reactive protein (hs-CRP). The CDC/AHA 2003 statement set hs-CRP risk categories of low <1 mg/L, average 1–3 mg/L and high >3 mg/L, which approximate tertiles in US adults (Pearson 2003, as cited by Chiu 2011). In JUPITER, 17,802 adults with LDL-C <130 mg/dL (3.4 mmol/L) and hs-CRP ≥2.0 mg/L received rosuvastatin or placebo. Rosuvastatin lowered LDL-C by 50% and hs-CRP by 37%, and the primary end point hazard ratio was 0.56 (Ridker 2008). The 2026 ACC/AHA guideline recommends hs-CRP and coronary artery calcium selectively to refine risk (Williams 2026).
  • Homocysteine. After adjustment, a 25% lower homocysteine (about 3 µmol/L) was associated with 11% lower ischemic heart disease risk and 19% lower stroke risk. Elevated homocysteine is at most a modest independent predictor in healthy populations (Homocysteine Studies Collaboration 2002).
  • Coronary artery calcium. The 2026 ACC/AHA guideline recommends selective noncontrast calcium scanning for men ≥40 years and women ≥45 years at borderline or intermediate 10-year risk (ACC 2026).

Risk-enhancing factors, 2018 AHA/ACC (previous rule) and 2026 ACC/AHA.

Factor 2018 AHA/ACC (Grundy 2018) 2026 ACC/AHA (ACC 2026)
Lp(a) ≥50 mg/dL or ≥125 nmol/L if measured Measured at least once; ≥125 nmol/L or ≥50 mg/dL
ApoB ≥130 mg/dL if measured Used to assess residual risk
hs-CRP ≥2.0 mg/L if measured Listed among markers that refine risk
Triglycerides Persistently ≥175 mg/dL Elevated triglycerides listed among markers that refine risk
Clinical conditions Family history of premature ASCVD; metabolic syndrome; CKD; preeclampsia or premature menopause; chronic inflammatory disease; South Asian ancestry Family history; chronic inflammatory conditions; obesity, diabetes or CKD; South Asian, Filipino or other higher-risk ancestry; early menopause, preeclampsia, gestational diabetes

Water, Electrolytes, Osmolality and Acid-Base Disorders

Definition. Hyponatremia is a serum sodium concentration <135 mmol/L and is the most common disorder of body fluid and electrolyte balance (Spasovski 2014). The anion gap is serum sodium minus the sum of chloride and bicarbonate, and it is used to analyze acid-base disorders, to check laboratory quality and to detect myeloma, bromide intoxication and lithium intoxication (Kraut 2007).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (direct and indirect ion-selective electrodes, osmometry methods and the calculated osmolality formula) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (pseudohyperkalemia from hemolysis, fist clenching and thrombocytosis; blood gas stability; point-of-care electrolytes) Related page: Liver, Kidney and Gastrointestinal Function Tests (renal tubular acidosis patterns, the urine anion gap in RTA and the fecal osmotic gap) Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (diabetic ketoacidosis, β-hydroxybutyrate and hyperglycemic hyperosmolar state) Related page: Lipids, Lipoproteins and Cardiovascular Risk Markers: LDL-C Equations, ApoB and Lp(a) (severe hypertriglyceridemia as a cause of pseudohyponatremia) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (primary aldosteronism and other mineralocorticoid excess states) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (methemoglobin, sulfhemoglobin and hemoglobin variants in oximetry) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (IgG paraproteins and the low anion gap) Related page: Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring (osmolal gap time course in toxic alcohol poisoning, carbon monoxide, cyanide and methemoglobinemia) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (sweat chloride testing in cystic fibrosis) Related page: Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate (calcium, magnesium and phosphate disorders, PTH and vitamin D)

Hyponatremia classified by sodium level, tonicity and volume

  • Classification. The European and Korean guidelines grade hyponatremia by serum sodium, symptom severity, time of development, serum osmolality and volume status (Lee 2022; Spasovski 2014).
  • Tonicity categories. Hyponatremia is classified as hypotonic, hypertonic or isotonic (pseudohyponatremia). Hypotonic hyponatremia causes cell swelling from excess body water. Hypertonic hyponatremia results from water exit from cells driven by solutes other than sodium salts. In pseudohyponatremia, cell volume remains normal (Garrett 2026).

Classification of hyponatremia (Korean Society of Nephrology 2022, compared with the European 2014 guideline).

Parameter Category Criterion Source
Serum sodium Mild 130–134 mmol/L Lee 2022
Serum sodium Moderate 125–129 mmol/L Lee 2022
Serum sodium Severe (European: profound) <125 mmol/L Lee 2022
Time of development Acute <48 hours Lee 2022
Time of development Chronic ≥48 hours Lee 2022
Serum osmolality Hypotonic <275 mOsm/kg Lee 2022
Serum osmolality Isotonic 275–295 mOsm/kg Lee 2022
Serum osmolality Hypertonic >295 mOsm/kg Lee 2022

Stepwise laboratory evaluation of hyponatremia

  1. Plasma osmolality. A low plasma osmolality confirms hypotonic hyponatremia. When plasma osmolality is above 275 mOsm/kg, hyperglycemia is checked and sodium is corrected for glucose. Hyperproteinemia, hyperlipidemia, mannitol and radiocontrast media also cause iso-osmolar or hyperosmolar hyponatremia (Lee 2022).
  2. Urine osmolality. A urine osmolality <100 mOsm/kg indicates excessive water intake or excessive intake of hypotonic fluid with little solute, such as beer or a liquid diet (Lee 2022).
  3. Urine sodium. With urine sodium >30 mmol/L, diuretic use and cerebral salt wasting are considered in hypovolemia, and adrenal insufficiency, hypothyroidism and SIAD in euvolemia. With urine sodium <30 mmol/L, diarrhea or vomiting is considered in hypovolemia, and heart failure, cirrhosis and nephrotic syndrome in hypervolemia (Lee 2022).
  4. Fractional excretion of uric acid. The Korean guideline considers fractional uric acid excretion reasonable to separate SIAD from diuretic-induced hyponatremia. In patients taking diuretics, it performed best among urine sodium, FENa, fractional urea excretion and serum uric acid (AUC 0.96). SIAD and thiazide-induced hyponatremia gave similar values (Lee 2022).
  5. Copeptin to urine sodium ratio. The Korean guideline found insufficient data to recommend this ratio for volume status, because copeptin overlaps widely and is affected by nonosmotic stimuli (Lee 2022).

Diagnostic criteria for the syndrome of inappropriate antidiuresis

Criteria for SIAD (European 2014 and American 2013 criteria, as tabulated by the Korean Society of Nephrology 2022).

Type Criterion Source
Essential Effective serum osmolality <275 mOsm/kg Lee 2022
Essential Urine osmolality >100 mOsm/kg at some level of serum hypo-osmolality Lee 2022
Essential Clinical euvolemia Lee 2022
Essential Urine sodium >30 mmol/L with normal dietary salt and water intake Lee 2022
Essential No severe hypothyroidism or adrenal insufficiency Lee 2022
Essential Normal renal function and no diuretic use, especially thiazides Lee 2022
Supplemental Serum uric acid <4 mg/dL; serum urea <21.6 mg/dL Lee 2022
Supplemental No correction after 0.9% saline; correction with fluid restriction Lee 2022
Supplemental FENa >0.5%; fractional urea excretion >55%; fractional uric acid excretion >2% Lee 2022
  • Correction limits. Serum sodium is raised by less than 10 mmol/L per day, and by no more than 8 mmol/L per day in patients at high risk of osmotic demyelination: sodium ≤105 mmol/L, hypokalemia, alcoholism, malnutrition or advanced liver disease (Lee 2022). The target rise is 5–9 mmol/L in 24 h, and overcorrection is a rise >12 mmol/L in 24 h or >18 mmol/L in 48 h (Lee 2022). The European guideline limits the rise to 10 mmol/L in the first 24 h and 8 mmol/L in every 24 h thereafter until sodium reaches 130 mmol/L (Spasovski 2014, as cited by Ayus 2019).

Hyperglycemia and translocational hyponatremia

  • Correction factors. In healthy subjects made hyperglycemic, sodium fell by a mean of 2.4 mmol/L per 100 mg/dL rise in glucose, exceeding the commonly used factor of 1.6. The relationship was nonlinear: the 1.6 factor was accurate up to 400 mg/dL, and a factor of 4.0 fit better above 400 mg/dL (Hillier 1999). The Korean guideline uses corrected sodium = Na + 0.024 × (glucose in mg/dL − 100) (Lee 2022).
  • Effect on the anion gap. Translocational hyponatremia in hyperglycemia is a true hyponatremia and does not change the anion gap (Fong 2026).
  • Exogenous solutes. The calculated tonicity formula underestimates serum tonicity when hyponatremia is caused by exogenous solutes confined to the extracellular fluid, such as mannitol (Garrett 2026).

Corrected sodium in hyperglycemia.

Formula Factor Source
Corrected Na (mmol/L) = measured Na + 0.016 × (glucose mg/dL − 100) 1.6 per 100 mg/dL; adequate to 400 mg/dL Hillier 1999
Corrected Na (mmol/L) = measured Na + 0.024 × (glucose mg/dL − 100) 2.4 per 100 mg/dL; mean factor overall Hillier 1999; Lee 2022
Corrected Na (mmol/L) = measured Na + 0.4 × (glucose mmol/L − 5.6) SI form of the 2.4 factor Overgaard-Steensen 2013

Pseudohyponatremia from the electrolyte exclusion effect

  • Mechanism. The electrolyte exclusion effect of indirect ISE and flame photometry is taught in Analytical Methods and Immunoassays in Clinical Chemistry. Hyperproteinemia produces the same falsely low sodium as hyperlipidemia (Garrett 2026).
  • Osmolal gap. With indirect ISE in a high-solid sample, calculated osmolality is low and measured osmolality is normal, so the osmolal gap rises. The gap normalizes when sodium is measured by direct potentiometry, which establishes pseudohyponatremia (Garrett 2026).
  • Protein. The indirect-minus-direct sodium difference was inversely proportional to total protein (difference = −1.29 × TP + 8.6). With total protein >7.9 g/dL (>79 g/L), the mean difference was −6.1 mmol/L, and 69% of samples differed by ≥4.0 mmol/L. Only 10.9% of sodium orders included total protein on the same collection (Katrangi 2019).
  • Lipemia. Intralipid spiking showed no sodium effect up to a lipemic index of 2000. Endogenous hyperlipidemic samples differed by ≥4 mmol/L when the index approached or exceeded 700, and reflex to direct ISE above an index of 700 was recommended on that platform (Koch 2021).
  • Other causes. Pseudohyponatremia has also been reported in non-Hodgkin lymphoma, acute lymphoblastic leukemia and hereditary stomatocytosis (Garrett 2026).

Hypernatremia and water deficit

  • Definition. Hypernatremia is plasma sodium above 145 mmol/L (Overgaard-Steensen 2013).
  • Water and solute loss. Hypovolemic hypernatremia is the most common form in hospitalized patients. Contributors include reduced water intake, fever, skin and gastrointestinal losses and renal concentrating defects. Osmotic diuresis is suspected when urine osmolality is >300 mOsm/kg with hypernatremia, from hyperglycemia, urea or mannitol (Overgaard-Steensen 2013).
  • Pure water loss. Patients with AVP deficiency or AVP resistance (central or nephrogenic diabetes insipidus) develop hypernatremia only when water intake is restricted, and urine osmolality is inappropriately low (Overgaard-Steensen 2013).
  • Solute gain. Hypernatremia with an expanded extracellular volume follows a positive cation balance, for example from 0.9% saline, hypertonic saline or sodium bicarbonate (Overgaard-Steensen 2013).

Free water deficit.

Step Formula Source
Total body water (TBW) 0.6 × body weight (kg), as in the example below Overgaard-Steensen 2013
Water deficit (L) TBW × ([Na] corrected ÷ 140 − 1) Overgaard-Steensen 2013
Example 80 kg, corrected Na 169 mmol/L: 80 × 0.6 × (169 ÷ 140 − 1) = about 10 L Overgaard-Steensen 2013

AVP deficiency, AVP resistance and primary polydipsia

  • Terminology. The Working Group for Renaming Diabetes Insipidus proposed arginine vasopressin deficiency (AVP-D) for central diabetes insipidus and arginine vasopressin resistance (AVP-R) for nephrogenic diabetes insipidus. The proposal was endorsed by the Endocrine Society, the European Society of Endocrinology, the Pituitary Society and other societies, and the previous name is kept in parentheses during the transition (Arima 2022).
  • Indirect water deprivation test. In healthy individuals, urine osmolality rises to ≥750 mOsm/kg during water deprivation with little change after desmopressin. In complete AVP deficiency, urine osmolality stays <300 mOsm/kg and rises >50% after desmopressin. In AVP resistance, it stays <300 mOsm/kg and does not rise >50% (Akkara 2025). In a 2025 cohort, the serum osmolality cutoff of ≥300 mOsm/kg had a sensitivity of 76.19% and a specificity of 76.92%, and a serum sodium ≥148 mmol/L excluded primary polydipsia with 100% specificity (Akkara 2025).
  • Hypertonic saline-stimulated copeptin. In 141 patients with hypotonic polyuria, copeptin >4.9 pmol/L once plasma sodium reached ≥150 mmol/L gave a correct diagnosis in 96.5%. The indirect water deprivation test was correct in 76.6%. The saline test separated primary polydipsia from partial AVP deficiency (central diabetes insipidus) in 95.2% (Fenske 2018).
  • Arginine-stimulated copeptin. Copeptin rose with arginine in healthy adults and primary polydipsia and rose minimally in AVP deficiency (diabetes insipidus). A cutoff of 3.8 pmol/L at 60 minutes gave a pooled accuracy of 93%, with sensitivity 93% and specificity 92% (Winzeler 2019).
  • Head-to-head trial. In 158 patients, diagnostic accuracy was 74.4% for arginine-stimulated copeptin (3.8 pmol/L at 60 minutes) and 95.6% for hypertonic saline-stimulated copeptin (4.9 pmol/L at sodium >149 mmol/L). Arginine-stimulated copeptin ≤3.0 pmol/L indicated AVP deficiency with 90.9% specificity, and >5.2 pmol/L indicated primary polydipsia with 91.4% specificity (Refardt 2023).

Tests for hypotonic polyuria with diagnostic cutoffs.

Test Cutoff Interpretation Accuracy Source
Indirect water deprivation Urine osmolality <300 mOsm/kg, rise >50% after desmopressin Complete AVP deficiency 76.6% overall Akkara 2025; Fenske 2018
Indirect water deprivation Urine osmolality <300 mOsm/kg, rise ≤50% after desmopressin AVP resistance 76.6% overall Akkara 2025; Fenske 2018
Hypertonic saline copeptin >4.9 pmol/L at sodium ≥150 mmol/L Primary polydipsia 96.5% Fenske 2018
Arginine copeptin at 60 min 3.8 pmol/L ≤3.8 AVP deficiency; >3.8 primary polydipsia 93% (pooled); 74.4% (head-to-head) Winzeler 2019; Refardt 2023
Arginine copeptin at 60 min ≤3.0 or >5.2 pmol/L AVP deficiency or primary polydipsia, each with about 91% specificity Not applicable Refardt 2023

Potassium disorders: causes, urine potassium indices and pseudohyperkalemia

  • Shift or deficit. In 43 patients with hypokalemia and paralysis, the transtubular potassium gradient and the urine potassium-to-creatinine ratio separated hypokalemic periodic paralysis (a shift into cells) from paralysis with a large potassium deficit. Rebound hyperkalemia >5 mmol/L occurred in 63% of periodic paralysis patients after a mean of 63 mmol of potassium chloride (Lin 2004).
  • Renal or extrarenal loss. In 130 patients with hypokalemia, fractional excretion of potassium from a spot urine predicted renal potassium loss at a cutoff of 9.29%, with sensitivity 80.6% and specificity 85.7%. It correlated best with measured 24-hour urine potassium (Li 2020).
  • Transtubular potassium gradient. About twice as much urea reaches the distal convoluted tubule as is excreted, and a large quantity of urea is reabsorbed in the inner medullary collecting duct. The TTKG assumption of no appreciable osmole reabsorption downstream of the cortical collecting duct is therefore invalid (Kamel 2011).
  • Drug-induced hyperkalemia. High-dose trimethoprim raised serum potassium by 0.6 mmol/L, and 15 of 30 patients exceeded 5 mmol/L. Trimethoprim blocks apical sodium channels in the distal nephron in the same way as amiloride and inhibits potassium secretion (Velázquez 1993).
  • Reverse pseudohyperkalemia. In leukemic patients, heparin plasma potassium can exceed serum potassium because heparin damages cell membranes (Meng 2015). In a patient with chronic lymphocytic leukemia and hyperleukocytosis, pneumatic tube transport raised heparin plasma potassium, and serum potassium was lower than plasma potassium (Garwicz 2012).
  • Hyperkalemia thresholds. The UK Kidney Association defines hyperkalemia as serum potassium ≥5.5 mmol/L and grades it as mild (5.5–5.9 mmol/L), moderate (6.0–6.4 mmol/L) and severe (≥6.5 mmol/L) (Alfonzo 2026). No standardized severity grading exists internationally, and serum potassium is usually higher than plasma potassium (Lindner 2020). Pseudohyperkalemia is present when serum potassium exceeds paired plasma potassium by >0.4 mmol/L (Alfonzo 2026).

Causes of hyperkalemia by mechanism.

Mechanism Causes Source
Pseudohyperkalemia (in vitro) Hemolysis; delayed transport or poor storage, including cold storage; thrombocytosis, leukocytosis and erythrocytosis; fist clenching or prolonged tourniquet; K2-EDTA contamination Lindner 2020; Alfonzo 2026
Shift out of cells Acute metabolic acidosis; insulin deficiency, including DKA; β-blockers, α-agonists, digoxin and succinylcholine; mannitol (solvent drag); tumor lysis and rhabdomyolysis; hyperkalemic periodic paralysis (SCN4A gain of function) Hunter 2019; Alfonzo 2026; Lindner 2020; D'Ambrosio 2026
Reduced GFR Acute kidney injury; CKD, typically once eGFR falls below 15 mL/min Hunter 2019
Low renin or aldosterone Hyporeninemic hypoaldosteronism (type 4 RTA) in diabetes; adrenal disease; β-blockers and NSAIDs (low renin); ACE inhibitors, ARBs and aliskiren; heparin and ketoconazole (low aldosterone synthesis) Hunter 2019; Ertek 2025
Aldosterone resistance or distal sodium channel block Spironolactone and eplerenone; amiloride, triamterene, trimethoprim and pentamidine (ENaC block); calcineurin inhibitors; pseudohypoaldosteronism type 1 (ENaC or mineralocorticoid receptor loss of function); pseudohypoaldosteronism type 2 (Gordon syndrome: hypertension, hyperkalemia and hyperchloremic acidosis) Hunter 2019; Ahn 2026
Increased intake Potassium supplements, potassium-based salt substitutes, intravenous penicillin; intake alone seldom causes hyperkalemia with normal kidney function Lindner 2020; Hunter 2019
  • Electrocardiographic monitoring. The KDIGO Controversies Conference recommended cardiac monitoring and a 12-lead ECG for potassium >6.0 mmol/L (Lindner 2020).
  • Mineralocorticoid excess. Primary aldosteronism, exogenous mineralocorticoids, licorice, apparent mineralocorticoid excess and Liddle syndrome cause hypokalemic metabolic alkalosis with an expanded extracellular volume (Emmett 2020). Their hormone testing is taught in Endocrine Function Tests: Thyroid, Adrenal and Pituitary.

Total carbon dioxide and calculated bicarbonate

  • Measured total CO2. Serum total CO2 is the sum of bicarbonate, carbonate and dissolved CO2, and it approximates bicarbonate because most blood CO2 is bicarbonate (Hirai 2019). Chemistry panel total CO2 is usually about 2 mmol/L higher than the bicarbonate calculated on a blood gas, and the anion gap is calculated from the chemistry panel total CO2 (Achanti 2023).
  • Calculated bicarbonate. Blood gas analyzers derive bicarbonate from the Henderson-Hasselbalch equation, pH = 6.1 + log([HCO₃⁻] ÷ (0.03 × pCO₂)), with pCO₂ in mm Hg. The same equation checks a result for internal consistency (Fong 2026).
  • Spurious low bicarbonate. Prolonged exposure of the sample to air produces a spurious normal anion gap acidosis (Fong 2026).
  • Underfilled tubes. In 10-mL clot tubes, mean bicarbonate fell from 21.7 mmol/L (10 mL) to 19.4 (3 mL) and 16.3 mmol/L (1 mL), and the anion gap rose from 16.7 to 19.1 mmol/L. Venting did not correct the effect, so tubes are filled completely to avoid a pseudometabolic acidosis (Herr 1992).
  • Hyperchloremic acidosis from saline. Infusion of 6 L of 0.9% saline lowered arterial pH to slightly below 7.35 in two small studies. The acidosis results from dilution of serum bicarbonate without a change in pCO₂ (Achanti 2023).

Anion gap: calculation, albumin correction and low values

  • Normal value. The anion gap is positive because unmeasured anions, mainly albumin, exceed unmeasured cations. A normal anion gap is 6–12 mmol/L, and 10 mmol/L is a practical normal value (Achanti 2023). The normal value varies with the electrolyte methods used and between individuals (Kraut 2007).
  • Thresholds. An anion gap >18 mmol/L, regardless of pH, almost always indicates an organic acid. Retained sulfate and phosphate in kidney failure raise the gap, rarely above 18 (Achanti 2023). In a single-centre cohort of 16,475 patients summarized by Fong 2026, an anion gap >19 mmol/L best predicted lactic acidosis or ketoacidosis (sensitivity 81%, specificity 77%). A cutoff of ≥15 mmol/L gave a sensitivity of 98% and a specificity of 34% (Fong 2026).
  • Albumin correction. Each 1 g/L fall in albumin lowers the observed anion gap by 0.25 mmol/L, or 2.5 mmol/L per 1 g/dL (Figge 1998). Uncorrected hypoalbuminemia can conceal an anion gap acidosis: a gap of 13 mmol/L with albumin 2 g/dL corrects to 18 mmol/L (Haber 2023).
  • Low anion gap. Low values most commonly indicate laboratory error or hypoalbuminemia. They also occur with paraproteinemia and with lithium, bromide or iodide intoxication (Kraut 2007). IgG paraproteins have an isoelectric point above physiologic pH and carry a positive charge (Haber 2023). Lithium is balanced by a compensatory rise in chloride (Haber 2023).
  • Halide interference. Bromide is read as chloride by the chloride ion-selective electrode. A patient taking a bromide sedative had chloride of 176 mmol/L and an anion gap of −60 mmol/L, with serum bromide 352 mg/dL (Vasuyattakul 1995). Salicylate can also produce pseudohyperchloremia and a negative anion gap with an aging chloride electrode (Achanti 2023).

Anion gap with albumin correction.

Quantity Formula Source
Anion gap (mmol/L) Na − (Cl + total CO₂) Achanti 2023
Albumin-corrected anion gap, albumin in g/L Observed gap + 0.25 × (normal albumin − observed albumin) Figge 1998
Albumin-corrected anion gap, albumin in g/dL Observed gap + 2.5 × (4 − observed albumin) Haber 2023

Causes of an abnormal anion gap (Fong 2026, with sources as marked).

Pattern True causes Spurious causes Source
High anion gap Lactic acidosis; diabetic, alcoholic and starvation ketoacidosis; late renal insufficiency; toxic alcohols (methanol, ethylene glycol, diethylene glycol, propylene glycol); salicylate; D-lactic acidosis; 5-oxoproline Severe hyperphosphatemia; severe hypertriglyceridemia; hyperalbuminemia; IgA paraprotein Fong 2026
High anion gap, other reported causes Metabolic alkalosis Laboratory error Kraut 2007
Low anion gap IgG paraprotein; hypercalcemia; hypermagnesemia; lithium; polymyxin B Hypoalbuminemia; pseudohyperchloremia from bromide- or iodide-containing drugs Fong 2026; Haber 2023
  • Mnemonic. The GOLDMARK mnemonic lists glycols, 5-oxoproline, L-lactate, D-lactate, methanol, aspirin, renal failure and ketoacidosis (Achanti 2023). GOLDMARK was proposed to replace older mnemonics such as MUDPILES, which include causes that have become exceedingly rare (Zand Irani 2020).

Delta gap and the delta ratio in mixed metabolic disorders

  • Principle. A 1:1 change between the rise in anion gap (ΔAG) and the fall in bicarbonate (ΔHCO₃⁻) has been used to detect a second metabolic disorder in high anion gap acidosis (Kraut 2007).
  • Limitations. The mean ΔAG/ΔHCO₃⁻ ratio is close to 1, but its range is wide, so its use in individual patients is problematic (Rastegar 2007).

Delta gap and corrected bicarbonate.

Calculation Result Interpretation Source
Delta gap = ΔAG − ΔHCO₃⁻ > +6 Coexisting metabolic alkalosis Wrenn 1990
Delta gap = ΔAG − ΔHCO₃⁻ < −6 Coexisting hyperchloremic (normal gap) acidosis Wrenn 1990
Total CO₂ + (anion gap − 10) >28 mmol/L Likely concurrent metabolic alkalosis Achanti 2023
Anion gap >30 mmol/L (delta gap >20) Almost always an underlying metabolic alkalosis Achanti 2023

Osmolality and the osmolal gap

  • Calculation and methods. The calculated osmolality formula, the osmolal gap definition and the freezing point and vapor pressure methods are taught in Analytical Methods and Immunoassays in Clinical Chemistry.
  • Normal value. The normal osmolal gap with the most commonly used formula is up to about 10 mOsm/kg. Measured osmolality is in mOsm/kg H₂O and calculated osmolarity in mOsm/L, a difference usually ignored (Garrett 2026).
  • Variability. The osmolal gap predicted toxic volatiles accurately under controlled conditions, but decision points ranged from +10 to +33 mOsm/kg depending on the formula. Mean patient gaps rose by 12 mOsm/kg between 1996 and 2004, and a reference interval of −10 to +10 mOsm/kg gave poor long-term accuracy (Krahn 2006).
  • Causes of a high gap. A high gap establishes pseudohyponatremia or indicates endogenous or exogenous solutes absent from the formula. Urea is in the formula and does not raise the gap (Garrett 2026). The ethanol contribution is taught in Analytical Methods and Immunoassays in Clinical Chemistry, and the time course of the gap in toxic alcohol poisoning in Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring.

Blood gas analysis: electrodes, derived values and specimen errors

  • Electrodes. The pO₂ electrode is a membrane-covered polarographic (Clark) electrode, and the pCO₂ electrode is a pH electrode behind a CO₂-permeable membrane (Severinghaus 1986a, 1986b).
  • Base excess. Base excess is the amount of acid or base needed to return blood to pH 7.40 at pCO₂ 40 mm Hg and 37 °C. Standard base excess (SBE) = 0.9287 × [HCO₃⁻ − 24.4 + 14.83 × (pH − 7.40)], with a normal range of −2 to +2 mmol/L. The equation assumes normal albumin and phosphate (Köner 2026).
  • Collection. Gas-tight syringes are required. Plastic syringes become more permeable to oxygen when chilled, so icing of plastic syringes is no longer recommended (Baird 2013).
  • Air bubbles. Equilibration with air moves pO₂ toward about 150 mm Hg (20 kPa). Prolonged exposure lowers pCO₂ and raises pH, and the higher pH lowers ionized calcium (Baird 2013).
  • Heparin. Syringes contain lyophilized balanced heparin. Excess liquid heparin dilutes bicarbonate and pCO₂, and its own pO₂ of about 150 mm Hg alters pO₂ results (Baird 2013).
  • Time. The IFCC recommends analysis within 15 minutes for samples in plastic syringes at room temperature when pO₂ or oxygen saturation is required, and within 30 minutes otherwise (Baird 2013). At 22 °C, pO₂ falls by 2 mm Hg/hour, pCO₂ rises by 1 mm Hg/hour and pH falls by 0.02–0.03/hour, more with leukocytosis (Baird 2013). In five sample types, pO₂ and lactate were the least stable analytes, and chilling did not lengthen stability for every sample type and analyte (Higgins 2023).
  • Temperature correction. Instruments measure at 37 °C. Lower patient temperature lowers pO₂ and pCO₂ and raises pH because gas solubility increases. Use of temperature-corrected values is controversial, and when a corrected value is reported, the uncorrected value is reported with it (Baird 2013).
  • Interferences. High oxygen-affinity hemoglobins, fetal hemoglobin, methylene blue and some vitamin B12 preparations interfere with oximetry. Massive hemolysis raises potassium with little effect on pH and gas tensions (Baird 2013).
  • Venous samples. In hemodynamically stable patients, arterial and venous specimens differ minimally and either can be used. An arterial specimen is recommended in shock (Achanti 2023).

Stepwise interpretation and expected compensation

  1. History and examination (Achanti 2023).
  2. Blood gas: acidemia or alkalemia, and a metabolic or respiratory process. When pCO₂ and bicarbonate move in the same direction, a single disturbance is usual. Opposite directions indicate a mixed disturbance or laboratory error (Achanti 2023).
  3. Compensation is compared with expected values. Compensation almost never returns pH to normal (Achanti 2023).
  4. The anion gap is calculated at any pH and corrected for albumin (Achanti 2023).
  5. The rise in anion gap is compared with the fall in total CO₂ (Achanti 2023).
  6. In high anion gap acidosis, the osmolal gap and the delta gap are evaluated. In normal anion gap acidosis, the urine anion gap is evaluated. Metabolic alkalosis is evaluated with urine chloride (Morikawa 2025).

Expected compensation in primary acid-base disorders (Winters formula and compensation rules).

Primary disorder Expected compensation Source
Metabolic acidosis pCO₂ = 1.5 × HCO₃⁻ + 8 ± 2 (Winters formula) Achanti 2023; Albert 1967
Metabolic acidosis pCO₂ = HCO₃⁻ + 15 Achanti 2023
Metabolic alkalosis pCO₂ rises 0.5–0.7 mm Hg per 1 mmol/L rise in HCO₃⁻ Achanti 2023
Metabolic alkalosis pCO₂ ≈ HCO₃⁻ + 10 for HCO₃⁻ 30–50 mmol/L Emmett 2020
Acute respiratory acidosis HCO₃⁻ rises 1 mmol/L per 10 mm Hg rise in pCO₂ Achanti 2023
Chronic respiratory acidosis HCO₃⁻ rises 3.5 mmol/L per 10 mm Hg rise in pCO₂ Achanti 2023
Acute respiratory alkalosis HCO₃⁻ falls 2 mmol/L per 10 mm Hg fall in pCO₂ Achanti 2023
Chronic respiratory alkalosis HCO₃⁻ falls 5 mmol/L per 10 mm Hg fall in pCO₂ Achanti 2023
  • Severe alkalosis. Above a bicarbonate of 55 mmol/L, pCO₂ may rise markedly, probably from respiratory muscle weakness caused by severe hypokalemia (Emmett 2020).

Physicochemical (Stewart) approach

  • Independent variables. Stewart defined three independent variables in body fluids: pCO₂, the strong ion difference (SID) and total weak acid, mainly protein. Bicarbonate and hydrogen ion are dependent variables (Stewart 1983).
  • Comparison with the bicarbonate approach. A 2023 review found no advantage of the Stewart method over the classic approach (Achanti 2023).
  • Simplified partitioning. In the "Stewart light" method, the strong ion effect on SBE is [Na⁺ − Cl⁻] − 35, the albumin effect is 0.3 × (40 − albumin in g/L), and the unexplained remainder of SBE is attributed to unmeasured ions. Each 10 g/L fall in albumin raises SBE by about 3 mmol/L, so hypoalbuminemia is an alkalinizing process (Duška 2026).

Base excess partitioning ("Stewart light").

Component Formula Source
Standard base excess 0.9287 × [HCO₃⁻ − 24.4 + 14.83 × (pH − 7.40)] Köner 2026
Strong ion component SBE_SID = [Na⁺ − Cl⁻] − 35; reference 35 raised 1.5 per 0.1 pH below 7.40 and lowered 1.5 per 0.1 pH above 7.40 when pH is outside 7.30–7.50 Duška 2026
Albumin component SBE_Alb = 0.3 × (40 − albumin g/L) Duška 2026
Unmeasured ions SBE_UI = SBE − SBE_SID − SBE_Alb Duška 2026

Metabolic acidosis: anion gap, normal gap and urine indices

  • Normal anion gap causes. Gastrointestinal bicarbonate loss (diarrhea, pancreatic fistula, urinary diversion), renal bicarbonate loss (early renal insufficiency, renal tubular acidosis, carbonic anhydrase inhibitors, hypoaldosteronism), chloride-rich fluid infusion, recovery from ketoacidosis with excretion of the acid anion and compensation for respiratory alkalosis (Fong 2026).
  • Urine anion gap. Urine sodium plus potassium minus chloride was negative in normal subjects given ammonium chloride (−27 mmol/L) and in diarrhea (−20 mmol/L, urine pH >5.3). It was positive in classic distal RTA (23 mmol/L), hyperkalemic distal RTA (30 mmol/L) and selective aldosterone deficiency (39 mmol/L). The gap correlated inversely with urine ammonium (Batlle 1988). RTA patterns are taught in Liver, Kidney and Gastrointestinal Function Tests.
  • Urine osmolal gap. Urine osmolal gap = measured urine osmolality − [2 × (Na⁺ + K⁺) + urea + glucose], and urine ammonium ≈ urine osmolal gap ÷ 2. In 36 patients with non-dialysis CKD, the gap ÷ 2 correlated with measured ammonium (r = 0.925) but overestimated it by a mean of 4.7 mmol/L (Fujimaru 2021).
  • Ketoacidosis. Diabetic, alcoholic and starvation ketoacidosis raise the anion gap (Fong 2026). Ketone testing and DKA criteria are taught in Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup.
  • 5-Oxoproline (pyroglutamic acid). In 22 reported adults, 21 had major acetaminophen exposure, 18 were women, and most were malnourished with kidney dysfunction. The disorder is underdiagnosed because 5-oxoproline assays are not readily available (Fenves 2006). Acetaminophen levels are usually therapeutic or low. The proposed mechanism is an ATP-depleting futile 5-oxoproline cycle activated by depletion of glutathione and cysteine (Emmett 2014). In one patient, urine organic acid analysis identified 5-oxoproline, and the urine anion gap was about +49 mmol/L (Duewall 2010). Septic patients have higher pyroglutamic acid and lower glutathione than healthy controls, so even acute acetaminophen use may carry a risk (Achanti 2023).

Metabolic alkalosis: urine chloride, Bartter and Gitelman syndromes

  • Generation and maintenance. Metabolic alkalosis requires a phase of base gain or acid loss and a maintenance phase in which the kidney cannot excrete bicarbonate. Urine chloride narrows the cause when history and examination do not (Achanti 2023).
  • Gastric alkalosis. Volume depletion and secondary hyperaldosteronism maintain bicarbonate reabsorption after vomiting or gastric suction. Hypokalemia worsens the alkalosis, which persists until volume and potassium are restored (Achanti 2023).
  • Other causes in critical illness. Diuretic contraction, base-containing fluids, rebound after organic acidosis, citrate from more than 8–10 units of red cells or regional citrate anticoagulation, and post-hypercapnic alkalosis after rapid ventilation of chronic CO₂ retention (Achanti 2023).

Metabolic alkalosis grouped by volume status and urine chloride (Emmett 2020).

Group Urine chloride Causes Source
Extracellular volume contracted <20 mmol/L Vomiting or gastric suction; congenital chloride diarrhea; post-hypercapnia; cystic fibrosis with heavy sweating; diuretics after the effect has dissipated; some villous adenomas Emmett 2020
Extracellular volume expanded >20 mmol/L Primary aldosteronism; severe Cushing syndrome, especially ectopic ACTH; exogenous mineralocorticoids; licorice or carbenoxolone; apparent mineralocorticoid excess; renin-secreting tumors; 11β-hydroxylase and 17α-hydroxylase deficiency; Liddle syndrome Emmett 2020
Extracellular volume contracted with a tubular defect >20 mmol/L Active thiazide or loop diuretics; Bartter syndrome; Gitelman syndrome Emmett 2020
Other Variable Severe potassium deficiency; milk-alkali syndrome Emmett 2020
  • Bartter syndrome. Bartter syndrome is an inherited salt-losing tubulopathy with defective salt reabsorption in the thick ascending limb. It causes secondary hyperaldosteronism with hypokalemic, hypochloremic metabolic alkalosis and low to normal blood pressure, and five causative genes are described (Konrad 2021). It resembles a loop diuretic lesion (Emmett 2020). Bartter types I (SLC12A1) and II (KCNJ1) cause hypercalciuria and medullary nephrocalcinosis. Classic type III (CLCNKB) causes hypochloremia with mild hypomagnesemia (Seyberth 2011). Bartter syndrome is often accompanied by hypercalciuria, and Gitelman syndrome by hypocalciuria (Kardalas 2018).
  • Gitelman syndrome. Gitelman syndrome is a recessive salt-losing tubulopathy caused by inactivating SLC12A3 variants in the thiazide-sensitive sodium-chloride cotransporter. It causes hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria and is usually detected in adolescence or adulthood (Blanchard 2017).

Respiratory acidosis and alkalosis

  • Respiratory acidosis. It results from a rise in pCO₂ from hypoventilation, increased dead space or, less commonly, increased CO₂ production. Chronic lung disease is the most common cause in critical care, and permissive hypercapnia in lung injury is an increasing cause (Achanti 2023).
  • Respiratory alkalosis. Causes in critical illness include sepsis, cirrhosis, hypoxemia from heart failure, asthma, pulmonary embolism and interstitial lung disease, anxiety, inadequate sedation and salicylate overdose (Achanti 2023).
  • Mixed pattern of salicylate toxicity. Salicylate causes a respiratory alkalosis by stimulating the respiratory center together with an anion gap metabolic acidosis (Achanti 2023).
  • Chronic compensation. The electrolyte pattern of compensated chronic respiratory acidosis (high bicarbonate and low chloride) is identical to that of metabolic alkalosis, and blood pH separates them (Emmett 2020).

Lactate and lactic acidosis

  • Definition. L-lactic acidosis is an L-lactate level >4 mmol/L and is the most common metabolic acidosis in critically ill patients. The anion gap, even after albumin correction, predicts lactate poorly, so lactate is measured directly (Achanti 2023). A normal lactate range is 0.5–1.8 mmol/L (Cardenas Fimbres 2026).
  • Type A and type B. Type A lactic acidosis results from tissue hypoperfusion or hypoxia. Type B occurs despite adequate perfusion and oxygenation (Cardenas Fimbres 2026).

Causes of type B lactic acidosis (Cardenas Fimbres 2026).

Group Examples Source
Comorbid disease Hepatic dysfunction; diabetic ketoacidosis; Warburg effect in malignancy; thiamine deficiency Cardenas Fimbres 2026
Medications and toxins Albuterol; epinephrine; theophylline; corticosteroids; nucleoside reverse transcriptase inhibitors; propofol; ethanol and methanol; cyanide; salicylate; metformin Cardenas Fimbres 2026
Inborn errors Pyruvate carboxylase deficiency; mitochondrial myopathies; glycogen storage diseases; long-chain fatty acid oxidation disorders Cardenas Fimbres 2026
  • Metformin. Metformin raises lactate in a concentration-dependent manner by inhibiting mitochondrial respiration, mainly in the liver. Metformin-associated lactic acidosis usually requires a high metformin level, as in renal impairment, plus a second event such as sepsis or hypoperfusion (DeFronzo 2016). Its incidence is 3–10 per 10,000 patient-years, and renal replacement therapy is started when lactate is >20 mmol/L or pH ≤7.0 (Achanti 2023).
  • D-lactate. D-lactic acidosis occurs mainly in short bowel syndrome and presents with Kussmaul breathing, confusion, slurred speech and gait disturbance. It also follows large amounts of propylene glycol (Bianchetti 2018). D-lactate is not measured by the usual L-lactate assay, so the anion gap exceeds what the measured lactate explains (Achanti 2023).
  • Specimen handling. Delayed centrifugation raises lactate from continued anaerobic metabolism of blood cells. In unspun sodium fluoride/potassium oxalate tubes, lactate increased by a maximum of 9.8% at 48 hours at room temperature, within allowable limits (Stevic 2024). Whole-blood metabolism during transport consumes oxygen and glucose and produces lactate and acidosis (Baird 2013).

Co-oximetry and the limits of pulse oximetry

  • Principle. A CO-oximeter measures oxyhemoglobin and carboxyhemoglobin (and other hemoglobin species) spectrophotometrically as percentages of total hemoglobin on an arterial sample (Barker 1987). Hemoglobin species detail is taught in Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia.
  • Carboxyhemoglobin. As carboxyhemoglobin rose to 75% in dogs, two pulse oximeters read >90% while oxyhemoglobin fell below 30%. The pulse oximeter reading approximated the sum of carboxyhemoglobin and oxyhemoglobin (Barker 1987).
  • Methemoglobin. Pulse oximeter readings overestimated fractional saturation in proportion to methemoglobin until about 35%, then plateaued at 84–86% (Barker 1989).
  • Saturation gap. A saturation gap is a low pulse oximetry reading with a preserved arterial oxygen tension, and it indicates a possible dyshemoglobinemia (Santiago 2026).
  • Pulse CO-oximetry. An eight-wavelength pulse oximeter measured carboxyhemoglobin within ±2% over 0–15% and methemoglobin within 0.5% over 0–12% in volunteers (Barker 2006).
  • Fetal hemoglobin. In neonatal blood, fetal hemoglobin falsely raised spectrophotometric carboxyhemoglobin in proportion to its concentration, and gas chromatography was unaffected (Vreman 1988).
  • Occult hypoxemia. Occult hypoxemia is an arterial saturation <88% with a pulse oximeter reading ≥92%. In 30,039 paired readings, its unadjusted probability was 15.6% in White patients and 19.6% in Black patients (Valbuena 2022). In inpatients receiving supplemental oxygen with pulse oximetry 92–96%, arterial saturation was <88% in 11.7% of measurements in Black patients and 3.6% in White patients. In intensive care patients at 178 hospitals, the corresponding values were 17.0% and 6.2% (Sjoding 2020).
  • Poisonings. Clinical management of carbon monoxide and methemoglobin poisoning is taught in Toxic Alcohols, Acetaminophen, Salicylate and Other Poisonings: Laboratory Evaluation and Monitoring.

anion gap calculator with albumin correction, corrected bicarbonate and Winters formula

Cardiac Biomarkers: High-Sensitivity Troponin, the Fourth Universal Definition of Myocardial Infarction and Natriuretic Peptides

Definition. Cardiac troponin I (cTnI) and troponin T (cTnT) are components of the contractile apparatus of cardiomyocytes and are the preferred biomarkers for detecting myocardial injury (Thygesen 2018). A cTn value above the 99th percentile upper reference limit (URL) defines myocardial injury, and acute myocardial infarction (MI) requires a rise and/or fall of cTn with evidence of acute myocardial ischemia (Thygesen 2018). B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are quantitative plasma markers of hemodynamic cardiac stress, used mainly to exclude heart failure (HF) (Mueller 2019; Heidenreich 2022).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (heterophile antibodies, biotin interference and the FDA biotin-troponin communication) Related page: Diagnostic Enzymes and Serum Tumor Markers (CK isoenzymes and macro-CK) Related page: Liver, Kidney and Gastrointestinal Function Tests (eGFR equations and CKD categories) Related page: Lipids, Lipoproteins and Cardiovascular Risk Markers: LDL-C Equations, ApoB and Lp(a) (hs-CRP, homocysteine, lipoprotein(a) and apolipoprotein B as cardiovascular risk markers) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (hemolysis and point-of-care testing)

Cardiac troponin biology, tissue specificity and release kinetics

  • Troponin complex. The troponin complex of the thin filament contains troponin I (about 24 kDa), the inhibitory subunit, troponin T (about 35–36 kDa), the tropomyosin-binding subunit, and troponin C (about 18 kDa), the calcium-binding subunit. cTnI and cTnT have cardiac-specific isoforms with a cardiac N-terminal extension. Troponin C is also expressed in slow-twitch skeletal muscle (Mair 2025).
  • Cardiac expression. cTnI and cTnT are expressed almost exclusively in the heart. Increases in cTnI have not been reported after injury to noncardiac tissues (Thygesen 2018).
  • cTnT and skeletal muscle. Injured skeletal muscle expresses proteins detected by the cTnT assay, so some cTnT elevations arise from skeletal muscle (Thygesen 2018). In 211 patients with skeletal muscle disorders, median hs-cTnT (Elecsys) was 16 ng/L versus 5 ng/L in controls, and hs-cTnT exceeded the upper limit of normal in 55% versus 13%. Concentrations measured by three hs-cTnI assays were similar to controls (du Fay de Lavallaz 2022).
  • Mechanisms of release. Proposed mechanisms include normal myocyte turnover, apoptosis, release of cTn degradation products, increased membrane permeability, release of membranous blebs and necrosis. The mechanism cannot be identified from the cTn value (Thygesen 2018).
  • Release kinetics. cTn rises rapidly after myocardial injury (Mair 2025). The downslope of the time–concentration curve is much slower than the upslope, and increased cTn values can often be detected for days after an acute event (Thygesen 2018).
  • Peak timing. After early reperfusion, cTnT and cTnI peak about 12 h after symptom onset. When early reperfusion fails, cTnI peaks about 24 h after onset and cTnT reaches its maximum several days after the infarction. cTnT elevation typically lasts a couple of days longer than cTnI elevation (Mair 2025).
  • Kinetics after primary PCI for STEMI. The first peak occurred at a median of 11.8 h for hs-cTnT (Roche) and hs-cTnI (Abbott) and at 10.7 h for total creatine kinase. hs-cTnI and creatine kinase then fell in a nearly log-linear fashion. hs-cTnT followed a biphasic curve with a second peak at a median of 76.9 h, and at 77 h it had fallen from its peak about half as much as the other markers (Laugaudin 2016).
  • Elimination. The true elimination half-life ranged from 134.1 min (Elecsys hs-cTnT) to 239.7 min (Vitros hs-cTnI). Clearance was 77.0 mL/min for cTnT and 40.3–52.7 mL/min for cTnI. The clinically observed post-MI half-life of 7–20 h reflects continued release together with elimination (Kristensen 2024).
  • Exercise. After strenuous endurance exercise, cTn peaks usually remain below 3 times the URL and return below the URL within 48–72 h (Mair 2025).

High-sensitivity troponin assays and the 99th percentile upper reference limit

Analytical criteria for cardiac troponin assays (Fourth Universal Definition 2018; AACC Academy/IFCC 2018).

Characteristic Requirement or finding Source
Definition of a high-sensitivity assay Measures cTn above the limit of detection in >50% of healthy individuals Thygesen 2018
Imprecision at the 99th percentile URL ≤10% CV for hs-cTn assays; 10%–20% acceptable for clinical use; >20% not used Thygesen 2018
Reporting units Whole numbers in ng/L (1 ng/L = 1 pg/mL); units of contemporary and hs assays are not mixed Thygesen 2018
Reference limits Sex-specific 99th percentile URLs recommended for hs-cTn assays Thygesen 2018; Wu 2018
Analytical sensitivity Limit of detection varies 10-fold between assays; assays are not standardized, so values are not interchangeable Thygesen 2018
Reference population IFCC process; at least 400 adults; imaging screening not required Coyle 2025; Thygesen 2018
  • Assay-specific values. The 99th percentile URL is assay specific and is listed in package inserts and in the IFCC C-CB reference tables, which also list interferences for cTn and natriuretic peptide assays (Thygesen 2018; IFCC C-CB 2026).
  • Example: Elecsys hs-cTnT. The 99th percentile URL is 14 ng/L, the limit of detection 5 ng/L and the limit of blank 3 ng/L (Yildirim 2025).
  • Example: Architect hs-cTnI. Sex-specific 99th percentile URLs of 15.6 ng/L (female) and 34.2 ng/L (male) were used in one multicenter study, with a limit of detection of 1.1 ng/L (Lin 2024). Another study used a uniform 99th percentile of 26.2 ng/L (Bima 2025).
  • Point-of-care assay reporting. The FDA-cleared Pathfast hs-cTnI point-of-care assay reports concentrations only down to the limit of quantification (4 ng/L). The 0/1-hour algorithm with an FDA-compliant direct rule-out cutoff of <4 ng/L (the derived cutoff was <3 ng/L) gave a negative predictive value (NPV) of 100% in 1532 patients (Koechlin 2025).
  • Point-of-care assay in primary care. With the TriageTrue hs-cTnI point-of-care assay run by nonlaboratory staff, a single sample assigned 65% of 199 patients to direct rule-out, compared with 32% for central-laboratory hs-cTnT. After the 1-h sample, rule-out was 73% and 74%, and the CV was <10% (Johannessen 2026).
  • Age. hs-cTn 99th percentile URLs shift to higher values with comorbidities and age over 60 years. The Fourth Universal Definition does not recommend age-dependent cutoffs (Thygesen 2018).
  • Age-specific thresholds (proposal only). A 2025 viewpoint proposed age-specific 99th percentile URLs for a future fifth universal definition, citing NHANES data in which adults ≥60 years had consistently higher URLs (Coyle 2025). No fifth universal definition has been published.
  • Variables that change hs-cTn concentrations. Age, renal function and time from chest pain onset each change hs-cTn concentrations by up to 300%, and sex by about 40% (Byrne 2023).
  • Sex-specific thresholds in ESC 2023. Data on sex-specific hs-cTn thresholds are controversial and have not shown a clear clinical benefit. Uniform cutoffs remain the standard of care until tools combining age, eGFR, time from symptom onset and sex are available (Byrne 2023).

Serial troponin change and acute versus chronic myocardial injury

  • Acute and chronic injury. Myocardial injury is acute when cTn values rise and/or fall. Stable values (≤20% variation) above the 99th percentile URL indicate chronic injury in the appropriate clinical context (Thygesen 2018).
  • Biological variation. The conjoint analytical and biological variation of hs-cTn assays is 50%–60%, and a change of this size has been suggested as the criterion when the baseline value is ≤99th percentile URL (Thygesen 2018).
  • Baseline above the URL. A change >20% is used when the initial value exceeds the 99th percentile URL (Thygesen 2018).
  • Absolute and relative change. Absolute changes are assay dependent and appear superior to relative percent changes with hs-cTn assays (Thygesen 2018).
  • Contemporary assays. A significant change is ≥3 standard deviations of the assay variation at the relevant concentration (Thygesen 2018).
  • Sampling times. cTn is drawn at first assessment (0 h) and 3–6 h later, or earlier with hs-cTn assays (Thygesen 2018). With contemporary assays the sampling interval is 3–6 h from emergency department arrival (Rao 2025).
  • Reinfarction. When cTn is elevated but stable or falling at the time of suspected reinfarction, reinfarction requires a >20% increase in a second sample drawn 3–6 h later, or earlier with more sensitive assays (Thygesen 2018). The 2012 definition used a rise of ≥20% in a sample drawn 3–6 h later (Thygesen 2012).
  • Chronic kidney disease. With hs-cTn assays, most patients with end-stage kidney disease have values above the 99th percentile URL. This is more frequent for hs-cTnT than for hs-cTnI. Renal clearance has only a minor effect on low cTn values (Thygesen 2018).

Rapid rule-out and rule-in pathways for suspected NSTEMI

ESC 2023 algorithms (current ESC rule)

  • Preferred algorithms. ESC 2023 recommends the 0 h/1 h algorithm (best option) or the 0 h/2 h algorithm (second-best option) with hs-cTn, in patients without an indication for immediate invasive angiography (Byrne 2023).
  • Triage. A very low initial value, or a low initial value with no 1-h or 2-h change, assigns the patient to rule-out. A high initial value or a 1-h or 2-h change assigns the patient to rule-in. Other patients enter the observe pathway (Byrne 2023).
  • Performance. The NPV in the rule-out pathway exceeded 99% in several large validation cohorts, and the positive predictive value (PPV) in the rule-in pathway was about 70%–75% (Byrne 2023).
  • Observe zone. Observe-zone patients have mortality comparable to rule-in patients. A third cTn measurement at 3 h is recommended (Byrne 2023).
  • Sampling rule. Samples at 0 h and 1 h are drawn regardless of pending results. This adds unnecessary measurements in about 10%–15% of patients with very low 0-h values and chest pain onset >3 h (Byrne 2023).
  • Assay-specific cutoffs. ESC 2023 states that the cutoffs are assay specific and lists them in its online Supplementary Table S4 (Byrne 2023).
  • Other biomarkers. ESC 2023 does not recommend biomarkers other than cTn for diagnosis of acute coronary syndrome (ACS) unless cTn is unavailable. CK-MB, myosin-binding protein C and copeptin may be clinically relevant alongside standard cTn, but their added value beyond hs-cTn is usually limited (Byrne 2023).

ESC 2020 assay-specific cutoffs (previous ESC guideline)

The ESC 2020 NSTE-ACS guideline published the cutoffs below in its main text. They apply irrespective of age and renal function. The very low cutoff allows rule-out on a single sample when chest pain began >3 h before presentation (Collet 2020; Byrne 2023).

ESC 2020 assay-specific cutoffs (ng/L) for the 0 h/1 h and 0 h/2 h algorithms (Collet 2020, Table 5).

Assay Very low (0 h) Low (0 h) No 1-h change High (0 h) 1-h change Low (0 h), 0 h/2 h No 2-h change 2-h change
hs-cTnT Elecsys (Roche) <5 <12 <3 ≥52 ≥5 <14 <4 ≥10
hs-cTnI Architect (Abbott) <4 <5 <2 ≥64 ≥6 <6 <2 ≥15
hs-cTnI Centaur (Siemens) <3 <6 <3 ≥120 ≥12 <8 <7 ≥20
hs-cTnI Access (Beckman Coulter) <4 <5 <4 ≥50 ≥15 <5 <5 ≥20
hs-cTnI Clarity (Singulex) <1 <2 <1 ≥30 ≥6 TBD TBD TBD
hs-cTnI Vitros (Clinical Diagnostics) <1 <2 <1 ≥40 ≥4 TBD TBD TBD
hs-cTnI Pathfast (LSI Medience) <3 <4 <3 ≥90 ≥20 TBD TBD TBD
hs-cTnI TriageTrue (Quidel) <4 <5 <3 ≥60 ≥8 TBD TBD TBD

TBD, to be determined. The very low and high cutoffs are identical in the 0 h/1 h and 0 h/2 h algorithms (Collet 2020).

  • Earlier ESC values. Studies applying the 2015 ESC 0 h/1 h algorithm used a very low Architect hs-cTnI cutoff of <2 ng/L and a rule-in cutoff of ≥52 ng/L. The 2020 values were <4 ng/L and ≥64 ng/L (Lin 2024).
  • Very early presenters. ESC 2020 advised an additional cTn at 3 h for patients presenting <1 h after chest pain onset and triaged to rule-out (Collet 2020).
  • Emergency department performance. In 3216 emergency department patients tested with hs-cTnT, the ESC 0 h/1 h algorithm assigned 54.4% to rule-out, 31.3% to observe and 12.3% to rule-in. Rule-out sensitivity and NPV were 100%, and rule-in PPV was 59.14% (Kudu 2025).
  • Primary care performance. In emergency primary care, a single hs-cTnT measurement assigned 24.1% of 995 patients to rule-out, rising to 63.8% after the 1-h sample. Length of stay fell by 2.2 h compared with a 0/4-hour protocol (Johannessen 2025).
  • Cancer and diagnostic accuracy. Among 8267 patients with chest pain, the 711 with cancer more often had AMI (26.8% versus 21.1%). hs-cTnT had lower diagnostic accuracy for NSTEMI in cancer (AUC 0.89 versus 0.94), and hs-cTnI did not (0.93 versus 0.95). Both ESC 0/1-h algorithms kept very high safety, with twice as many patients in the observe zone (Bima 2023).
  • Cancer-optimized cutoffs. Efficacy of the ESC 0 h/1 h algorithms was lower in patients with active or past cancer, with more than 40% in the observe zone. Cancer-optimized cutoffs raised efficacy from 58.6% to 68.0% for hs-cTnT and from 59.3% to 78.9% for hs-cTnI (Bima 2025).

ACC/AHA 2025 recommendations (current ACC/AHA rule)

  • Biomarker of choice. cTn is the biomarker of choice for possible cardiac injury, and hs-cTn assays are preferred because their sensitivity and NPV are greater (Rao 2025).
  • Serial testing. Clinical decision pathways use hs-cTn at presentation (0 h) and 1–2 h later. Pathways with assay-specific thresholds and a delta value identify very-low-risk patients (for example NPV >99.5%) (Rao 2025).
  • Single-sample pathways. When a pathway uses a single hs-cTn value, the sample is drawn at least 3 h after symptom onset (Rao 2025).
  • Assay knowledge. Clinicians are expected to know the limit of quantification, the 99th percentile URL and the criteria for significant change of the local assay. Men and women may have different hs-cTn cutoffs (Rao 2025).
  • Previous rule (AHA/ACC 2014). The 2025 guideline updates the 2013 ACCF/AHA STEMI and 2014 AHA/ACC NSTE-ACS guidelines (Rao 2025; Rao 2025 corrections; O'Gara 2013). In 2014, cTnI or cTnT measured with a contemporary assay was obtained at presentation and 3–6 h after symptom onset to identify a rising and/or falling pattern (Amsterdam 2014).

Single-sample rule-out evidence

  • hs-cTnT below the limit of detection. In a meta-analysis of 9241 patients from 11 cohorts, hs-cTnT <5 ng/L with a nonischemic ECG classified 30.6% as low risk, with a pooled sensitivity for AMI of 98.7% (Pickering 2017).
  • hs-cTnI <5 ng/L. In 4870 patients, hs-cTnI (Architect) <5 ng/L at presentation had an NPV of 99.6% for index MI or 30-day MI or cardiac death. The NPV was 99.4% in two validation cohorts (Shah 2015).

Fourth Universal Definition of Myocardial Infarction (2018)

  • Myocardial infarction. Acute MI is acute myocardial injury with clinical evidence of acute myocardial ischemia. Without evidence of ischemia, the diagnosis is myocardial injury (Thygesen 2018).

Clinical classification of MI (Fourth Universal Definition, Thygesen 2018).

Type Mechanism cTn criterion Additional criteria
1 Atherothrombotic coronary artery disease, usually plaque disruption Rise and/or fall, ≥1 value >99th percentile URL ≥1 of: ischemic symptoms, new ischemic ECG changes, new pathological Q waves, imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in an ischemic pattern, coronary thrombus at angiography or autopsy
2 Oxygen supply-demand imbalance unrelated to acute atherothrombosis Rise and/or fall, ≥1 value >99th percentile URL ≥1 of the type 1 clinical criteria except thrombus
3 Cardiac death with presumed new ischemic ECG changes or ventricular fibrillation before cTn is available or elevated, or MI detected at autopsy Not available Symptoms suggesting ischemia
4a (PCI related) Procedure-related >5 × 99th percentile URL within 48 h of the procedure with a normal baseline; with an elevated stable (≤20% variation) or falling baseline, a rise >20% and an absolute value still >5 × URL ≥1 of: new ischemic ECG changes, new pathological Q waves, imaging evidence, angiographic flow-limiting complication
4b Stent or scaffold thrombosis Type 1 criteria Thrombosis at angiography or autopsy
4c Restenosis Type 1 criteria Focal or diffuse restenosis or a complex lesion
5 (CABG related) Procedure-related >10 × 99th percentile URL within 48 h with normal baseline; with elevated stable or falling baseline, rise >20% to >10 × URL ≥1 of: new pathological Q waves, angiographic new graft or native artery occlusion, imaging evidence of new loss of viable myocardium
  • Postmortem type 1. Postmortem atherothrombus in the artery supplying the infarct, or a large circumscribed area of necrosis, meets type 1 criteria regardless of cTn values (Thygesen 2018).
  • Isolated Q waves. New pathological Q waves alone meet type 4a criteria with rising cTn <5 × URL, and type 5 criteria with rising cTn <10 × URL (Thygesen 2018).
  • Procedural myocardial injury. A cTn rise above the 99th percentile URL from a normal baseline, or a >20% rise from an elevated stable or falling baseline, defines cardiac procedural myocardial injury. Isolated cTn increases after a procedure do not establish type 4a MI (Thygesen 2018).
  • Stent thrombosis timing. Type 4b timing categories are acute (0–24 h), subacute (>24 h to 30 days), late (>30 days to 1 year) and very late (>1 year) (Thygesen 2018).
  • Prior or silent MI. Pathological Q waves without nonischemic causes, imaging loss of viable myocardium in an ischemic pattern, or pathological findings of prior MI each meet the definition (Thygesen 2018).
  • Takotsubo syndrome. Takotsubo syndrome occurs in 1%–2% of patients presenting with suspected STEMI, and over 90% of patients are postmenopausal women. QTc prolongation >500 ms in the acute phase and recovery of LV function over 2–4 weeks help separate it from MI (Thygesen 2018).
  • Type 2 MI outcomes. Type 2 MI is more frequent in women, and its short- and long-term mortality is generally higher than that of type 1 MI (Thygesen 2018).

Previous rule: Third Universal Definition (2012)

  • Myocardial injury. The Fourth Universal Definition separates myocardial injury, defined by cTn alone, as an entity in itself and requires additional criteria for MI (Thygesen 2018).
  • Type 4a in 2012. The Third Universal Definition required cTn >5 × 99th percentile URL within 48 h of PCI from a normal baseline, plus prolonged ischemia (≥20 min) shown by prolonged chest pain, ischemic ST changes or new pathological Q waves, angiographic flow-limiting complication, or imaging evidence. With an elevated stable or falling baseline, a rise >20% was required (Thygesen 2012).
  • Type 5 in 2012. cTn >10 × 99th percentile URL in the first 48 h after CABG from a normal baseline defined type 5 MI with supporting criteria. The 2018 document kept this threshold for consistency (Thygesen 2012; Thygesen 2018).

Causes of troponin elevation other than type 1 myocardial infarction

Causes of myocardial injury (Fourth Universal Definition, Thygesen 2018).

Category Examples
Supply-demand imbalance, reduced perfusion Coronary spasm, microvascular dysfunction, coronary embolism, coronary dissection, sustained bradyarrhythmia, hypotension or shock, respiratory failure, severe anemia
Supply-demand imbalance, increased demand Sustained tachyarrhythmia, severe hypertension with or without LV hypertrophy
Cardiac conditions Heart failure, myocarditis, cardiomyopathy, Takotsubo syndrome, revascularization and other cardiac procedures, catheter ablation, defibrillator shocks, cardiac contusion
Systemic conditions Sepsis, chronic kidney disease, stroke or subarachnoid hemorrhage, pulmonary embolism or pulmonary hypertension, amyloidosis or sarcoidosis, chemotherapeutic agents, critical illness, strenuous exercise

Macrotroponin and other analytical interferences

  • Definition. Macrotroponin is cTn bound to immunoglobulin. The complex is retained by immunoglobulin-depletion resins, which lowers cTn recovery. Recovery after depletion is 100% in acute MI (Bularga 2022).
  • Detection by immunoglobulin depletion. IgG, IgA or IgM were removed with protein G, anti-IgA or anti-IgM resins. In three patients with suspected myocarditis, hs-cTnI recovery was 16%, 3% and <1% (Bularga 2022).
  • Detection by size. Sucrose gradient ultracentrifugation estimated macrotroponin complexes of 200–500 kDa (Bularga 2022). Gel filtration chromatography and sucrose gradient ultracentrifugation performed similarly in identifying the high-molecular-weight immunocomplex. Protein G spin columns identified all interference cases but had high between-run variability (Hammarsten 2023).
  • Gel filtration frequency. Sephacryl S-300 gel filtration identified macrotroponin I in 5% of patients with elevated Architect hs-cTnI (Warner 2016).
  • Detection by PEG precipitation. A polyethylene glycol (PEG) hs-cTnI recovery <20% (Abbott assay) indicated a macrocomplex in women receiving breast cancer treatment (Kavsak 2023).
  • Frequency in elevated hs-cTnI. Among 188 community patients with elevated hs-cTnI (Siemens Centaur), 99 had recovery <40% after immunoglobulin depletion. Patients with macrotroponin more often had multifactorial or indeterminate injury (56% versus 25%) and less often ACS (9% versus 28%) (Lam 2022).
  • Endogenous anti-troponin antibodies. Macro-cTnI (recovery <40% after protein A depletion, validated by gel filtration and PEG precipitation) was present in 123 of 223 (55%) community specimens. cTnT recovery was unaffected in 72% of them (Lam 2020).
  • Assay dependence. Diagnostic performance differed between hs-cTnI assays in the presence of macrotroponin, attributed to differences in assay reactivity (Lam 2022).
  • Population data. In 19,499 adults, elevated cTnI was present in 1% and elevated cTnT in 6%. Biochemical testing attributed 92.5% of discordant cTnI elevations (>3-fold difference between cTnI and cTnT) and 15.4% of discordant cTnT elevations to macrotroponin. Participants with suspected macrotroponin had cardiovascular risk similar to those without elevated cTn (de Bakker 2026).
  • Hemolysis. In nine hs-cTn assays, increasing hemolysis lowered cTn recovery in susceptible assays: Beckman Access 2, Ortho Vitros XT 7600 and both Roche Elecsys hs-cTnT assays (Harley 2021).
  • Biotin. Biotin lowered cTn recovery with both Roche Elecsys hs-cTnT assays and the Siemens Dimension EXL. A newer Roche version showed about 100-fold less biotin interference. Hemolysis lowered the biotin interference threshold in susceptible assays (Harley 2021).
  • False results overall. False-positive and false-negative cTn results from analytical problems are uncommon (<0.5%) and less common with hs-cTn assays (Thygesen 2018).

CK-MB and myoglobin

  • AHA/ACC 2014. With contemporary troponin assays, CK-MB and myoglobin are not useful for diagnosis of ACS (Level of Evidence A). CK-MB is much less sensitive than troponin and requires substantially more tissue injury for detection (Amsterdam 2014).
  • CK-MB as fallback. When cTn is unavailable, CK-MB by mass assay is the best alternative, with a decision limit at its sex-specific 99th percentile URL (Thygesen 2018).
  • Reinfarction. CK-MB declines more rapidly after MI and may help detect early reinfarction (Collet 2020).

Natriuretic peptides

Natriuretic peptide physiology and assay use

  • Biochemistry. BNP and NT-proBNP come from a 134-amino-acid pre-proBNP. Removal of a 26-amino-acid signal peptide gives proBNP (108 amino acids), which corin or furin cleaves into active BNP (32 amino acids) and inactive NT-proBNP (76 amino acids) (Cao 2019).
  • Half-lives. BNP has a half-life of about 20 min and NT-proBNP of 90–120 min (Cao 2019).
  • Triggers. End-diastolic wall stress, intracardiac filling pressures and intracardiac volumes are the dominant triggers of release (Mueller 2019).
  • Comparable accuracy. BNP, NT-proBNP and mid-regional pro-atrial natriuretic peptide (MR-proANP) have comparable diagnostic and prognostic accuracy. Their values correlate but are not interchangeable, and cutoffs differ (Mueller 2019; Heidenreich 2022).
  • Clearance. Only about 25% of natriuretic peptide clearance is renal filtration. The remainder occurs in organs with high blood flow (Mueller 2019).
  • Neprilysin substrates. BNP and ANP are cleared by neprilysin. NT-proBNP is not a neprilysin substrate (Mueller 2019; Myhre 2019).

Natriuretic peptide thresholds for heart failure

Natriuretic peptide thresholds (pg/mL; 1 pg/mL = 1 ng/L).

Setting BNP NT-proBNP Source
Nonacute: HF unlikely below <35 <125 McDonagh 2021
Acute: HF unlikely below <100 <300 McDonagh 2021
Elevated, ambulatory (universal definition 2021) ≥35 ≥125 Bozkurt 2021
Elevated, hospitalized or decompensated (universal definition 2021) ≥100 ≥300 Bozkurt 2021
Acute HF rule-in, age-stratified Not applicable >450 (<50 y), >900 (50–75 y), >1800 (>75 y) Mueller 2019; Januzzi 2018
Acute HF rule-in, PPV >400 Not applicable Mueller 2019
  • Nonacute performance. In primary care studies, NPVs below 35 pg/mL (BNP) and 125 pg/mL (NT-proBNP) ranged from 0.94 to 0.98 (McDonagh 2021).
  • BNP in the emergency department. In 1586 patients with acute dyspnea, BNP at 100 pg/mL had a diagnostic accuracy of 83.4%, and BNP <50 pg/mL had an NPV of 96% (Maisel 2002).
  • NT-proBNP in the emergency department. In 1461 patients, the age-stratified cutoffs of 450, 900 and 1800 pg/mL had PPVs of 53.6%, 58.4% and 62.0%. NT-proBNP <300 pg/mL had a sensitivity of 93.9% and an NPV of 98.0% (Januzzi 2018).
  • HFmrEF. Elevated BNP (≥35 pg/mL) or NT-proBNP (≥125 pg/mL) makes the diagnosis of HF with mildly reduced EF more likely but is not mandatory when LVEF measurement is certain (McDonagh 2021).
  • Screening for pre-HF. In STOP-HF, patients with BNP ≥50 pg/mL underwent echocardiography and specialist care, which reduced the composite of LV dysfunction with or without new HF (Heidenreich 2022).

Factors that alter natriuretic peptide concentrations

Causes of altered natriuretic peptide concentrations (Bozkurt 2021).

Direction Causes
Higher, cardiovascular ACS, pulmonary embolism, myocarditis, hypertrophic cardiomyopathy, valvular and congenital heart disease, atrial or ventricular arrhythmias, cardioversion or ICD shock, pericardial disease, cardiac procedures, pulmonary hypertension, infiltrative cardiomyopathies
Higher, noncardiovascular Advanced age, kidney disease, sepsis and critical illness, stroke, pneumonia or COPD, liver disease, severe anemia, thyrotoxicosis, diabetic ketoacidosis, severe burns
Lower Obesity or increased BMI, pericardial disease
  • Age and renal function. NT-proBNP correlates more strongly with age and renal dysfunction than BNP, so age-dependent rule-in cutoffs are used (Mueller 2019). HF cutoffs may need to be raised when eGFR is <60 mL/min (Mueller 2019).
  • Atrial fibrillation. Atrial fibrillation raises natriuretic peptides without HF. A 20%–30% increase in thresholds has been suggested for HF trial enrollment (Bozkurt 2021).
  • Obesity. BNP, NT-proBNP and MR-proANP are lower in obesity, most likely from lower release. Concentrations rise after substantial weight loss, and BNP and NT-proBNP cutoffs about 50% lower have been proposed for obese patients (Mueller 2019). Obesity reduces diagnostic sensitivity (Heidenreich 2022).
  • Low values in true HF. Low concentrations occur in some patients with end-stage HF, flash pulmonary edema or right-sided acute HF (McDonagh 2021).
  • Sacubitril/valsartan. In PARADIGM-HF, median BNP rose from 202 ng/L to 235 ng/L after 8–10 weeks of sacubitril/valsartan. BNP doubled in 18% and tripled in 6% of patients. Such increases in NT-proBNP were extremely rare. Both peptides kept prognostic accuracy (Myhre 2019).
  • Monitoring on sacubitril/valsartan. The HFA considers NT-proBNP the preferred biomarker to quantify HF severity and monitor prognosis during sacubitril/valsartan therapy (Mueller 2019).
  • Treatment guidance. Evidence for guiding treatment by serial BNP or NT-proBNP remains insufficient (Heidenreich 2022). In GUIDE-IT (894 patients), an NT-proBNP target <1000 pg/mL gave no benefit over usual care (Mueller 2019).

Heart failure definitions: 2026 rule and 2021 rule

  • Universal definition 2021 (previous rule). HF is a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality, corroborated by elevated natriuretic peptides and/or objective evidence of pulmonary or systemic congestion (Bozkurt 2021).
  • 2021 EF categories. HFrEF has LVEF ≤40%, HFmrEF LVEF 41%–49% and HFpEF LVEF ≥50%. HF with improved EF has a baseline LVEF ≤40%, a ≥10-point increase and a second LVEF >40% (Bozkurt 2021).
  • 2021 stages. The stages are at risk for HF (A), pre-HF (B), symptomatic HF (C) and advanced HF (D). Pre-HF includes asymptomatic patients with elevated natriuretic peptides (Bozkurt 2021).
  • Second Universal Definition 2026 (current). The 2026 AHA/ACC/ESC/WHF document reaffirms stages A–D. Pre-HF (stage B) includes asymptomatic patients with structural or functional abnormality, or with elevated natriuretic peptide or cardiac troponin levels. It moves away from rigid LVEF cutoffs and groups HF into reduced, preserved and improved EF categories, with no separate mildly reduced category. HF with improved EF keeps the 2021 criteria (Walsh 2026).
  • Natriuretic peptides in the 2026 definition. Elevated BNP or NT-proBNP, or imaging evidence of congestion and elevated filling pressures, increases diagnostic certainty. A substantial proportion of patients with HFpEF have normal natriuretic peptides despite invasive hemodynamic evidence of HF, and obesity can produce falsely normal values. The 2026 document gives no numeric natriuretic peptide thresholds (Walsh 2026). The numeric thresholds in this unit are those of the 2021 universal definition and the 2021 ESC guideline (Bozkurt 2021; McDonagh 2021).

Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate

Definition. Mineral metabolism testing measures total and ionized calcium, intact parathyroid hormone (PTH), vitamin D metabolites, magnesium, phosphate and bone turnover markers to classify hypercalcemia, hypocalcemia, phosphate disorders and metabolic bone disease. The differential diagnosis of hypercalcemia depends on the PTH result: PTH-independent causes are characterized by suppressed PTH (Bilezikian 2022). 25-hydroxyvitamin D [25(OH)D] reflects vitamin D status, and 1,25-dihydroxyvitamin D [1,25(OH)2D] is the active metabolite (Demay 2024; Holick 2011).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (ion-selective electrodes, LC-MS/MS for 25(OH)D, biotin interference) Related page: Liver, Kidney and Gastrointestinal Function Tests (eGFR, CKD categories and renal tubular function) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (albumin, monoclonal proteins and myeloma) Related page: Diagnostic Enzymes and Serum Tumor Markers (alkaline phosphatase and its isoenzymes) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (hemolysis, tube types and blood gas sampling) Related page: Water, Electrolytes, Osmolality and Acid-Base Disorders (Gitelman syndrome with hypomagnesemia and hypocalciuria; pH and ionized calcium in blood gas specimens)

Total and ionized calcium measurement

  • Total calcium methods. Colorimetric methods include o-cresolphthalein complexone (OCP), arsenazo III and NM-BAPTA (Yan 2014; Bourguignon 2014).
  • Gadolinium interference. Gadodiamide interfered with OCP calcium from 0.5 mmol/L (−9% bias) and caused a 90% positive bias with arsenazo III at 50 mmol/L. Gadobenate, gadobutrol and gadoteridol did not interfere with the three methods tested (Yan 2014).
  • NM-BAPTA performance. The NM-BAPTA method showed a CV <1.5% and interference from gadobenate and gadoteric acid did not exceed 5% (Bourguignon 2014).
  • OCP at low concentrations. In one evaluation, OCP read at 572 nm showed a mean bias of −0.55 mg/dL at calcium <9 mg/dL (Hira 2026).
  • Protein binding. Calcium bound to albumin is about 50% of total circulating calcium. Calcium is adjusted when albumin is below 4 g/dL (Bilezikian 2022).
  • Ionized calcium and pH. Hydrogen ions compete with calcium for binding sites on albumin. Ionized calcium and ionized magnesium both fall as specimen pH rises, by about 0.36 mmol/L and 0.12 mmol/L per pH unit (Wang 2002).
  • pH-adjusted ionized calcium. Adjustment of ionized calcium to pH 7.4 with published normative equations misclassified 15% of subjects with high and 60% of subjects with low unadjusted ionized calcium in one standardized study (Lam 2013).
  • Heparin underfilling. Venous lithium or sodium heparin tubes filled to one-third raised pH and lowered ionized calcium significantly. Tubes are filled at least two-thirds for accurate pH and ionized calcium (Mahler 2023).
  • Ionized versus total calcium. In 1350 patients, agreement between total calcium and pH-adjusted ionized calcium was very poor (κ = −0.14) (Kur 2020).

Albumin-adjusted calcium and its limits

Albumin-adjusted calcium (Payne formula).

Units Formula Source
Conventional Adjusted calcium (mg/dL) = measured calcium (mg/dL) − albumin (g/dL) + 4.0 Payne 1973
SI (simplified Payne) Adjusted calcium (mmol/L) = measured calcium (mmol/L) + 0.02 × [40 − albumin (g/L)] Desgagnés 2025
Example Calcium 8.0 mg/dL with albumin 2.5 g/dL: 8.0 − 2.5 + 4.0 = 9.5 mg/dL Payne 1973
  • Derivation. The formula came from the regression of calcium on albumin in 200 specimens, where calcium correlated with albumin (r = 0.867) more closely than with total protein (r = 0.682) (Payne 1973).
  • Performance against ionized calcium. In 22,658 adults with simultaneous total and ionized calcium, unadjusted total calcium correlated with ionized calcium better (R² = 71.7%) than the simplified Payne formula (R² = 68.9%). Unadjusted total calcium had the best agreement (74.5%) in classifying calcium status (Desgagnés 2025).
  • Normocalcemic PHPT. In suspected normocalcemic primary hyperparathyroidism, ionized calcium is measured (Bilezikian 2022).

Parathyroid hormone assays

Generations of PTH immunoassays (Bai 2025).

Generation Design Specificity
First (1963) Competitive radioimmunoassay with polyclonal antibodies to mid-region epitopes Cross-reacts with C-terminal fragments
Second, "intact PTH" (1987) Sandwich assay: C-terminal capture antibody (residues 39–84) and N-terminal detection antibody (residues 13–24) Up to 50% cross-reactivity with N-terminally truncated fragments, such as PTH 7–84, in CKD
Third, "whole" or "bioactive" PTH (1999) N-terminal antibody to residues 1–4 Excludes PTH 7–84
  • Circulating forms. Non-(1–84) PTH fragments have longer half-lives than PTH 1–84 and accumulate in CKD. Second-generation assays cross-react with them and overestimate bioactive PTH in CKD, and the intraoperative PTH decline measured by these assays can be slower and smaller (Bai 2025).
  • Assay choice in guidelines. The 2022 workshop criteria for primary and normocalcemic hyperparathyroidism and for hypoparathyroidism accept either a second- or third-generation intact PTH assay (Bilezikian 2022; Khan 2022).
  • CKD. Differences between intact and whole PTH assays and their reference ranges contribute to differences across CKD studies. No PTH assay alone or with other markers predicted bone histology reliably (KDIGO 2017).
  • Biotin. Biotin supplements may falsely lower some PTH results. Discontinuation for at least 48 hours before PTH measurement has been suggested (Bilezikian 2022).
  • Specimen stability. In plain, SST and EDTA tubes, a 2-h delay before separation lowered intact PTH by 3.8% (serum) and 7.4% (plasma), which the authors judged clinically insignificant. EDTA plasma was stable at room temperature for up to 4 days. Serum at room temperature fell by 45% at 2 days (Khalil 2021).

Intraoperative PTH monitoring

  • Miami criterion. A drop of ≥50% from the highest of the preincision or pre-excision PTH value, 10 minutes after gland excision, predicts complete excision (Carneiro 2003).
  • Accuracy. The Miami criterion correctly predicted postoperative calcium in 329 of 341 patients. Other published criteria raised false-negative predictions from 3% to 6%–24% (Carneiro 2003).
  • Outcome. In 421 patients with limited parathyroidectomy guided by the quick PTH assay, operative success was 97%, compared with 94% for 340 bilateral neck explorations (Irvin 2004).

Miami criterion calculation (Carneiro 2003).

Step Calculation
Decline at 10 min (higher of preincision and pre-excision PTH − 10-min PTH) ÷ that baseline × 100
Example Preincision 300 pg/mL, pre-excision 250 pg/mL, 10-min 140 pg/mL: (300 − 140) ÷ 300 × 100 = 53%

Hypercalcemia

Classification of hypercalcemia by PTH.

PTH result Causes Distinguishing tests Source
Elevated or inappropriately normal Primary hyperparathyroidism; familial hypocalciuric hypercalcemia (FHH); lithium or thiazide use; tertiary hyperparathyroidism in end-stage kidney disease Calcium/creatinine clearance ratio, medication withdrawal, CASR genetic testing Bilezikian 2022
Suppressed PTHrP-secreting tumors; osteolytic metastases; tumor or granulomatous production of 1,25(OH)2D; vitamin D toxicity; milk-alkali syndrome PTHrP, 25(OH)D, 1,25(OH)2D Bilezikian 2022; Jha 2025; Beso 2026

Primary hyperparathyroidism (Fifth International Workshop 2022)

  • Hypercalcemic PHPT. Albumin-adjusted calcium is elevated with an elevated or inappropriately normal intact PTH on two occasions at least 2 weeks apart (Bilezikian 2022).
  • Normocalcemic PHPT. Adjusted total calcium and ionized calcium are normal and intact PTH is elevated on at least two occasions over 3–6 months, after secondary causes are excluded. Secondary causes include CKD stages 3–5, vitamin D deficiency, calcium malabsorption, and bisphosphonate or denosumab use (Bilezikian 2022).
  • Pathology. Sporadic PHPT is caused by a single adenoma in 85%, multigland disease in 15% and carcinoma in <1%. Multigland disease is a feature of lithium-associated PHPT (Bilezikian 2022).
  • Initial evaluation. Adjusted calcium, phosphate, intact PTH, 25(OH)D and creatinine are measured. eGFR or creatinine clearance and a 24-hour urine calcium complete the renal assessment (Bilezikian 2022).
  • Urine calcium caveats. Lithium and thiazides make urine calcium inaccurate. Vitamin D deficiency and CKD lower urinary calcium (Bilezikian 2022).
  • Prevalence. Age-adjusted prevalence in the United States is 233 per 100,000 women and 85 per 100,000 men (Bilezikian 2022).

Indications for parathyroidectomy in asymptomatic PHPT: 2022 rule and 2013 rule (Bilezikian 2022, Table 2).

Parameter 2022 (Fifth Workshop, current) 2013 (Fourth Workshop, previous)
Serum calcium >1.0 mg/dL (0.25 mmol/L) above the upper limit of normal >1.0 mg/dL (0.25 mmol/L) above the upper limit of normal
Skeletal T-score < −2.5 at lumbar spine, total hip, femoral neck or distal one-third radius, or vertebral fracture by imaging or VFA T-score < −2.5 at the same sites, or vertebral fracture by imaging or VFA
Renal function eGFR or creatinine clearance <60 mL/min eGFR <60 mL/min
Urine calcium >250 mg/day (>6.25 mmol/day) in women or >300 mg/day (>7.5 mmol/day) in men >400 mg/day (>10 mmol/day) with increased stone risk on biochemical stone risk analysis
Stones Nephrolithiasis or nephrocalcinosis on imaging Nephrolithiasis or nephrocalcinosis on imaging
Age <50 years <50 years
  • Symptomatic PHPT. All symptomatic patients are offered surgery unless it is contraindicated. One criterion is sufficient in asymptomatic patients (Bilezikian 2022).
  • Normocalcemic PHPT. Data are insufficient to recommend surgical guidelines (Bilezikian 2022).

Familial hypocalciuric hypercalcemia

  • Genetics. FHH1 is caused by loss-of-function variants of the calcium-sensing receptor (CaSR), FHH2 by loss-of-function variants of G-protein subunit α11 (GNA11) and FHH3 by variants of the adaptor protein-2 σ subunit (AP2S1) (Gorvin 2016).
  • FHH3. AP2S1 variants affecting Arg15 were found in >20% of FHH families without CASR variants (Nesbit 2013).
  • Clinical suspicion. FHH is considered when hypercalcemia is lifelong, the patient is younger than 30 years or there is a family history of hypercalcemia. Genetic testing is indicated, and surgery is contraindicated in most patients with FHH (Bilezikian 2022).

Calcium/creatinine clearance ratio (CCCR).

Item Value Source
Formula CCCR = (urine calcium × serum creatinine) ÷ (serum calcium × urine creatinine), all in the same units, from a 24-h collection Christensen 2008
Favors FHH <0.01; sensitivity 65%–80% and specificity 74%–88% for FHH Asla 2024
Overlap CCCR >0.02 virtually excludes FHH and suggests PHPT; values between 0.01 and 0.02 do not discriminate Asla 2024
ROC-optimal cutoff <0.0115 (specificity 0.88, sensitivity 0.80); CCCR AUC 0.923 Christensen 2008
Screening cutoff <0.020 captures 98% of FHH and 35% of PHPT; followed by CASR analysis Christensen 2008

PTH-independent hypercalcemia

  • Malignancy. Hypercalcemia of malignancy is the most common metabolic complication of cancer (El-Hajj Fuleihan 2023). It is most often due to PTHrP, and PTH and PTHrP assays do not cross-react. Ectopic PTH secretion by tumors is extremely rare (Bilezikian 2022).
  • 1,25(OH)2D production. Sarcoidosis and tuberculosis cause hypercalcemia by producing 1,25(OH)2D (Bilezikian 2022). A B-cell lymphoma produced 1,25(OH)2D (235 pmol/L) with hypercalcemia of 3.13 mmol/L, and both normalized with treatment (Mudde 1987).
  • Monitoring with extrarenal 1,25(OH)2D. In patients with extrarenal 1,25(OH)2D production treated with vitamin D, serial 25(OH)D and calcium monitoring is suggested to prevent hypercalcemia (Holick 2011).
  • Vitamin D toxicity. Vitamin D toxicity causes PTH-independent hypercalcemia. In three family members exposed to unregulated fortification, 25(OH)D by LC-MS/MS was 886–988 ng/mL (2215–2470 nmol/L), intact PTH was suppressed (1.2–6.1 pg/mL) and 24-hour urine calcium was elevated in two of the three (415–452 mg/day) (Jha 2025). Hypercalciuria followed by hypercalcemia appears to become more frequent when 25(OH)D exceeds 150 ng/mL (375 nmol/L) (Aberger 2024).
  • Milk-alkali syndrome. The triad is hypercalcemia, metabolic alkalosis and acute kidney injury from excess calcium and absorbable alkali (Beso 2026).

Hypocalcemia

Hypoparathyroidism (Second International Workshop 2022 and 2025 best practice)

  • Diagnosis. Hypocalcemia (low ionized calcium or albumin-adjusted total calcium) with an undetectable, low or inappropriately normal intact PTH on two occasions at least 2 weeks apart confirms chronic hypoparathyroidism (Khan 2022).
  • Supporting findings. Elevated phosphate, reduced 1,25(OH)2D and an elevated urinary fractional excretion of calcium support the diagnosis (Khan 2022).
  • Postsurgical hypoparathyroidism. Postsurgical disease makes up about 75% of cases. It is considered permanent when it persists >12 months after surgery. PTH measured 12–24 hours after total thyroidectomy predicts which patients will not develop permanent disease, and PTH >10 pg/mL (1.05 pmol/L) virtually excludes long-term hypoparathyroidism (Khan 2022).
  • Genetic testing. Genetic testing is undertaken in nonsurgical hypoparathyroidism with a family history, syndromic features or age <40 years. AIRE testing is done when APECED features are present (Khan 2022).
  • Autosomal dominant hypocalcemia type 1. Gain-of-function CASR variants cause autosomal dominant hypocalcemia type 1. Thiazides increase urinary magnesium losses in this disorder (Khan 2022).
  • Magnesium dependence. Hypomagnesemia and hypermagnesemia both impair parathyroid function. Magnesium activates the CaSR and decreases PTH synthesis and secretion. Hypomagnesemia also causes PTH resistance because intracellular magnesium is a cofactor for adenylate cyclase (Khan 2022).
  • Infant hypocalcemia. Maternal hypercalcemia, including maternal FHH, can cause hypoparathyroidism in the infant (Khan 2022).

Vitamin D deficiency

  • Mechanism. Loss of vitamin D action reduces duodenal calcium transport. Hypocalcemia causes secondary hyperparathyroidism, which lowers proximal tubular reabsorption of phosphate and bicarbonate, giving hypophosphatemia and hyperchloremic acidosis (Levine 2020).

Pseudohypoparathyroidism

  • Biochemistry. Pseudohypoparathyroidism (PHP) shows the hypocalcemia and hyperphosphatemia of hypoparathyroidism, with raised PTH from target-tissue resistance to PTH. Resistance to other Gsα-coupled hormones (TSH, gonadotropins, GHRH, calcitonin) may occur (Mantovani 2018).
  • Diagnosis. Major criteria are PTH resistance, ectopic ossifications, brachydactyly and early-onset obesity, confirmed by molecular genetic analysis (Mantovani 2018).
  • Course. In PHP1A, PTH resistance is usually absent at birth and develops over time (Mantovani 2018).

Hungry bone syndrome

  • Definition. Hungry bone syndrome is rapid, profound and prolonged hypocalcemia with hypophosphatemia and hypomagnesemia after parathyroidectomy for severe PHPT with high preoperative bone turnover (Witteveen 2013).
  • Frequency. It occurs in 25%–90% of patients with radiological hyperparathyroid bone disease and 0%–6% of patients without skeletal involvement (Witteveen 2013).

Vitamin D

  • Metabolism. Vitamin D from skin or diet is converted to 25(OH)D in the liver by a step that is not tightly regulated, so 25(OH)D best reflects vitamin D status. 1α-hydroxylation forms 1,25(OH)2D (Demay 2024).
  • Forms. Vitamin D2 comes from UV irradiation of ergosterol and vitamin D3 from 7-dehydrocholesterol in skin. Both are used in fortification and supplements (Holick 2011).
  • Enzymes. CYP2R1 performs hepatic 25-hydroxylation, and renal CYP27B1 performs 1α-hydroxylation. PTH induces CYP27B1 and FGF23 suppresses it (Levine 2020).
  • Half-lives. 25(OH)D has a half-life of 2–3 weeks. 1,25(OH)2D has a half-life of about 4 hours and circulates at 1000-fold lower concentration (Holick 2011).
  • 1,25(OH)2D testing. 1,25(OH)2D does not reflect vitamin D stores and is often normal or elevated in vitamin D deficiency from secondary hyperparathyroidism. It is measured for acquired and inherited disorders of vitamin D and phosphate metabolism (Holick 2011).

25(OH)D assays and standardization

  • VDSP performance criteria. The Vitamin D Standardization Program set criteria of ≤10% CV and ≤±5% mean bias against reference measurement procedures. All 12 assays met the CV criterion, and 9 met the bias criterion (Wise 2021).
  • 25(OH)D2 recovery. Ten immunoassays changed response with high-25(OH)D2 samples. The largest deviations were in the Abbott, bioMérieux, DiaSorin, DIAsource and IDS-iSYS assays (Wise 2021).
  • C-3 epimers. C-3 epimers of 25(OH)D were found in 22.7% of infants <1 year and made up 8.7%–61.1% of total 25(OH)D. None were detected in older children or adults. Epimers cause overestimation unless the method separates them (Singh 2006).

Vitamin D guidelines: 2024 rule and 2011 rule

25(OH)D testing and thresholds (Endocrine Society).

Item Endocrine Society 2024 (current) Endocrine Society 2011 (previous)
Scope Vitamin D to lower disease risk in people without established indications for treatment or 25(OH)D testing Evaluation, treatment and prevention of vitamin D deficiency
Testing Suggests against routine 25(OH)D testing in all populations considered, including the general population and people with obesity or dark complexion, in the absence of established indications 25(OH)D by a reliable assay in patients at risk of deficiency
Deficiency No 25(OH)D thresholds endorsed for sufficiency, insufficiency or deficiency <20 ng/mL (50 nmol/L)
Insufficiency Not defined 21–29 ng/mL (52.5–72.5 nmol/L)
Target Target of 30 ng/mL (75 nmol/L) no longer endorsed 30 ng/mL (75 nmol/L) suggested
1,25(OH)2D for status Not addressed Recommended against
  • 2024 empiric supplementation. The 2024 guideline suggests empiric vitamin D for ages 1–18 years, adults >75 years, pregnancy and high-risk prediabetes (Demay 2024).
  • Dietary reference intakes. The 2024 guideline assumes the IOM (now National Academy of Medicine) dietary reference intakes as baseline: 600 IU (15 µg) daily for adults up to 70 years and 800 IU (20 µg) for those older than 70 years (Demay 2024).
  • IOM cutoff. The IOM recommended 25(OH)D <20 ng/mL as the definition of deficiency (Holick 2011).

Vitamin D-dependent rickets

Vitamin D-dependent rickets (Levine 2020; Roizen 2018).

Type Gene Inheritance 25(OH)D 1,25(OH)2D PTH
VDDR1A CYP27B1 Autosomal recessive Normal or increased Decreased Increased
VDDR1B CYP2R1 Autosomal recessive Decreased Decreased Increased
VDDR2A VDR Autosomal recessive Normal or increased Normal or increased Increased
VDDR2B Unknown (nuclear ribonucleoprotein interfering with VDR-DNA binding) Autosomal recessive Normal or increased Normal or increased Increased
VDDR3 CYP3A4 gain of function Autosomal dominant Decreased Decreased Increased
  • VDDR3 mechanism. The CYP3A4 p.I301T variant oxidized 1,25(OH)2D with 10-fold greater activity than wild-type CYP3A4 (Roizen 2018).

Magnesium

  • Distribution. Only 1% of total body magnesium is extracellular, and no simple serum measurement reflects intracellular magnesium (Sanders 1999).
  • Ionized magnesium. Measuring ionized magnesium offers minimal advantage in renal disease (Sanders 1999).
  • Causes of hypomagnesemia. Most hypomagnesemia from drugs (diuretics, chemotherapeutic agents, immunosuppressive agents, antibiotics) is due to renal loss (Sanders 1999). Proton pump inhibitor use is associated with hypomagnesemia (Alanazi 2024).
  • Correction of magnesium. Correction of magnesium is necessary to improve calcium homeostasis and is part of hypoparathyroidism treatment (Khan 2022; Khan 2025). The PTH mechanisms are given under hypoparathyroidism.

Phosphate

  • FGF23 in X-linked hypophosphatemia. Loss of PHEX function increases FGF23 secretion from osteocytes, causing renal phosphate wasting and diminished 1,25(OH)2D synthesis (Haffner 2019).
  • XLH diagnosis. Renal phosphate wasting is assessed by the tubular maximum reabsorption of phosphate per GFR (TmP/GFR) from a spot urine. Intact FGF23 is usually elevated, and a normal FGF23 does not exclude XLH. In patients without a family history, PHEX analysis gives a negative or positive confirmation in ~70%–90% of cases (Haffner 2019).
  • TmP/GFR caveat. With low phosphate intake or impaired absorption, TmP/GFR can be falsely low until serum phosphate is restored (Haffner 2019). Serum phosphate may be normal in the first 3–4 months of life (Haffner 2019).
  • Renal Fanconi syndrome. Nonselective tubular phosphate wasting is excluded by testing urine for bicarbonate, amino acid, glucose and uric acid losses and low-molecular-mass proteinuria (Haffner 2019).

TmP/GFR calculation (Jan de Beur 2023).

Step Formula or value
Specimens Second-morning-void urine phosphate and creatinine with simultaneous fasting serum phosphate and creatinine
TRP 1 − (urine phosphate × serum creatinine) ÷ (serum phosphate × urine creatinine)
TRP ≤0.86 TmP/GFR = TRP × serum phosphate
TRP >0.86 TmP/GFR = [0.3 × TRP ÷ (1 − 0.8 × TRP)] × serum phosphate
Alternative Walton–Bijvoet nomogram
Adult reference values TmP/GFR 0.80–1.35 mmol/L (2.48–4.18 mg/dL); TRP 85%–95%

Laboratory pattern of tumor-induced osteomalacia (Jan de Beur 2023).

Test Finding
Serum phosphate Decreased
TmP/GFR Decreased
Serum calcium Normal or slightly decreased
25(OH)D Normal or decreased
1,25(OH)2D Inappropriately normal or decreased
Alkaline phosphatase Increased
PTH Normal or increased
Intact FGF23 (preferred) and C-terminal FGF23 Increased or inappropriately normal
  • TmP/GFR interpretation. Increased TmP/GFR indicates impaired intake or intestinal absorption, and reduced TmP/GFR indicates renal phosphate loss. TmP/GFR is calculated only when hypophosphatemia is confirmed. An intact FGF23 >30 pg/mL is a sensitive cutoff for FGF23-mediated hypophosphatemia (Jan de Beur 2023).
  • Refeeding syndrome. ASPEN 2020 criteria grade a decrease in serum phosphorus, potassium and/or magnesium within 5 days of reintroducing calories: 10%–20% mild, 20%–30% moderate, >30% or organ dysfunction severe (da Silva 2020).
  • Spurious hyperphosphatemia from paraproteins. In 19 myeloma patients, IgG-kappa paraproteins were most frequent. Phosphate elevated by phosphomolybdate methods normalized after protein precipitation, dilution or alternative methods (Dabir 2026).
  • Spurious hyperphosphatemia from hemolysis. Hemolysis falsely raises phosphate and magnesium because both are concentrated in red cells (Yeganeh 2026).

Bone turnover markers

  • Reference markers. IOF and IFCC recommend serum procollagen type I N-propeptide (PINP) as the formation marker and serum C-terminal telopeptide of type I collagen (CTX) as the resorption marker (Vasikaran 2011).
  • CTX sampling. CTX samples are collected in the morning in the fasting state. EDTA plasma is preferred for CTX stability (Szulc 2017).
  • PINP sampling. PINP has minimal circadian variation and is not affected by food intake (Szulc 2017).
  • Other markers. Urinary N-telopeptide (NTX), bone-specific alkaline phosphatase (BALP) and osteocalcin are also bone turnover markers (LeBoff 2022).
  • Uses. Bone turnover markers can predict bone loss in untreated postmenopausal women and assess adherence: CTX for antiresorptive drugs and PINP for anabolic drugs. The least significant change is about a 40% reduction in CTX (LeBoff 2022).
  • Reproducibility. Poor within-subject and between-laboratory reproducibility has limited clinical adoption of CTX and PINP (Szulc 2017).

Metabolic bone disease

Laboratory evaluation for secondary osteoporosis

Laboratory tests for secondary causes of osteoporosis (BHOF 2022, LeBoff 2022).

Specimen Routine Selected patients
Blood CBC; albumin; albumin-adjusted calcium, renal function, phosphorus, magnesium; liver tests; 25(OH)D; PTH; total testosterone and gonadotropins (men aged 50–69) SPEP, immunofixation and serum free light chains; TSH ± free T4; tissue transglutaminase antibodies with IgA; iron and ferritin; homocysteine; prolactin; tryptase; bone turnover markers
Urine 24-h calcium and creatinine UPEP with light chains; salivary or urinary free cortisol; urinary histamine

CKD-mineral and bone disorder (KDIGO 2017)

  • Monitoring. Calcium, phosphate, PTH and alkaline phosphatase are monitored from CKD G3a in adults and from CKD G2 in children (KDIGO 2017).
  • Calcium and phosphate. Individual calcium and phosphate values, evaluated together, guide practice. The calcium-phosphate product is not used (KDIGO 2017).
  • 25(OH)D. 25(OH)D may be measured in CKD G3a–G5D, and deficiency is corrected as in the general population (KDIGO 2017).
  • PTH in CKD G3a–G5. The optimal PTH is unknown. Progressively rising or persistently elevated intact PTH prompts evaluation for hyperphosphatemia, hypocalcemia, high phosphate intake and vitamin D deficiency (KDIGO 2017).
  • PTH in CKD G5D. Intact PTH is maintained at about 2–9 times the upper normal limit of the assay (KDIGO 2017).
  • Bone turnover markers in CKD. Markedly high or low PTH or bone-specific alkaline phosphatase predicts underlying bone turnover. Routine measurement of collagen-derived turnover markers (such as procollagen type I C-terminal propeptide or type I collagen cross-linked telopeptide) is not suggested in CKD G3a–G5D (KDIGO 2017).
  • Bone biopsy. Bone biopsy is reasonable when the type of renal osteodystrophy will change treatment. The 2017 update removed the requirement for biopsy before antiresorptive therapy (KDIGO 2017).

Paget disease of bone

  • Paget disease of bone. Serum total alkaline phosphatase with liver function tests is the recommended first-line biochemical screen for metabolically active Paget disease. Treatment aimed at symptom improvement is recommended over a treat-to-target strategy that normalizes total alkaline phosphatase (Ralston 2019).

Endocrine Function Tests: Thyroid, Adrenal and Pituitary

Definition. Endocrine function testing measures a hormone, its binding protein or its regulator under basal conditions, and it measures the response to a stimulus or a suppressor in dynamic tests. Interpretation depends on the assay, the specimen conditions and the state of the feedback axis (Nieman 2008; Fleseriu 2021; Lenders 2014; Adler 2025).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (biotin interference, heterophile antibodies, macroprolactin and macro-TSH by PEG precipitation, the high-dose hook effect, LC-MS/MS for steroids) Related page: Diagnostic Enzymes and Serum Tumor Markers (thyroglobulin and anti-thyroglobulin antibodies, calcitonin and CEA in medullary thyroid carcinoma, chromogranin A) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (TPO, thyroglobulin and TSH-receptor antibody methods; 21-hydroxylase antibodies) Related page: The Bethesda System for Reporting Thyroid Cytopathology (thyroid fine-needle aspiration categories) Related page: Graves Disease and Thyroiditis in Thyroid FNA (cytology of Hashimoto, subacute and Graves thyroiditis) Related page: Medullary Thyroid Carcinoma (Cytology) (medullary thyroid carcinoma cytology) Related page: Water, Electrolytes, Osmolality and Acid-Base Disorders (AVP deficiency, SIADH and mineralocorticoid excess as a cause of hypokalemic alkalosis) Related page: Calcium, Parathyroid Hormone, Vitamin D, Magnesium and Phosphate (primary hyperparathyroidism and PTH assays) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia; this unit covers the confirmatory hormone tests) Related page: Reproductive Endocrinology and Pregnancy Screening: Gonadal Hormones, hCG and Prenatal Testing (gonadal axis, hCG, thyroid tests in pregnancy)

Free hormone, binding proteins and feedback

  • Free hormone hypothesis. The biological activity of a hormone depends on its unbound concentration. The hypothesis holds for all tissues for thyroid hormones, cortisol and the hydroxylated vitamin D metabolites. For several other steroids it holds for some tissues only, and for progesterone it may not hold (Mendel 1989).
  • Thyroid hormone binding. Only 0.03% of serum T4 and 0.3% of serum T3 circulate unbound (Pappa 2015).
  • Cortisol-binding globulin (CBG). Serum assays measure total cortisol. Estrogens raise CBG, and the overnight dexamethasone suppression test (DST) is falsely positive in 50% of women taking oral contraceptives. Estrogen-containing drugs are withdrawn for 6 weeks before testing where possible. Low CBG or albumin in critical illness lowers total cortisol (Nieman 2008).

Thyroid hormone-binding proteins (Pappa 2015).

Protein Share of serum T4 (%) Share of serum T3 (%) Half-life (days)
Thyroxine-binding globulin (TBG) 75 75 5 (longer with estrogen)
Transthyretin 20 <5 2
Albumin 5 20 15

Thyroid function tests

TSH-first testing and free T4 measurement

  • TSH as the screening test. Serum TSH has the highest sensitivity and specificity of any single blood test for suspected hyperthyroidism. TSH and free T4 together improve accuracy when hyperthyroidism is strongly suspected. The free T4-TSH relationship is inverse log-linear, so small changes in free T4 cause large changes in TSH (Kahaly 2018).
  • TSH reference limits by age and race. In 22,116 outpatients without thyroid disease, median TSH was 1.61 mIU/L at age >80 years and 1.13 mIU/L at age 20–29 years. Median TSH was 1.54 mIU/L in White and 1.18 mIU/L in Black patients. Population limits misclassified 3% of all patients aged >80 years as having high TSH, and age- and race-specific limits reduced misclassification (Boucai 2009).
  • Reflex TSH strategy. The reflex TSH strategy, which screens thyroid function by a first-line TSH measurement, is widely accepted. Central hypothyroidism, with low free T4 and a low or normal TSH, is its major false-negative result (Persani 2018).
  • Equilibrium dialysis. Equilibrium dialysis is the recommended method for free T4 when binding-protein affinity is abnormal. Analog and indirect free T4 methods can give falsely high results in familial dysalbuminemic hyperthyroxinemia (Pappa 2015).
  • Analog-method artifacts. Abnormal albumin or transthyretin can falsely raise T4 and T3, particularly with one-step analog methods (Beck-Peccoz 2013). Thyroid hormone autoantibody and heterophile antibody interference is covered in Analytical Methods and Immunoassays in Clinical Chemistry.
  • Heparin. After one subcutaneous dose of enoxaparin 2000 units, measured free T4 rose in vitro by up to 63%, in proportion to serum triglycerides and in vitro free fatty acid release. In inpatients on twice-daily enoxaparin, free T4 rose up to 171% in samples drawn 2–6 hours after injection. Samples are drawn ≥10 hours after the dose and analyzed within 24 hours (Stevenson 1998).
  • Biotin. Biotin interference with thyroid tests (falsely high free T4, free T3 and TSH-receptor antibody; falsely low TSH) is covered in Analytical Methods and Immunoassays in Clinical Chemistry.

Hypothyroidism

  • Subclinical hypothyroidism. Subclinical hypothyroidism is a raised TSH with T4 and T3 within the population reference range. It is graded as mild (TSH 4.0–10.0 mU/L) or more severe (TSH >10 mU/L). An initially raised TSH is repeated with free T4 and thyroid peroxidase antibodies (TPOAb), preferably after 2–3 months (Pearce 2013).
  • Autoimmune thyroiditis. Chronic autoimmune thyroiditis is the most common cause of persistent subclinical hypothyroidism. TPOAb is the most sensitive serological marker. TPOAb and thyroglobulin antibodies are absent in about 20% of patients with subclinical hypothyroidism (Pearce 2013).
  • Transient TSH elevation. TSH rises transiently in subacute and painless thyroiditis, after withdrawal of levothyroxine and during recovery from illness (Pearce 2013).
  • Central hypothyroidism. Central hypothyroidism is suspected with a subnormal free T4 and an inappropriately low TSH. Some forms show normal TSH concentrations. In patients followed for hypothalamic-pituitary disease, the diagnosis is considered when free T4 falls in the lowest quartile of the reference range, particularly with a fall >20% from previous values. Treatment is monitored by free T4, with TSH or T3 measured only when insufficient or excessive replacement is suspected (Persani 2018).
  • Drugs that raise TBG. Estrogen, tamoxifen, raloxifene and clofibrate raise TBG and total T4. In treated hypothyroidism they can raise TSH above the reference range, signaling a need for a higher levothyroxine dose (Jonklaas 2014).

Hyperthyroidism and thyrotoxicosis

  • Overt and mild disease. In overt hyperthyroidism, free T4 and T3 are high and TSH is suppressed. In milder hyperthyroidism, total and free T4 can be normal with only free T3 raised and TSH undetectable (Kahaly 2018).
  • TSH-receptor antibodies (TRAb). Most immunoassays are competitive-binding assays that measure TSH-receptor binding inhibitory immunoglobulins (TBII). These assays report presence and concentration without functional activity. Pooled sensitivity and specificity of second- and third-generation binding assays are 97% and 98%. Cell-based bioassays separate stimulating antibodies (TSAb) from blocking antibodies (Kahaly 2018).
  • TRAb in pregnancy. Fetal monitoring for thyroid dysfunction is recommended when maternal TRAb remains >3 times the cutoff (Kahaly 2018).
  • Thyrotoxicosis in critical illness. A suppressed TSH with high free T4 and normal T3 suggests thyrotoxicosis combined with nonthyroidal illness, called T4 thyrotoxicosis (Fliers 2015).

Amiodarone-associated thyroid dysfunction

  • Expected test changes. Amiodarone raises plasma inorganic iodide 40-fold. TSH rises early through the Wolff-Chaikoff effect. After escape, total T4, free T4 and reverse T3 (rT3) increase and total and free T3 decrease through inhibition of hepatic type 1 deiodinase. The rise in rT3 exceeds the fall in T3. TSH returns to baseline after about 3 months (Bartalena 2018).
  • Hypothyroidism. Amiodarone-induced hypothyroidism occurs in up to 26% (subclinical) and 5% (overt) of treated patients (Bartalena 2018).
  • Thyrotoxicosis types. Type 1 is iodine-induced hormone synthesis in nodular goiter or latent Graves disease. Type 2 is destructive thyroiditis. Free T4 and free T3 levels do not separate the types. Type 2 shows no goiter, reduced radioiodine uptake in iodine-deficient areas, no hypervascularity on color-flow Doppler and usually negative thyroid antibodies. TSH-receptor antibodies are absent in type 2 (Bartalena 2018).

Nonthyroidal illness

  • Thyroid test pattern in NTIS. Nonthyroidal illness syndrome (NTIS) shows decreased T3, low T4 and increased rT3, with TSH normal or slightly decreased. Serum T3 falls within 2 hours of the start of abdominal surgery (Fliers 2015).
  • Mechanisms of NTIS. Central downregulation of the hypothalamic-pituitary-thyroid axis and decreased hepatic type 1 deiodinase activity contribute (Fliers 2021). Fasting in healthy people reproduces the pattern (Fliers 2015).
  • Diagnosis of hypothyroidism in the ICU. A normal TSH excludes primary hypothyroidism. TSH remains high in primary hypothyroidism with NTIS, but dopamine or high-dose glucocorticoids can lower it during acute illness (Fliers 2015).

Inherited binding-protein disorders and central hyperthyroidism

  • TBG deficiency and excess. These disorders present as an abnormal total T4 with normal free T4 in clinically euthyroid people. Inherited TBG defects are X-linked except for one, and they are fully expressed in hemizygous males. Partial TBG deficiency occurs in about 1:4,000 newborns. Estrogen excess is the most common cause of high TBG, through a longer TBG half-life. Inherited TBG excess (about 1:25,000) results from gene duplication or triplication, giving about 2- and 3-fold TBG in hemizygous males (Pappa 2015).
  • Familial dysalbuminemic hyperthyroxinemia (FDH). FDH is autosomal dominant and caused by gain-of-function albumin mutations. Prevalence ranges from 0.01% to 1.8% and is highest in Hispanic populations. The common R218H variant raises total T4 without a proportional rise in total T3, with unsuppressed TSH and usually raised total rT3. R218P gives total T4 about 17-fold the normal mean (Pappa 2015).
  • TSH-secreting adenoma (TSHoma). TSHomas and resistance to thyroid hormone (RTH) both show high free T4 and free T3 with measurable TSH. TSHomas account for about 0.5%–3% of pituitary adenomas, and 70%–80% secrete only TSH (Beck-Peccoz 2013).

Findings that separate a TSHoma from resistance to thyroid hormone (Beck-Peccoz 2013).

Test Finding favoring TSHoma Finding favoring RTH
TRH test (200 µg IV; samples at 0, 20, 60, 90 and 120 min) Blunted TSH response in 90% TSH response usually preserved
T3 suppression test (80–100 µg/day for 10 days) Complete TSH inhibition never reported Partial TSH inhibition
Glycoprotein hormone α-subunit High in about 70%; high α-subunit/TSH molar ratio in about 80% Not applicable
Family studies and genetics Not applicable Same pattern in first-degree relatives (dominant inheritance in about 70%); THRB mutation in about 75%–80%
Pituitary MRI and clinical features Lesion on MRI; visual defects, headache or co-secretion (acromegaly, galactorrhea) Not applicable
  • Tissue markers. SHBG (liver) and carboxy-terminal telopeptide of type I collagen (bone) reflect peripheral thyroid hormone action and help separate TSHoma from RTH (Beck-Peccoz 2013). SHBG is elevated in TSHoma and normal or mildly elevated in RTH (Kageyama 2026). SHBG is the most discriminatory tissue marker. Estrogen therapy, liver dysfunction, insulin resistance, obesity and growth hormone excess also alter it, and growth hormone is co-secreted in about 18% of TSHomas (Koulouri 2013). Pituitary incidentalomas in healthy people reduce the specificity of MRI (Beck-Peccoz 2013).

  • α-Subunit/TSH molar ratio. The ratio is [α-subunit (µg/L) ÷ TSH (mU/L)] × 10. Its cutoff depends on gonadotropin concentrations, which differ with menopause (Beck-Peccoz 2013).

Prolactin and macroprolactin

  • Single measurement. A single serum prolactin is recommended, and dynamic tests of prolactin secretion are not used for diagnosis. Assay reference limits are generally <25 µg/L (ng/mL) and higher in women (Melmed 2011).
  • Thresholds. Prolactin >500 µg/L is diagnostic of a macroprolactinoma. Prolactin >250 µg/L usually indicates a prolactinoma. Medication-induced hyperprolactinemia usually gives 25–100 µg/L, and some drugs raise prolactin above 200 µg/L without an adenoma (Melmed 2011).
  • Exclusions. In symptomatic nonphysiological hyperprolactinemia, medication use, renal failure, hypothyroidism and pituitary or parasellar tumors are excluded. Pregnancy, breastfeeding, stress, exercise and sleep are physiological causes (Melmed 2011).
  • Drug-induced elevation. The drug is stopped for 3 days or replaced, and prolactin is remeasured. Antipsychotics are changed only with the prescribing physician. When the drug cannot be stopped and the elevation did not begin with the drug, pituitary MRI is performed (Melmed 2011).
  • Macroprolactin. Macroprolactin is assessed in asymptomatic patients with hyperprolactinemia (Melmed 2011). PEG precipitation is described in Analytical Methods and Immunoassays in Clinical Chemistry.
  • Hook effect. Serial dilution, including 1:100, is recommended for a large pituitary tumor with a mildly raised prolactin (Melmed 2011). The mechanism is covered in Analytical Methods and Immunoassays in Clinical Chemistry.

Growth hormone and IGF-1

  • IGF-1 assays. IGF-1 assays are calibrated to the international standard 02/254 and use method-specific age-adjusted reference intervals. In 15,014 subjects aged 0–94 years, IGF-1 fell after birth, rose to a pubertal peak at 15 years and then declined continuously. Women had lower mean IGF-1 across the lifespan (Bidlingmaier 2014). Sex-stratified intervals are likely unnecessary after puberty when the normative population is large. High BMI lowers IGF-1. No evidence shows that IGF-1 measurement by mass spectrometry is superior to immunoassay. GH immunoassays are calibrated to standard 98/574 (Giustina 2024).
  • Acromegaly diagnosis (14th Acromegaly Consensus Conference, Giustina 2024). With typical clinical features, IGF-1 >1.3 times the upper limit of normal for age confirms acromegaly. A fasting random GH informs prognosis and is not required. Equivocal IGF-1 is repeated in the same assay, and an oral glucose tolerance test (OGTT) may help.
  • OGTT protocol. Glucose 75 g is given after fasting, and GH nadir is measured at 30, 60, 90 and 120 minutes. BMI-based nadir cutoffs of <0.4 µg/L (BMI <25 kg/m²) and <0.2 µg/L (BMI ≥25 kg/m²) are proposed. Oral estrogen is stopped 4 weeks before the OGTT where possible (Giustina 2024).
  • Previous criteria. The 1999 Cortina conference excluded acromegaly with random GH <0.4 µg/L or OGTT nadir <1 µg/L with normal IGF-1. The 2010 conference made the OGTT unnecessary when IGF-1 and GH are clearly raised and allowed a nadir <0.4 µg/L with ultrasensitive assays. The Endocrine Society 2014 guideline used IGF-1 normalized for age, confirmed when needed by failure of GH to suppress below 1 µg/L on OGTT (Giustina 2024).

GH stimulation tests for adult GH deficiency.

Test Peak GH cutoff for deficiency Comment Source
Insulin tolerance test (ITT) 5.1 ng/mL Reference standard; labor intensive; risk of severe hypoglycemia; evaluable in 82% of first tests Garcia 2018
ITT as reference in the glucagon study <3 ng/mL (cortisol <18 µg/dL for adrenal insufficiency) Gold standard used to derive GST cutoffs Hamrahian 2016
Oral macimorelin 2.8 ng/mL (sensitivity 87%, specificity 96%); 5.1 ng/mL gave 92% and 96% Evaluable in 99%; 97% reproducible Garcia 2018
Glucagon stimulation test (GST), fixed dose (1 mg, or 1.5 mg if >90 kg) 1.0 ng/mL (sensitivity 92%, specificity 100%) Cortisol cutoff 8.8 µg/dL for secondary adrenal insufficiency Hamrahian 2016
GST, weight-based (0.03 mg/kg) 2.0 ng/mL (sensitivity 96%, specificity 100%) Cortisol cutoff 11.2 µg/dL; a 3-ng/mL GH cutoff misclassifies some GH-sufficient adults Hamrahian 2016
  • Assay variation. GH and IGF-1 results differ among assays, and GH cutoffs are specific to the stimulation test (Yuen 2019).

Hypopituitarism: basal cutoffs, axis-by-axis testing and causes

Axis Test Interpretation Source
Adrenal (secondary) ITT, GST or 250-µg cosyntropin test Cortisol cutoffs are assay and test specific; GST cortisol 8.8 µg/dL (fixed dose) or 11.2 µg/dL (weight-based) Hamrahian 2016; Javorsky 2021
Thyroid (central) Free T4 with TSH Low free T4 with inappropriately low or normal TSH; treatment monitored by free T4 Persani 2018
Growth hormone ITT, macimorelin or GST Test-specific cutoffs (table above) Garcia 2018; Hamrahian 2016
Prolactin Single serum prolactin Pituitary and parasellar tumors are causes of hyperprolactinemia Melmed 2011
Gonadal Fasting morning total testosterone in men, repeated to confirm, then evaluation of the cause Covered in Reproductive Endocrinology and Pregnancy Screening: Gonadal Hormones, hCG and Prenatal Testing Bhasin 2018
Posterior pituitary Water deprivation and copeptin tests Covered in Water, Electrolytes, Osmolality and Acid-Base Disorders Not applicable
  • Order of replacement. In central hypothyroidism, levothyroxine is started only after cortisol secretion is shown to be preserved or hydrocortisone replacement is in place (Persani 2018).
  • Basal cortisol in suspected secondary adrenal insufficiency. An 08:00–09:00 serum cortisol <3 µg/dL (83 nmol/L) on two measurements with a normal or low ACTH is highly suggestive of secondary adrenal insufficiency. A basal cortisol >15 µg/dL (414 nmol/L) in an unstressed patient virtually excludes it, and values of 3–15 µg/dL require dynamic testing. Cortisol is drawn at least 18–24 h after the last hydrocortisone dose (Iglesias 2024).
  • Assay dependence of basal cutoffs. The Endocrine Society hypopituitarism cutoffs rest on very low-quality evidence and were derived with older cortisol immunoassays. With the Roche Elecsys Cortisol II assay, morning cortisol ≤60.9 µg/L (6.1 µg/dL) predicted central adrenal insufficiency with 96.3% specificity, and >141 µg/L (14.1 µg/dL) excluded it with 96.2% sensitivity, against a 1-µg ACTH test reference (Gasco 2026).
  • Central hypothyroidism. Free T4 below the reference interval with an inappropriately low or normal TSH on at least two determinations confirms central hypothyroidism. TSH may be slightly elevated (<10 mU/L). In pituitary disease follow-up, a fall in free T4 >20% with a low or normal TSH suggests mild central hypothyroidism (Persani 2018).
  • Gonadotropin deficiency. In men, low testosterone with low or normal LH and FSH on at least two mornings indicates hypogonadotropic hypogonadism. In women, low estradiol with low or normal FSH and LH indicates it. In a postmenopausal woman not taking hormone therapy, the absence of raised FSH and LH is sufficient for the diagnosis (Iglesias 2024).
  • GH deficiency without stimulation. A low IGF-1 with three or more other pituitary hormone deficiencies is sufficient to diagnose GH deficiency (Iglesias 2024), with a probability above 97% (Aversa 2024). About 20% of adults with GH deficiency have a normal IGF-1 (Iglesias 2024).
  • Causes. Sellar tumors and masses cause about 50% of acquired hypopituitarism (Zhang 2025). Sheehan syndrome is pituitary necrosis after postpartum hemorrhage and accounted for 13.8% of hypopituitarism cases in one series. Pituitary apoplexy is hemorrhage or infarction of the pituitary, often into an adenoma, and hypoprolactinemia at diagnosis predicts a lower chance of recovery (Iglesias 2024). Primary empty sella is found in 8%–35% of the general population (Zhang 2025), and hypopituitarism occurs in 31%–65% of patients with primary empty sella syndrome (Iglesias 2024).

ACTH-cortisol axis: circadian rhythm and cortisol assays

  • Circadian rhythm and late-night saliva. Patients with Cushing syndrome lose the normal late-night cortisol nadir. The nadir is entrained to sleep onset, so saliva is collected at the usual bedtime. Late-night salivary cortisol (LNSC) is unsuitable in night-shift workers (Fleseriu 2021).
  • Assay specificity. Immunoassays cross-react with cortisol metabolites and synthetic glucocorticoids. HPLC and LC-MS/MS do not (Nieman 2008). One cortisol immunoassay cross-reacted 23.9% with prednisolone and 17.8% with 11-deoxycortisol (Javorsky 2021). Mass spectrometry for LNSC measures cortisol and cortisone and avoids contamination from topical hydrocortisone, with higher sensitivity and lower specificity than immunoassay (Fleseriu 2021).
  • Assay-dependent cutoffs. Specific monoclonal immunoassays and LC-MS/MS give about 20% lower cortisol than older polyclonal assays (Javorsky 2021).

Cushing syndrome testing

Initial tests and cutoffs for Cushing syndrome

  • Who is tested. Exogenous glucocorticoid use is excluded by drug history first. Testing is recommended for multiple progressive features and for adrenal incidentaloma (Nieman 2008).
  • Tests not recommended for diagnosis. Random serum cortisol, random plasma ACTH, urinary 17-ketosteroids, the insulin tolerance test, the loperamide test and tests of cause (imaging, 8-mg DST) are not used to establish Cushing syndrome (Nieman 2008).

First-line tests for Cushing syndrome: Endocrine Society 2008 and Pituitary Society 2021.

Test Abnormal result (Nieman 2008) Practice points (Fleseriu 2021)
24-hour urine free cortisol (UFC) Above the assay reference range; at least 2 collections 2–3 collections; random variability up to 50%; affected by sex, BMI, age, urine volume and sodium intake; LNSC preferred with CrCl <60 mL/min or urine >5 L/24 h
Late-night salivary cortisol >145 ng/dL (4 nmol/L); 2 samples At least 2–3 samples; bedtime sampling; used for cyclic disease and recurrence
1-mg overnight DST (dexamethasone at 2300–2400 h, cortisol at 0800 h) >1.8 µg/dL (50 nmol/L) Preferred first test when an adrenal tumor is suspected; serum dexamethasone measured when a false positive is suspected
Low-dose DST (2 mg/day for 48 h) Listed as an initial test Listed with the 1-mg DST
  • Changed emphasis. The 2008 guideline recommended one of four initial tests chosen by patient suitability (Nieman 2008). The 2021 consensus recommends starting with DST, UFC or LNSC by local availability and starting with the DST when an adrenal tumor is suspected, using LNSC then only if cortisone is also reported (Fleseriu 2021).
  • Second test. An abnormal first result is followed by another recommended test. Concordantly negative results on two different tests end testing except in suspected cyclic disease. Concordantly positive results lead to tests of cause (Nieman 2008).
  • DST cutoffs in adrenal incidentaloma. Cortisol <1.8 µg/dL after 1 mg dexamethasone excludes dysregulated cortisol production from an incidentaloma. Values >5 µg/dL (138 nmol/L) generally indicate overt Cushing syndrome, and a 5-µg/dL cutoff lowers sensitivity when used for diagnosis (Fleseriu 2021). The 2025 Endocrine Society primary aldosteronism guideline suggests a 1-mg DST in every patient with primary aldosteronism and an adrenal adenoma (Adler 2025).

Sources of error in dexamethasone and cortisol testing

Effect Cause Source
False-positive DST Rapid dexamethasone transit or malabsorption (chronic diarrhea, celiac disease) Fleseriu 2021
False-positive DST CYP3A4 inducers: phenytoin, phenobarbital, carbamazepine, rifampicin, St John's wort, alcohol Nieman 2008; Fleseriu 2021
False-positive DST High CBG from oral estrogen, pregnancy or chronic active hepatitis Fleseriu 2021
False-negative DST Inhibited dexamethasone metabolism (fluoxetine, cimetidine, diltiazem) Fleseriu 2021
Nonneoplastic hypercortisolism Pregnancy, depression, alcohol dependence, glucocorticoid resistance, severe obesity, poorly controlled diabetes, physical stress, malnutrition, intense exercise, hypothalamic amenorrhea Nieman 2008
  • Special populations. UFC is used in pregnancy, and dexamethasone testing is avoided. Patients on antiepileptic drugs that speed dexamethasone clearance are tested by nonsuppressed cortisol in blood, saliva or urine. UFC or LNSC is used for suspected cyclic Cushing syndrome (Nieman 2008).

ACTH-dependent Cushing syndrome: pituitary versus ectopic source

  • ACTH-dependent versus ACTH-independent. Once Cushing syndrome is established, plasma ACTH is generally >20 pg/mL in ACTH-dependent and <10 pg/mL in ACTH-independent disease. About 30% of patients have ACTH in a 5–20 pg/mL gray zone and need repeat testing and adrenal imaging. ACTH-dependent disease is 80%–85% of Cushing syndrome (Savas 2022).
  • High-dose DST. With 8 mg dexamethasone, a fall in basal cortisol of ≥50% is the proposed positive response. The test is most often negative in ectopic ACTH secretion (Savas 2022).
  • Dynamic tests. Corticotroph adenomas retain glucocorticoid-receptor feedback at high dexamethasone doses and overexpress V2 and V1b (V3) vasopressin receptors and CRH receptors. A rise in ACTH and cortisol after CRH or desmopressin usually indicates Cushing disease. Well-differentiated neuroendocrine tumors can express these receptors and give false positives. Test results are discordant in up to one-third of patients (Fleseriu 2021).
  • Inferior petrosal sinus sampling (IPSS). Of 215 surgically confirmed cases of Cushing disease among 281 patients studied, a basal central-to-peripheral ACTH ratio ≥2.0 identified 205 (95% sensitivity) with 100% specificity. A peak ratio ≥3.0 after CRH identified all 203 tested patients with Cushing disease with no false positives. An intersinus gradient ≥1.4 predicted the adenoma side in 68%–71% (Oldfield 1991). A gradient <2 before or <3 after stimulation suggests an ectopic tumor, with false negatives and false positives reported. IPSS is not sufficiently reliable for lateralization (Fleseriu 2021).
  • MRI size and IPSS. All patients with lesions <6 mm have IPSS, and lesions ≥10 mm with dynamic tests consistent with Cushing disease do not need it. Expert opinion differs for 6–9 mm lesions, and most experts recommend IPSS. The high-dose DST has low overall accuracy. Positive high-dose DST and CRH tests together predict Cushing disease, and discordant results require IPSS (Fleseriu 2021).
  • Recurrence. LNSC is the most sensitive test for recurrence and becomes abnormal before DST and UFC (Fleseriu 2021).

IPSS interpretation (Oldfield 1991; Fleseriu 2021).

Measure Calculation Cutoff for a pituitary source
Basal ratio Inferior petrosal sinus ACTH ÷ peripheral ACTH ≥2.0
Stimulated ratio (CRH) Peak inferior petrosal sinus ACTH ÷ peripheral ACTH ≥3.0
Intersinus gradient Higher sinus ACTH ÷ lower sinus ACTH ≥1.4 predicted the side in 68%–71% (Oldfield 1991); not reliable for lateralization (Fleseriu 2021)

Adrenal insufficiency testing

  • Standard test. The 250-µg cosyntropin test (15 µg/kg in infants; 125 µg below age 2 years) with cortisol at 30 or 60 minutes is suggested. A peak cortisol <500 nmol/L (18 µg/dL), assay dependent, indicates adrenal insufficiency. Its sensitivity for primary adrenal insufficiency is 0.92 (Bornstein 2016).
  • Assay-specific cutoffs. The 18-µg/dL cutoff derives from older polyclonal assays. Deming-derived 30-minute cutoffs were 14.6 µg/dL (Roche Elecsys II), 14.8 µg/dL (Beckman Access) and 14.5 µg/dL (LC-MS/MS). With 18 µg/dL applied to the newer assays, 22%–32% of patients were classified as insufficient, against 14.5% with the older assay (Javorsky 2021).
  • Morning cortisol. When cosyntropin testing is not feasible, a morning (6–10 am) cortisol <140 nmol/L (5 µg/dL) with ACTH is a preliminary test. Proposed rule-out values range from >285 nmol/L (10.3 µg/dL) to >480 nmol/L (17 µg/dL). Random cortisol does not rule out adrenal insufficiency (Bornstein 2016).
  • Primary versus secondary. Plasma ACTH >2-fold the upper reference limit with confirmed cortisol deficiency indicates primary adrenal insufficiency. Renin and aldosterone are measured together, and a high renin with normal or low aldosterone indicates mineralocorticoid deficiency, which can be the first sign. DHEAS well below the age- and sex-specific lower limit is an early clue. The cosyntropin test is the gold standard for primary but not secondary adrenal insufficiency (Bornstein 2016).

Glucocorticoid-induced adrenal insufficiency: morning cortisol on a physiologic dose (ESE/ES 2024, Beuschlein 2024).

Morning serum cortisol Interpretation
>300 nmol/L (10 µg/dL) HPA axis recovered; glucocorticoids stopped
150–300 nmol/L (5–10 µg/dL) Physiologic dose continued; repeat after weeks to months
<150 nmol/L (5 µg/dL) Physiologic dose continued; repeat after a few months
  • LC-MS/MS performance. Morning cortisol by LC-MS/MS >327 nmol/L (11.8 µg/dL) gave 98% sensitivity for excluding glucocorticoid-induced adrenal insufficiency, and <152 nmol/L (5.5 µg/dL) gave 98% specificity for confirming it (Beuschlein 2024).
  • Physiologic dose. The physiologic daily dose equivalent is hydrocortisone 15–25 mg, prednisone or prednisolone 4–6 mg, methylprednisolone 3–5 mg or dexamethasone 0.25–0.5 mg (Beuschlein 2024).

Primary aldosteronism

Primary aldosteronism screening: Endocrine Society 2025 and 2016

Primary aldosteronism screening and confirmation: Endocrine Society 2025 with the 2016 rule.

Element Current rule (Adler 2025) Previous rule (Funder 2016)
Who is screened All individuals with hypertension Defined groups: BP >150/100 mm Hg on 3 days; resistant hypertension or BP controlled on ≥4 drugs; hypertension with spontaneous or diuretic-induced hypokalemia, adrenal incidentaloma or sleep apnea; family history of early hypertension or stroke before age 40 years; hypertensive first-degree relatives of patients with PA
Screening test Aldosterone, renin and aldosterone-to-renin ratio (ARR), morning, seated ARR
Positive screen Renin suppressed (PRA ≤1 ng/mL/h or DRC ≤8.2 mU/L); aldosterone ≥10 ng/dL (277 pmol/L) by immunoassay or ≥7.5 ng/dL (208 pmol/L) by LC-MS/MS; ARR >20 (ng/dL per ng/mL/h) or >70 (pmol/L per mU/L) by immunoassay; ARR cutoff about 25% lower with LC-MS/MS Most common ARR cutoff 30 (ng/dL per ng/mL/h)
Confirmatory (suppression) testing Only with intermediate probability of lateralizing PA when surgery is wanted; not recommended in resistant hypertension with hypokalemia and overt renin-independent aldosterone production; unnecessary in familial hyperaldosteronism One or more confirmatory tests after a positive ARR; may be omitted with spontaneous hypokalemia, undetectable renin and aldosterone >20 ng/dL (550 pmol/L)
Lateralization CT and adrenal venous sampling (AVS) AVS by an experienced radiologist; patients <35 years with spontaneous hypokalemia, marked aldosterone excess and a unilateral adenoma on CT may proceed without AVS
  • Sodium intake. Dietary sodium restriction is avoided before screening, and local laboratory cutoffs are used where possible (Adler 2025).
  • Interfering drugs. A positive screen on a β-blocker or central α2-agonist is repeated after 2 weeks off the drug if safe. A negative screen is repeated after withdrawal, for 4 weeks for mineralocorticoid receptor antagonists. Aldosterone of 10–15 ng/dL (277–416 pmol/L) by immunoassay on a β-blocker may be a false positive (Adler 2025).

Effects of drugs and potassium on screening tests (Adler 2025).

Direction Agents
Lower renin (false-positive ARR) β-blockers, clonidine, α-methyldopa, NSAIDs
Raise renin (false-negative ARR) Mineralocorticoid receptor antagonists, diuretics including amiloride and triamterene, ARBs, ACE inhibitors, SGLT2 inhibitors
Lower aldosterone ARBs, ACE inhibitors, β-blockers, clonidine, α-methyldopa; hypokalemia
Raise aldosterone Diuretics, mineralocorticoid receptor antagonists, combined estrogen-progestin contraceptives or hormone therapy, drospirenone
Estrogen-progestin preparations Lower direct renin concentration and raise plasma renin activity

Aldosterone suppression tests and adrenal venous sampling

Aldosterone suppression tests (Adler 2025).

Test Protocol PA unlikely if
Oral sodium suppression Sodium 4–5 g/day for 3–4 days, then 24-hour urine Urine aldosterone <10 µg/24 h
Captopril challenge Seated 1 h; captopril 50 mg; sample at 2 h With suppressed renin, aldosterone <10 ng/dL (277 pmol/L) by immunoassay or <7.5 ng/dL (208 pmol/L) by LC-MS/MS
Saline suppression Seated 1 h; saline 2 L over 4 h Aldosterone <7.8 ng/dL (217 pmol/L) by immunoassay or <5.8 ng/dL (162 pmol/L) by LC-MS/MS
  • Before suppression testing. Potassium is normalized because hypokalemia causes false negatives. Saline loading is avoided with uncontrolled blood pressure or risk of pulmonary edema. The 2016 guideline named oral sodium loading, saline infusion, fludrocortisone suppression and captopril challenge as confirmatory tests (Funder 2016).

Adrenal venous sampling indices (Adler 2025).

Index Cutoff without cosyntropin Cutoff with cosyntropin
Selectivity index >1.4 to 3 >5
Lateralization index ≥4 lateralizing; <3 bilateral; 3–4 interpreted with caution ≥4 lateralizing; <3 bilateral; 3–4 interpreted with caution
  • Cosyntropin during AVS. No consensus exists on cosyntropin stimulation for lateralization (Adler 2025).

Congenital adrenal hyperplasia: 21-hydroxylase deficiency and other enzyme defects

  • Testing beyond infancy. Symptomatic individuals are screened with an early-morning (before 8 am) serum 17-hydroxyprogesterone (17OHP) by LC-MS/MS. Menstruating females are sampled in the early follicular phase. Borderline 17OHP is followed by a cosyntropin test with a full adrenocortical profile to separate 21-hydroxylase deficiency from other enzyme defects. Random 17OHP can be normal in nonclassic disease (Speiser 2018).
  • Other raised steroids. 21-Deoxycortisol, androstenedione and testosterone are usually raised in 21-hydroxylase deficiency (Speiser 2018).
  • Newborn period. 17OHP is high at birth and falls in healthy infants, and it rises in affected infants. Prematurity, illness and stress raise 17OHP, and antenatal corticosteroids may lower it. Cosyntropin tests are deferred until after 24–48 hours of life. 21-Deoxycortisol is normally low, so a raised value is highly specific for 21-hydroxylase deficiency (Speiser 2018). Newborn screening programs are covered in Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders.
  • LC-MS/MS thresholds for nonclassic disease. In 99 hyperandrogenic females, LC-MS/MS thresholds for nonclassic CAH were 3.0 nmol/L (basal 17OHP) and 20.7 nmol/L (stimulated 17OHP). Basal 21-deoxycortisol ≥0.31 nmol/L and stimulated ≥13.3 nmol/L gave 100% sensitivity with 96.8% and 100% specificity. Stimulated 17OHP ≥8.0 nmol/L or 21-deoxycortisol ≥1.0 nmol/L identified heterozygotes with 100% sensitivity. LC-MS/MS 17OHP thresholds are lower than immunoassay-based thresholds (Ng 2023).
  • Stress dosing. In nonclassic CAH, hydrocortisone stress dosing for major surgery, trauma or childbirth is suggested only with a cosyntropin-stimulated cortisol <14–18 µg/dL (<400–500 nmol/L) or iatrogenic adrenal suppression (Speiser 2018).

Other enzyme defects causing congenital adrenal hyperplasia.

Defect (gene) Frequency Raised Low Blood pressure and potassium Genital phenotype Source
11β-hydroxylase (CYP11B1) About 5%–8% of CAH 11-Deoxycortisol, DOC, 17OHP, androgens, ACTH Cortisol, renin Low-renin hypertension in about two-thirds; hypokalemia 46,XX virilized Lu 2024; Chan 2026; Bala 2026
17α-hydroxylase/17,20-lyase (CYP17A1) About 1% of CAH DOC, corticosterone, progesterone, ACTH, FSH, LH Cortisol, sex steroids; 17OHP normal in 79% Hypertension 57%; hypokalemia 45% 46,XY undervirilized; 46,XX primary amenorrhea without breast development Willemsen 2025
3β-HSD type 2 (HSD3B2) Rare Δ5 steroids (17-OH-pregnenolone, DHEA, DHEAS); high 17-OH-pregnenolone/17OHP ratio Δ4 steroids Salt wasting in severe forms 46,XY undervirilized; 46,XX mildly virilized Nicola 2022
P450 oxidoreductase (POR) Rare Progesterone, 17OHP Variable cortisol reserve Usually normal Disorder of sex development; maternal virilization; skeletal malformations Wang 2026
Lipoid CAH (STAR) Rare ACTH All adrenal and gonadal steroids; no accumulating precursor Salt wasting in 58.6% Female external genitalia regardless of karyotype in the classic form Lee 2026; Chan 2026
  • 11β-Hydroxylase deficiency. 11β-Hydroxylase converts DOC to corticosterone and 11-deoxycortisol to cortisol. Accumulated DOC is a mineralocorticoid and causes low-renin hypertension with hypokalemia (Bala 2026). Hypertension with androgen excess separates 11β-hydroxylase deficiency from 21-hydroxylase deficiency (Chan 2026).
  • 17α-Hydroxylase deficiency. In a meta-analysis of 465 patients, corticosterone was high in 92.0%, cortisol low in 84.8% and the corticosterone-to-cortisol ratio raised in 94.9%. Mean age at diagnosis was 19 years (Willemsen 2025).
  • 3β-HSD2 deficiency. After ACTH stimulation, 17-OH-pregnenolone >150 nmol/L supports the diagnosis (Nicola 2022).

Pheochromocytoma and paraganglioma testing

  • Initial tests. Plasma free metanephrines or urinary fractionated metanephrines are the initial tests. Liquid chromatography with mass spectrometric or electrochemical detection is preferred over immunoassay. Urine collections include creatinine to verify completeness (Lenders 2014).
  • Sampling position. Blood for plasma metanephrines is drawn after ≥30 minutes fully recumbent, and reference intervals come from supine samples. A positive seated result is repeated supine (Lenders 2014).
  • 3-Methoxytyramine. An overnight fast is required only when 3-methoxytyramine is measured. Raised 3-methoxytyramine is common in SDHx-related tumors (Lenders 2014).
  • Reference intervals. Age-specific reference intervals apply to plasma normetanephrine, and sex-specific intervals apply to urinary metabolites. Plasma and urinary normetanephrine are slightly higher in hypertensive than normotensive people (Eisenhofer 2019).
  • Degree of elevation. A single metabolite ≥3-fold the upper cutoff is rarely false positive. Simultaneous elevation of normetanephrine and metanephrine is also rarely false positive. Borderline results are repeated supine or followed over time (Lenders 2014).
  • Genetic testing. Shared decision-making about germline testing is recommended for all patients with pheochromocytoma or paraganglioma (Lenders 2014).

Causes of falsely raised metanephrines (Lenders 2014).

Mechanism Examples
Analytical (some LC-ECD methods) Acetaminophen, α-methyldopa, sulfasalazine
Pharmacological Tricyclic antidepressants, phenoxybenzamine, MAO inhibitors, sympathomimetics, cocaine
Urinary metanephrines Labetalol, sotalol
Physiological Stress of critical illness
  • Clonidine suppression test. β-Blockers are withdrawn ≥48 hours before testing. The test is cancelled with blood pressure <110/60 mm Hg or volume depletion. Oral clonidine 300 µg/70 kg is given supine, and plasma normetanephrine is measured at 0 and 3 hours. A 3-hour normetanephrine that remains raised with a fall <40% is abnormal. The test lacks prospective validation (Lenders 2014).

Neuroblastoma: urinary catecholamine metabolites

  • Classic markers. In 114 patients, sensitivity was 80.7% for vanillylmandelic acid (VMA), 71.9% for homovanillic acid (HVA) and 61.3% for dopamine, and 91.2% had at least one raised value. High VMA was associated with favorable biology, high dopamine with unfavorable biology and normal HVA with better outcome. The dopamine/VMA ratio helped separate stage 4 from stage 4S in infants (Strenger 2007).
  • Expanded panel. In 301 patients, VMA and HVA together had 84% sensitivity. Normetanephrine was the most sensitive single metabolite (89%). An 8-metabolite panel (VMA, HVA, 3-methoxytyramine, dopamine, epinephrine, metanephrine, norepinephrine, normetanephrine) reached 95%. In MIBG-nonavid tumors, sensitivity rose from 33% with VMA and/or HVA to 89% with the panel (Verly 2017).

Multiple endocrine neoplasia: biochemical screening

  • MEN1 diagnosis. MEN1 is diagnosed by two or more primary MEN1-associated tumors (parathyroid, enteropancreatic, anterior pituitary), by one such tumor in a first-degree relative of a patient with MEN1, or by a germline MEN1 mutation (Thakker 2012).
  • MEN1 tumor frequencies. Parathyroid adenoma occurs in about 90%–95%, enteropancreatic tumors in 30%–70% (gastrinoma about 40%, insulinoma about 10%), pituitary adenoma in 30%–40% and adrenocortical tumors in about 40% (Thakker 2012).
  • MEN4. MEN4 is caused by CDKN1B mutations (12p13). Reported tumors include parathyroid and pituitary adenomas and reproductive organ tumors (Thakker 2012).

Biochemical screening in MEN1 mutation carriers (Thakker 2012).

Tumor Start age (years) Annual test
Parathyroid 8 Calcium, PTH
Gastrinoma 20 Gastrin (± gastric pH)
Insulinoma 5 Fasting glucose, insulin
Other pancreatic neuroendocrine tumors <10 Chromogranin A, pancreatic polypeptide, glucagon, VIP; annual imaging
Anterior pituitary 5 Prolactin, IGF-1; MRI every 3 years
  • MEN2 risk categories. The ATA classifies hereditary medullary thyroid carcinoma as highest risk (MEN2B and RET M918T), high risk (RET C634 and A883F) and moderate risk (other mutations). Patients with the MEN2B phenotype are tested for M918T first and A883F next (Wells 2015).
  • MEN2 screening. Pheochromocytoma screening with plasma free or 24-hour urinary metanephrines begins by age 11 years in high and highest risk and by age 16 years in moderate risk. Pheochromocytoma is excluded before thyroidectomy. Hyperparathyroidism screening with albumin-corrected or ionized calcium begins at the same ages in high and moderate risk (Wells 2015).
  • Calcitonin. Immunochemiluminometric calcitonin assays largely eliminate cross-reactivity with procalcitonin. Reference ranges are higher in men. Children have higher calcitonin, with proposed limits <40 pg/mL below 6 months and <15 pg/mL from 6 months to 3 years (Wells 2015). Calcitonin thresholds for imaging and doubling time are covered in Diagnostic Enzymes and Serum Tumor Markers.
  • Sporadic-appearing MTC. Germline RET testing in apparently sporadic MTC is covered in Medullary Thyroid Carcinoma (Cytology).

Reproductive Endocrinology and Pregnancy Screening: Gonadal Hormones, hCG and Prenatal Testing

Definition. Reproductive endocrine testing measures gonadal steroids, gonadotropins, anti-Müllerian hormone (AMH) and semen parameters to evaluate hypogonadism, hyperandrogenism, ovarian reserve and infertility (Bhasin 2018; Teede 2023; Björndahl 2022). Pregnancy testing covers hCG, prenatal screening for aneuploidy and neural tube defects, gestational diabetes screening and biomarkers of preeclampsia, preterm birth and fetal lung maturity (ACOG PB 226; Dungan 2023; ADA 2026).

Related page: Diagnostic Enzymes and Serum Tumor Markers (hCG outside pregnancy, phantom and pituitary hCG, germ cell tumor markers) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (high-dose hook effect, heterophile antibodies, LC-MS/MS for steroids) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (point-of-care urine hCG devices) Related page: Endocrine Function Tests: Thyroid, Adrenal and Pituitary (prolactin, thyroid function tests, nonclassic congenital adrenal hyperplasia) Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (diagnostic criteria for diabetes outside pregnancy) Related page: Drug Testing: Urine Drug Screening, Confirmation, Specimen Validity and Federal Workplace Rules (anabolic steroid testing) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (HELLP syndrome and thrombotic microangiopathy) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (hCG proficiency testing)

Male reproductive testing

  • Diagnosis of hypogonadism. Hypogonadism is diagnosed only with symptoms and signs of testosterone deficiency and unequivocally and consistently low testosterone. Fasting morning total testosterone measured with an accurate assay is the initial test, and a repeat fasting morning measurement confirms it. Free testosterone is measured by equilibrium dialysis or estimated with an accurate formula when total testosterone is near the lower limit or SHBG is altered. The cause of deficiency is then evaluated (Bhasin 2018).
  • Harmonized reference range. After cross-calibration to the CDC reference method, the harmonized 2.5th–97.5th percentile range for total testosterone in healthy nonobese men aged 19–39 years was 264–916 ng/dL. Assay differences explained much of the variation between cohorts (Travison 2017).
  • Assay standardization. The Endocrine Society position statement asked that proficiency testing judge accuracy against samples of known testosterone concentration, beyond agreement with peer methods, and that normative values be set for both sexes and children (Rosner 2007).
  • Free testosterone estimates. Calculated free testosterone from total testosterone and immunoassayed SHBG closely matched equilibrium dialysis except in pregnancy. Direct analog free testosterone immunoassays measured only a fraction of the dialysis value, varying with SHBG. The free androgen index (FAI = 100 × testosterone ÷ SHBG) varied with SHBG and is unreliable as an index of free testosterone. In pregnancy, estradiol occupies SHBG binding sites, so calculated free testosterone underestimates the dialysis value (Vermeulen 1999).

Free testosterone methods (Vermeulen 1999; Bhasin 2018).

Method Agreement with equilibrium dialysis Limitation
Equilibrium dialysis Reference Time-consuming
Calculation from total testosterone and SHBG Almost identical Underestimates in pregnancy
Direct analog immunoassay Fraction of the dialysis value Error varies with SHBG
Free androgen index Ratio varies with SHBG Unreliable as a free testosterone index

Semen analysis

  • Sixth edition (2021). The WHO manual, sixth edition, revised basic methods and is complemented by the ISO 23162:2021 standard for basic semen examination. It reintroduced the four-category classification of sperm motility and widened the purpose of semen examination to male reproductive function and general health (Björndahl 2022).
  • Reference distributions. The fifth-edition lower reference limits (5th centiles) came from men whose partners conceived within 12 months (Cooper 2010). Data collated for the 2021 manual combined the 2010 data with later studies of more than 3500 men from 12 countries (Campbell 2021). The sixth edition treats 5th centiles as one way to interpret results, and the 5th centile alone does not diagnose male infertility (Boitrelle 2021).

Semen lower reference limits (5th centiles): WHO 2021 (sixth edition) with WHO 2010 (fifth edition) (Boitrelle 2021; Cooper 2010; Campbell 2021).

Parameter 2021 data (Campbell 2021) 2010, fifth edition (Cooper 2010)
Semen volume 1.4 mL 1.5 mL
Sperm concentration 16 × 10⁶/mL 15 × 10⁶/mL
Total sperm number 39 × 10⁶ per ejaculate 39 × 10⁶ per ejaculate
Progressive motility 30% 32%
Total motility 42% 40%
Vitality 54% live 58% live
Normal forms 4% 4%
  • Post-vasectomy testing. Other contraception can be stopped when one uncentrifuged fresh semen specimen shows azoospermia or ≤100,000 nonmotile sperm/mL (Sharlip 2012).

Female reproductive hormones and reproductive aging

  • STRAW+10 staging. STRAW+10 stages reproductive aging by menstrual criteria with FSH, AMH, inhibin B and antral follicle count as supportive criteria. Age is not a staging criterion (Harlow 2012).
  • Early menopausal transition (stage −2). A persistent difference of ≥7 days in the length of consecutive cycles defines the stage. Early follicular FSH is raised but variable, and AMH and antral follicle count are low (Harlow 2012).
  • Late menopausal transition (stage −1). Amenorrhea of ≥60 days defines the stage. A random FSH >25 IU/L is characteristic, based on current international pituitary standards (Harlow 2012).
  • Postmenopause. FSH rises and estradiol falls until about 2 years after the final menstrual period, then both stabilize (Harlow 2012).
  • Premature ovarian insufficiency. Criteria used in STRAW+10 are age <40 years, 4 months of amenorrhea and two FSH values in the menopausal range at least 1 month apart (Harlow 2012).
  • After pelvic surgery. Endocrine status is assessed ≥3 months after hysterectomy or endometrial ablation because pelvic surgery can transiently raise FSH (Harlow 2012).
  • Method-specific cycle intervals. Automated immunoassays for estradiol, LH and progesterone show variable bias, so reference intervals are method specific. On Roche Elecsys in 85 normo-ovulatory women, median (5th–95th percentile) progesterone was 0.212 nmol/L (0.159–0.616) in the follicular phase and 28.8 nmol/L (13.1–46.3) in the luteal phase, peaking at 39.2 nmol/L in the intermediate luteal phase (Anckaert 2021).
  • Confirmation of ovulation. A single mid-luteal serum progesterone >3 ng/mL has been used to confirm ovulation retrospectively. A random progesterone ≥5 ng/mL confirmed ovulation with 89.6% sensitivity and 98.4% specificity in one European study (Su 2017). No minimum progesterone value guarantees normal luteal function (Abbib 2025).

Adult female reference intervals by cycle phase (Labcorp, Roche cobas electrochemiluminescence immunoassay, accessed 2026-11-17).

Analyte Follicular Ovulatory Luteal Postmenopausal
FSH (mIU/mL) 3.5–12.5 4.7–21.5 1.7–7.7 25.8–134.8
LH (mIU/mL) 2.4–12.6 14.0–95.6 1.0–11.4 7.7–58.5
Estradiol (pg/mL) 12.5–166.0 85.8–498.0 43.8–211.0 <6.0–54.7
Progesterone (ng/mL) 0.1–0.9 0.1–12.0 1.8–23.9 0.0–0.1

These intervals are specific to one immunoassay platform; cycle-phase intervals differ between methods, so each laboratory reports its own (Anckaert 2021).

Ovarian reserve and AMH

  • Ovarian reserve markers. Ovarian reserve is the number of oocytes remaining. Hormone levels and ultrasound features predict oocyte yield after controlled ovarian stimulation and are poor predictors of reproductive potential independent of age (ASRM 2020).
  • Factors that change AMH. Serum AMH peaks at age 20–25 years and is lower with higher BMI. Current or recent combined oral contraceptive use suppresses AMH, and AMH varies across the menstrual cycle. Laboratories use population- and assay-specific cutoffs (Teede 2023).

Hyperandrogenism and polycystic ovary syndrome

PCOS diagnostic criteria: 2023 international guideline and Rotterdam 2003

PCOS diagnostic criteria: 2023 international guideline with Rotterdam 2003.

Element Current rule (Teede 2023) Previous rule (Rotterdam 2003)
Diagnosis in adults Two of: clinical or biochemical hyperandrogenism; ovulatory dysfunction; polycystic ovarian morphology (PCOM) on ultrasound or by AMH; other causes excluded Two of: ovulatory dysfunction, hyperandrogenism and polycystic ovary morphology; no single criterion sufficient
AMH May define PCOM in adults in place of ultrasound; never a single diagnostic test; not used in adolescents; AMH and ultrasound are not both performed Not a criterion
Ultrasound PCOM Follicle number per ovary ≥20 in at least one ovary; ovarian volume ≥10 mL or follicle number per section ≥10 with older technology Polycystic ovary morphology
  • Simplified diagnosis. With irregular cycles and hyperandrogenism, PCOS is diagnosed without ultrasound or AMH. Adolescents require both hyperandrogenism and ovulatory dysfunction, and ultrasound and AMH are not recommended in adolescents because of poor specificity (Teede 2023).

  • Irregular cycles (Teede 2023). Cycles are irregular at 1 to <3 years after menarche when <21 or >45 days. From 3 years after menarche to perimenopause, cycles are irregular when <21 or >35 days or <8 per year. Any cycle >90 days after the first year, and primary amenorrhea by age 15 years or >3 years after thelarche, are also irregular.

Laboratory assessment of hyperandrogenism

  • Androgens measured. Total and free testosterone assess biochemical hyperandrogenism, and free testosterone can be estimated by the calculated free androgen index, which varies with SHBG (Vermeulen 1999). When testosterone is not raised, androstenedione and DHEAS can be measured, with poorer specificity and an age-related decline in DHEAS (Teede 2023).
  • Methods. Laboratories use validated LC-MS/MS for total testosterone, and for androstenedione and DHEAS when needed. Direct immunoassays for total or free testosterone have limited accuracy and poor sensitivity and precision in PCOS. Free testosterone is assessed by calculation, equilibrium dialysis or ammonium sulfate precipitation (Teede 2023).
  • Androgen-secreting tumors. Markedly raised androgens prompt evaluation for ovarian and adrenal neoplasms, congenital adrenal hyperplasia, Cushing syndrome, ovarian hyperthecosis after menopause, iatrogenic causes and severe insulin resistance. Some androgen-secreting neoplasms raise androgens only mildly to moderately. New-onset, severe or worsening hyperandrogenism, particularly after menopause, is investigated for androgen-secreting tumors and ovarian hyperthecosis (Teede 2023). Nonclassic congenital adrenal hyperplasia testing is covered in Endocrine Function Tests: Thyroid, Adrenal and Pituitary.

Human chorionic gonadotropin in pregnancy

  • Structure and variants. hCG has an α-subunit shared with LH, FSH and TSH and a hormone-specific β-subunit. Four independent variants share the hCGβ sequence: hCG from villous syncytiotrophoblast, hyperglycosylated hCG from cytotrophoblast, free β-subunit from nontrophoblastic malignancies and pituitary hCG from gonadotropes (Cole 2010a).
  • Hyperglycosylated hCG. Hyperglycosylated hCG averages 87% of total serum hCG in the third week of gestation, 51% in the fourth and 43% in the fifth week, and falls to <1% in the second and third trimesters. It is the principal variant made by choriocarcinoma cells (Cole 2010a).
  • Pituitary hCG. Pituitary hCG circulates at very low levels in men (mean 0.01 mIU/mL) and in pulses during the menstrual cycle in women (Cole 2010a). Its effect on low positive results outside pregnancy is covered in Diagnostic Enzymes and Serum Tumor Markers.
  • Serial hCG in symptomatic early pregnancy. In 287 women with pain or bleeding, a nondiagnostic ultrasound and a viable intrauterine pregnancy, log hCG rose linearly. The median rise was 50% at 1 day and 124% at 2 days. The minimal rise for a viable intrauterine pregnancy was 24% at 1 day and 53% at 2 days (Barnhart 2004).
  • hCG and gestational sac visualization. In early viable pregnancies, a gestational sac on transvaginal ultrasound was predicted in 50% at hCG 979 mIU/mL, 90% at 2,421 mIU/mL and 99% at 3,994 mIU/mL, in agreement with a 99% threshold of 3,510 mIU/mL reported in 2013. A yolk sac was predicted in 99% at 39,454 mIU/mL. Of ectopic pregnancies, 90% presented with hCG below 3,994 mIU/mL, so repeat hCG values are used to evaluate a pregnancy of unknown location (Park 2023).
  • Urine point-of-care devices. False-negative urine hCG devices from hCG β core fragment (hCGβcf) are covered in Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry. A screen with 500 pmol/L intact hCG plus 500,000 pmol/L hCGβcf showed that only 2 of 11 devices had minimal or no susceptibility (Nerenz 2014).
  • False-positive and persistent low hCG. Among 565 cases referred to the USA hCG Reference Service over 10 years were 83 false-positive hCG results, 103 cases of pituitary hCG, 168 cases of quiescent gestational trophoblastic disease and 60 nontrophoblastic tumors (Cole 2010b). Phantom hCG is covered in Diagnostic Enzymes and Serum Tumor Markers, and heterophile antibody interference in Analytical Methods and Immunoassays in Clinical Chemistry.

Gestational trophoblastic disease: hCG surveillance

  • Assay choice. GTN monitoring uses an hCG assay that detects all forms, including β-hCG, core hCG, C-terminal hCG, nicked free β, β core and preferably hyperglycosylated forms (Ngan 2025).
  • Persistent low hCG. Persistently low hCG is monitored continuously because some cases progress to GTN with rising hCG. A false-positive result is excluded by retesting with another assay kit or a urine hCG test (Ngan 2025).
  • Post-molar follow-up. hCG is measured every 1–2 weeks after evacuation. For a partial mole, one confirmatory normal hCG 1 month after normalization is recommended. For a complete mole, hCG is measured monthly for 6 months after normalization (Ngan 2025).
  • FIGO criteria for post-molar GTN. Post-molar GTN is usually diagnosed by hCG surveillance without symptoms (Ngan 2025). FIGO 2026 criteria are an hCG plateau (<10% rise or fall) over four measurements across ≥3 weeks (days 1, 7, 14 and 21), an hCG rise of >10% over three consecutive weekly measurements across ≥2 weeks (days 1, 7 and 14), or a histopathologic diagnosis of gestational choriocarcinoma, placental site trophoblastic tumor or epithelioid trophoblastic tumor. The former criterion of hCG elevation for 6 months or more was removed (Ngan 2026). A plateaued or rising hCG detects progression to GTN in 13%–20% of complete and 0.5%–5% of partial moles, and about 75% of GTN arises after a molar pregnancy (Ngan 2025).

Prenatal screening for aneuploidy

Serum and ultrasound screening for aneuploidy

  • ACOG Practice Bulletin 226 (2020). All patients are offered both screening and diagnostic tests and may accept or decline testing after counseling. The 2020 revision addresses cell-free DNA screening for all patients regardless of maternal age or baseline risk (ACOG PB 226).
  • Marker sets. First-trimester combined screening measures nuchal translucency, pregnancy-associated plasma protein A (PAPP-A) and free β-hCG at 10 weeks 3 days to 13 weeks 6 days. Second-trimester quadruple screening measures AFP, total hCG, unconjugated estriol (uE3) and inhibin A at 15–18 weeks (Malone 2005).
  • Multiples of the median (MoM). Serum AFP cutoffs expressed as MoM are more stable between centers and over time than percentiles (UK Collaborative Study 1977).

Detection of Down syndrome at a 5% false-positive rate (FASTER, Malone 2005).

Strategy Detection rate
First-trimester combined screening at 11 weeks 87%
First-trimester combined screening at 12 weeks 85%
First-trimester combined screening at 13 weeks 82%
Second-trimester quadruple screening 81%
Serum integrated screening 88%
Stepwise sequential screening 95%
Fully integrated screening (first-trimester measures at 11 weeks) 96%

Marker patterns in affected pregnancies.

Condition First-trimester markers Second-trimester markers Source
Trisomy 21 NT raised; PAPP-A reduced; free β-hCG raised AFP and uE3 low (about 0.8 MoM); hCG and inhibin A high (about 2 MoM) Mirsafaie 2022; Guibourdenche 2023
Trisomy 18 NT raised; free β-hCG and PAPP-A reduced AFP, uE3 and free β-hCG reduced; inhibin A not significantly different Bestwick 2013; Yoshida 2000
Trisomy 13 NT raised; free β-hCG and PAPP-A reduced Inhibin A raised Bestwick 2013
Open neural tube defect Not applicable AFP raised UK Collaborative Study 1977
  • Detection of trisomies 18 and 13 by Down syndrome screening. The Down syndrome algorithm in combined screening detected 42% of trisomy 18 and 59% of trisomy 13 at a 2.00% false-positive rate. The quadruple test detected 5% and 21%. Adding a trisomy 18 algorithm raised combined-test detection to 88% and 74% (Bestwick 2013).
  • Triple screen. Prospective second-trimester screening with AFP, hCG and uE3 plus maternal age detected 58% of Down syndrome cases (Haddow 1992).

Cell-free DNA screening (NIPS)

NIPS recommendations: ACMG 2023 with ACMG 2016.

Element Current rule (Dungan 2023) Previous rule (Gregg 2016)
Trisomies 21, 18 and 13 NIPS strongly recommended over traditional screening for all pregnant patients with singleton and twin gestations NIPS can replace conventional screening across the maternal age range from 9–10 weeks in patients who are not significantly obese
Sex chromosome aneuploidy NIPS strongly recommended to be offered Screening for sex chromosome aneuploidy becoming common practice
Copy-number variants and rare autosomal trisomies Emerging area of interest Screening for selected CNVs becoming common practice
  • Performance in a routine population (NEXT). In 15,841 women screened at 10–14 weeks, cfDNA detected 38 of 38 cases of trisomy 21 against 30 of 38 by standard screening. False-positive rates were 0.06% and 5.4%, and positive predictive values were 80.9% and 3.4%. The AUC for trisomy 21 was 0.999 against 0.958 (Norton 2015).
  • No-call results. Pretest counseling covers the consequences of positive, negative and no-call results (Gregg 2016).
  • Fetal fraction. Fetal fraction is the placental share of total cell-free DNA in maternal plasma. It generally reaches 10%–20% at its peak between 10 and 21 weeks and rises with gestational age. Most laboratories require a minimum fetal fraction of 2%–4% to report a result, and insufficient fetal fraction is the most common reason for a nonreportable result (SMFM 2025).
  • Causes of low fetal fraction. Fetal fraction falls as maternal weight rises because adipose tissue turnover adds maternal cfDNA. Low fetal fraction is more frequent in trisomy 13, trisomy 18 and digynic triploidy, and it is associated with low-molecular-weight heparin, autoimmune disorders and assisted reproduction (SMFM 2025).
  • Nonreportable results. Nonreportable rates range from 0.03% to 11.1% across studies, and an ACMG systematic evidence review estimated 0.85% across 31 studies. A nonreportable first attempt carried a relative risk of 130.3 for trisomy 21, 18 or 13 in a 2023 population-based cohort, so genetic counseling, comprehensive ultrasound and diagnostic testing are offered. A repeat screen succeeds in 75%–80% of cases (SMFM 2025).

Causes of discordant cfDNA results.

Cause Finding Source
Confined placental mosaicism Predicted false-positive rate 0.05% for sex chromosome aneuploidy; PPV for 45,X is 51%–71% without and 99% with ultrasound anomalies Grati 2017
Maternal copy-number variant Maternal duplications on chromosome 18 explained 2 of 4 discordant results Snyder 2015
Occult maternal malignancy 7 of 39 results with more than one aneuploidy were in women with cancer (18%); nonspecific gains and losses across multiple chromosomes Bianchi 2015
Vanishing twin Additional fetal haplotypes in 0.42% of SNP-based tests; 42.1% of confirmed cases were vanishing twins, detected up to 8 weeks after the loss Curnow 2015
  • Confirmation. Sex chromosome aneuploidy on cfDNA is confirmed prenatally, preferably by amniocentesis when ultrasound is normal (Grati 2017).

Neural tube defect screening

  • Maternal serum AFP. Open spina bifida is best detected by maternal serum AFP at 16–18 weeks. At these weeks, 88% of anencephaly, 79% of open spina bifida and 3% of unaffected singleton pregnancies had AFP ≥2.5 MoM. Retesting borderline values reduced unaffected screen-positive results by about one-third (UK Collaborative Study 1977).
  • Amniotic fluid acetylcholinesterase (AChE). Among amniotic fluids with positive AFP, gel AChE was positive in 99.6% of anencephaly and 99.4% of open spina bifida. AChE was positive in 6% of pregnancies without malformation and without miscarriage, 47% of those ending in miscarriage and 75% of exomphalos. Fetal blood staining lowered the odds of open spina bifida for a positive result (Collaborative Acetylcholinesterase Study 1981).

Gestational diabetes screening

Related page: Diabetes and Glycemic Markers: Glucose, HbA1c, Ketones and the Hypoglycemia Workup (GDM screening and diagnostic criteria, early-pregnancy and postpartum testing)

  • One-step versus two-step. A 2021 USPSTF review found GDM in 11.5% with one-step and 4.9% with two-step screening without improved health outcomes. A1C at 24–28 weeks performs worse than the 50-g glucose load test (ADA 2026).

Preeclampsia and HELLP syndrome

  • Burden. Preeclampsia complicates 2%–8% of pregnancies worldwide (ACOG PB 222).
  • sFlt-1/PlGF ratio in PRAECIS. PRAECIS enrolled 1014 women hospitalized with hypertensive disorders at 23–35 weeks, and the 65% PPV and 96% NPV come from the 715-woman validation cohort. The AUC for preeclampsia with severe features was 0.92 against <0.75 for standard tests. Adverse maternal outcomes occurred in 16.1% with a ratio ≥40 and 2.8% with a ratio <40 (Thadhani 2022).
  • ACOG Clinical Practice Update 2024. ACOG gives guidance on a biomarker immunoassay to aid risk assessment of progression to preeclampsia with severe features in pregnant patients hospitalized for hypertensive disorders, updating Practice Bulletin 222 (ACOG 2024).
  • HELLP syndrome. Diagnosis requires hemolysis (peripheral smear, raised indirect bilirubin or low haptoglobin), significantly raised liver enzymes and a platelet count <100,000/mm³ after other causes of hemolysis and thrombocytopenia are excluded (Sibai 2004). Thrombotic microangiopathy testing is covered in DIC, Thrombotic Microangiopathy and Viscoelastic Testing.

sFlt-1/PlGF ratio cutoffs in two validation studies.

Study Population Cutoff Outcome window NPV PPV
PROGNOSIS (Zeisler 2016) Singleton pregnancy with suspected preeclampsia, 24+0 to 36+6 weeks 38 Rule-out within 1 week; rule-in within 4 weeks 99.3% 36.7%
PRAECIS (Thadhani 2022) Hospitalized hypertensive disorders, 23–35 weeks 40 Severe features within 2 weeks 96% 65%

Preterm labor: fetal fibronectin

  • Assay basis. Fetal fibronectin was measured in cervical and vaginal secretions with a monoclonal antibody (FDC-6) immunoassay. Women delivering at term rarely had values >0.05 µg/mL (50 ng/mL) between 21 and 37 weeks (4% of cervical and 3% of vaginal samples) (Lockwood 1991).
  • Performance. In preterm contractions with intact membranes, fetal fibronectin identified preterm delivery with 81.7% sensitivity and 82.5% specificity. It was detected in 93.8% of women with preterm rupture of membranes (Lockwood 1991).
  • Systematic review. The test was most accurate for birth within 7–10 days of testing in symptomatic women, with a positive likelihood ratio of 5.42 and a negative likelihood ratio of 0.25 (Honest 2002).
  • Sources of false positives. Recent digital vaginal examination, unprotected intercourse, vaginal bleeding or amniotic fluid from ruptured membranes can give false-positive results and make testing infeasible in up to 50% of women. In asymptomatic women, sensitivity is 20%–29% and the negative predictive value 96%–97% for birth before 34 weeks (Heng 2015).

Fetal lung maturity testing: history

  • Lamellar body count. Lamellar bodies, the storage form of surfactant, are counted in the platelet channel of hematology analyzers. The consensus protocol omitted centrifugation and suggested maturity at ≥50,000/µL and immaturity at ≤15,000/µL. The count performed as well as traditional phospholipid analysis (Neerhof 2001a).
  • Phospholipid tests. In 833 deliveries within 72 hours of amniocentesis, the negative predictive value for respiratory distress syndrome was 97.7% for the lamellar body count, 96.8% for the lecithin/sphingomyelin ratio with site-specific cutoffs and 94.7% for phosphatidylglycerol, reported as present (mature) or absent (immature). Lamellar body counts are faster, more objective and less expensive (Neerhof 2001b).
  • Specificity. Fetal lung maturity tests have high sensitivity and low diagnostic specificity, and they predict immaturity poorly (Grenache 2006). Gestational-age-specific lamellar body count cutoffs gave an AUC of 0.906 against 0.746 for a single 50,000/µL cutoff (Zhao 2013).
  • Current practice. Amniocentesis for fetal lung maturity is not recommended to guide delivery timing, even in suboptimally dated pregnancies, because pulmonary maturity does not indicate maturity of other fetal systems (ACOG CO 765).

Thyroid function and other laboratory values in pregnancy

  • TSH limits in pregnancy. The ATA 2026 guideline is current and replaced the 2017 guideline (Korevaar 2026; Alexander 2017). Under ATA 2017, pregnancy- and assay-specific TSH ranges from the local population were preferred. When these were unavailable, a fixed first-trimester upper limit of 4.0 mU/L, or the nonpregnant upper reference limit minus 0.5 mU/L, could be used (Osinga 2022).
  • Older generalized ranges. The ATA 2014 hypothyroidism guideline cited generalized ranges of 0.1–2.5 mIU/L (first trimester), 0.2–3.0 mIU/L (second) and 0.3–3.0 mIU/L (third) (Jonklaas 2014).
  • Binding proteins. Pregnancy raises TBG and cortisol-binding globulin. Their effect on thyroid tests and on Cushing syndrome testing in pregnancy is covered in Endocrine Function Tests: Thyroid, Adrenal and Pituitary.
  • Creatinine. In 243,534 Ontario pregnancies, mean serum creatinine was 60 µmol/L (0.68 mg/dL) before pregnancy, fell by 4 weeks to a nadir of 47 µmol/L (0.53 mg/dL) between 16 and 32 weeks and peaked at 64 µmol/L (0.72 mg/dL) after delivery. The 95th percentile was about 15 µmol/L above the 50th during pregnancy (Harel 2019).
  • Coagulation. PT, INR, APTT and thrombin time decreased and fibrinogen, D-dimer and fibrin degradation products increased with advancing gestation, and trimester-specific intervals differed from nonpregnant intervals (Zhang 2026).
  • Alkaline phosphatase. Serum ALP rises progressively through pregnancy and peaks near term, mainly from placental ALP with a bone contribution (Zhang B 2025). Placental ALP is the heat-stable isoenzyme produced by the syncytiotrophoblast. Third-trimester ALP usually reaches about twice the nonpregnant level and normalizes after delivery (Connolly 2022). In 12,728 pregnancies measured by the IFCC method, the upper quartile of ALP began at 56 U/L at 9–13 weeks, 76 U/L at 22–26 weeks and 171 U/L at 32–36 weeks, with a maximum of 465 U/L (Zhang L 2026).
  • Albumin and lipids. The albumin reference interval was 26.1–42.8 g/L in pregnant and 32.8–47.8 g/L in nonpregnant women (Mohammed 2022). Median total cholesterol rose from 4.42 mmol/L (171 mg/dL) before pregnancy to 6.50 mmol/L (251 mg/dL) at 36–40 weeks, and triglycerides from 0.86 mmol/L (76 mg/dL) to 3.23 mmol/L (286 mg/dL), from increased hepatic synthesis and reduced lipoprotein lipase activity (Wu 2022).

References

  1. Abbib N, Heylen A, Neyens S, et al. Diagnostic workup for a couple with unexplained infertility: VVOG guidance. Eur J Obstet Gynecol Reprod Biol X. 2025;27:100415. doi:10.1016/j.eurox.2025.100415. PMID 40689345
  2. Aberger S, Schreiber N, Pilz S, et al. Targeting calcitriol metabolism in acute vitamin D toxicity: a comprehensive review and clinical insight. Int J Mol Sci. 2024;25(18):10003. doi:10.3390/ijms251810003. PMID 39337491 (Aberger 2024)
  3. Achanti A, Szerlip HM. Acid-base disorders in the critically ill patient. Clin J Am Soc Nephrol. 2023;18(1):102–112. doi:10.2215/CJN.04500422. PMID 35998977
  4. Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2025;110(9):2453–2495. doi:10.1210/clinem/dgaf284. PMID 40658480
  5. Ahn YH. Monogenic kidney disorders as hidden drivers of electrolyte imbalance and hypertension. Electrolyte Blood Press. 2026;24(3):147–157. doi:10.5049/EBP.2026.24.e15. PMID 42812492
  6. Akkara Y, Narula K, Lazarus K, et al. Redefining diagnostic cut-offs for the indirect water deprivation test. Clin Endocrinol (Oxf). 2025;102(2):149–155. doi:10.1111/cen.15172. PMID 39639680
  7. Alanazi AS, Almutairi H, Gupta JK, et al. Osseous implications of proton pump inhibitor therapy: an umbrella review. Bone Rep. 2024;20:101741. doi:10.1016/j.bonr.2024.101741. PMID 38348455 (Alanazi 2024)
  8. Albert MS, Dell RB, Winters RW. Quantitative displacement of acid-base equilibrium in metabolic acidosis. Ann Intern Med. 1967;66(2):312–322. doi:10.7326/0003-4819-66-2-312. PMID 6016545
  9. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315–389. doi:10.1089/thy.2016.0457. PMID 28056690
  10. Alfonzo A, Harrison A, Baines R, et al. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. UK Kidney Association; 2020, updated July 2026. https://www.ukkidney.org/sites/default/files/documents/FINAL%20VERSION%20-%20UKKA%20CLINICAL%20PRACTICE%20GUIDELINE%20-%20MANAGEMENT%20OF%20HYPERKALAEMIA%20IN%20ADULTS%20-%20UPDATED%20JULY%202026_0.pdf (accessed 2026-11-17)
  11. American College of Cardiology. ACC/AHA issue updated guideline for managing lipids, cholesterol. Press release, March 13, 2026. https://www.acc.org/About-ACC/Press-Releases/2026/03/13/18/01/ACCAHA-Issue-Updated-Guideline-for-Managing-Lipids-Cholesterol (accessed 2026-11-17) (ACC 2026)
  12. American College of Obstetricians and Gynecologists. ACOG Clinical Practice Update: Biomarker Prediction of Preeclampsia With Severe Features. Obstet Gynecol. 2024;143(6):e153–e154. doi:10.1097/AOG.0000000000005576. PMID 38569186 (ACOG 2024)
  13. American College of Obstetricians and Gynecologists. ACOG Clinical Practice Update: screening for gestational and pregestational diabetes in pregnancy and postpartum. Obstet Gynecol. 2024;144(1):e20–e23. doi:10.1097/AOG.0000000000005612. PMID 42131962 (ACOG 2024)
  14. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 765: Avoidance of Nonmedically Indicated Early-Term Deliveries and Associated Neonatal Morbidities. Obstet Gynecol. 2019;133(2):e156–e163. doi:10.1097/AOG.0000000000003076. PMID 30681546 (ACOG CO 765)
  15. American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237–e260. doi:10.1097/AOG.0000000000003891. PMID 32443079 (ACOG PB 222)
  16. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics, Committee on Genetics, Society for Maternal-Fetal Medicine. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet Gynecol. 2020;136(4):e48–e69. doi:10.1097/AOG.0000000000004084. PMID 32804883 (ACOG PB 226)
  17. American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S27–S49. doi:10.2337/dc26-S002. PMID 41358893 (ADA 2026 section 2)
  18. American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S132–S149. doi:10.2337/dc26-S006. PMID 41358894 (ADA 2026 section 6)
  19. American Diabetes Association Professional Practice Committee for Diabetes. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S6–S12. doi:10.2337/dc26-SREV. PMID 41358896 (ADA 2026 Summary of Revisions)
  20. Amniotic fluid acetylcholinesterase electrophoresis as a secondary test in the diagnosis of anencephaly and open spina bifida in early pregnancy. Report of the Collaborative acetylcholinesterase Study. Lancet. 1981;2(8242):321–324. PMID 6115108 (Collaborative Acetylcholinesterase Study 1981)
  21. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014;130(25):e344–e426. doi:10.1161/CIR.0000000000000134. PMID 25249585 (Amsterdam 2014)
  22. Anckaert E, Jank A, Petzold J, et al. Extensive monitoring of the natural menstrual cycle using the serum biomarkers estradiol, luteinizing hormone and progesterone. Pract Lab Med. 2021;25:e00211. doi:10.1016/j.plabm.2021.e00211. PMID 33869706
  23. Arima H, Cheetham T, Christ-Crain M, et al. Changing the name of diabetes insipidus: a position statement of the Working Group for Renaming Diabetes Insipidus. Endocr J. 2022;69(11):1281–1284. doi:10.1507/endocrj.EJ20220831. PMID 36244744
  24. Asla Q, Sarda H, Segui N, et al. Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemia. Endocrine. 2024;83(3):747–756. doi:10.1007/s12020-023-03560-y. PMID 38214877 (Asla 2024)
  25. Aversa LS, Cuboni D, Grottoli S, et al. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to real life. J Clin Med. 2024;13(20):6079. doi:10.3390/jcm13206079. PMID 39458028
  26. Ayus JC, Moritz ML. Misconceptions and barriers to the use of hypertonic saline to treat hyponatremic encephalopathy. Front Med (Lausanne). 2019;6:47. doi:10.3389/fmed.2019.00047. PMID 30931308
  27. Bai X, Xu K, Ma Z, et al. Parathyroid hormone assay standardization in CKD-MBD: resolving heterogeneity for precision medicine. Front Endocrinol (Lausanne). 2025;16:1702206. doi:10.3389/fendo.2025.1702206. PMID 41341132 (Bai 2025)
  28. Baird G. Preanalytical considerations in blood gas analysis. Biochem Med (Zagreb). 2013;23(1):19–27. doi:10.11613/bm.2013.005. PMID 23457763
  29. Bala A, Banerjee S, George A, et al. Rare types of congenital adrenal hyperplasia: report of five children with 11β-hydroxylase deficiency including pathogenic and novel CYP11B1 variants. Arch Endocrinol Metab. 2026;70(5):e260073. doi:10.20945/2359-4292-2026-0073. PMID 42429691
  30. Balling M, Afzal S, Varbo A, et al. Remnant cholesterol: quantification, concentrations by sex and age, and risk of ischemic heart disease. Clin Chem. 2025;71(4):451–462. doi:10.1093/clinchem/hvae217. PMID 39723642
  31. Bararu-Bojan I, Vladeanu MC, Iliescu-Halitchi D, et al. Decoding primary hyperlipoproteinemias: a focus on the pathogenesis and diagnosis of familial hypercholesterolemia and familial combined hyperlipidemia. Diagnostics (Basel). 2026;16(15):2313. doi:10.3390/diagnostics16152313. PMID 42587551
  32. Barker SJ, Curry J, Redford D, Morgan S. Measurement of carboxyhemoglobin and methemoglobin by pulse oximetry: a human volunteer study. Anesthesiology. 2006;105(5):892–897. doi:10.1097/00000542-200611000-00008. PMID 17065881
  33. Barker SJ, Tremper KK, Hyatt J. Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry. Anesthesiology. 1989;70(1):112–117. doi:10.1097/00000542-198901000-00021. PMID 2912291
  34. Barker SJ, Tremper KK. The effect of carbon monoxide inhalation on pulse oximetry and transcutaneous PO2. Anesthesiology. 1987;66(5):677–679. doi:10.1097/00000542-198705000-00014. PMID 3578881
  35. Barnhart KT, Sammel MD, Rinaudo PF, et al. Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined. Obstet Gynecol. 2004;104(1):50–55. doi:10.1097/01.AOG.0000128174.48843.12. PMID 15229000
  36. Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction. Eur Thyroid J. 2018;7(2):55–66. doi:10.1159/000486957. PMID 29594056
  37. Batlle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988;318(10):594–599. doi:10.1056/NEJM198803103181002. PMID 3344005
  38. Baud FJ, Barriot P, Toffis V, et al. Elevated blood cyanide concentrations in victims of smoke inhalation. N Engl J Med. 1991;325(25):1761–1766. doi:10.1056/NEJM199112193252502. PMID 1944484
  39. Beck-Peccoz P, Lania A, Beckers A, et al. 2013 European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76–82. doi:10.1159/000351007. PMID 24783044
  40. Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–2280. doi:10.2337/dc18-1581. PMID 30224348
  41. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989. doi:10.1210/jc.2011-3213. PMID 22962670
  42. Beso S, Abubshait L. A case report of milk-alkali syndrome secondary to excessive antacid use. Clin Pract Cases Emerg Med. 2026;10(1):59–62. doi:10.5811/cpcem.48354. PMID 41666902 (Beso 2026)
  43. Bestwick JP, Huttly WJ, Wald NJ. Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. J Med Screen. 2013;20(2):57–65. doi:10.1177/0969141313484904. PMID 23761419 (Bestwick 2013)
  44. Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. J Clin Endocrinol Metab. 2024;109(7):1657–1683. doi:10.1210/clinem/dgae250. PMID 38724043
  45. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229. PMID 29562364
  46. Bianchetti DGAM, Amelio GS, Lava SAG, et al. D-lactic acidosis in humans: systematic literature review. Pediatr Nephrol. 2018;33(4):673–681. doi:10.1007/s00467-017-3844-8. PMID 29218437
  47. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA. 2015;314(2):162–169. doi:10.1001/jama.2015.7120. PMID 26168314
  48. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712–1721. doi:10.1210/jc.2013-3059. PMID 24606072
  49. Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293–2314. doi:10.1002/jbmr.4677. PMID 36245251 (Bilezikian 2022)
  50. Bima P, Lopez-Ayala P, Koechlin L, et al. Chest pain in cancer patients: prevalence of myocardial infarction and performance of high-sensitivity cardiac troponins. JACC CardioOncol. 2023;5(5):591–609. doi:10.1016/j.jaccao.2023.08.001. PMID 37969646 (Bima 2023)
  51. Bima P, Lopez-Ayala P, Koechlin L, et al. Derivation and validation of ESC-0/1-h algorithm for high-sensitivity troponin T and I in cancer patients. JACC Adv. 2025;4(6 Pt 1):101821. doi:10.1016/j.jacadv.2025.101821. PMID 40408798 (Bima 2025)
  52. Björndahl L, Kirkman Brown J. The sixth edition of the WHO Laboratory Manual for the Examination and Processing of Human Semen: ensuring quality and standardization in basic examination of human ejaculates. Fertil Steril. 2022;117(2):246–251. doi:10.1016/j.fertnstert.2021.12.012. PMID 34986984
  53. Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24–33. doi:10.1016/j.kint.2016.09.046. PMID 28003083
  54. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154–e1276. doi:10.1161/CIR.0000000000001423. PMID 41824552 (Blumenthal 2026)
  55. Boitrelle F, Shah R, Saleh R, et al. The sixth edition of the WHO manual for human semen analysis: a critical review and SWOT analysis. Life (Basel). 2021;11(12):1368. doi:10.3390/life11121368. PMID 34947899
  56. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–389. doi:10.1210/jc.2015-1710. PMID 26760044
  57. Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol (Oxf). 2009;70(5):788–793. doi:10.1111/j.1365-2265.2008.03390.x. PMID 18727705
  58. Bourguignon C, Dupuy AM, Coste T, et al. Evaluation of NM-BAPTA method for plasma total calcium measurement on Cobas 8000. Clin Biochem. 2014;47(7-8):636–639. doi:10.1016/j.clinbiochem.2013.12.027. PMID 24406301 (Bourguignon 2014)
  59. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352–380. doi:10.1002/ejhf.2115. PMID 33605000 (Bozkurt 2021)
  60. Brooke J, Stiell M, Ojo O. Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis: a systematic review. Int J Environ Res Public Health. 2016;13(9):837. doi:10.3390/ijerph13090837. PMID 27563914
  61. Brouwers MCGJ, Klop B, Ribalta J, et al. Familial combined hyperlipidemia: myth or reality? Curr Atheroscler Rep. 2025;27(1):45. doi:10.1007/s11883-025-01289-9. PMID 40167575
  62. Bularga A, Oskoui E, Fujisawa T, et al. Macrotroponin complex as a cause for cardiac troponin increase after COVID-19 vaccination and infection. Clin Chem. 2022;68(8):1015–1019. doi:10.1093/clinchem/hvac100. PMID 35896175 (Bularga 2022)
  63. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191. PMID 37622654 (Byrne 2023)
  64. Campbell MJ, Lotti F, Baldi E, et al. Distribution of semen examination results 2020 - A follow up of data collated for the WHO semen analysis manual 2010. Andrology. 2021;9(3):817–822. doi:10.1111/andr.12983. PMID 33528873
  65. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019;20(8):1820. doi:10.3390/ijms20081820. PMID 31013779 (Cao 2019)
  66. Cappellani D, Macchia E, Falorni A, Marchetti P. Insulin autoimmune syndrome (Hirata disease): a comprehensive review fifty years after its first description. Diabetes Metab Syndr Obes. 2020;13:963–978. doi:10.2147/DMSO.S219438. PMID 32308449
  67. Cardenas Fimbres JA, Cardenas Fimbres JM, Stewart C, et al. Type B lactic acidosis: diagnosis, etiology and treatment: an educational review. Cardiol Res. 2026;17(5):394–405. doi:10.14740/cr2265. PMID 42730203
  68. Carneiro DM, Solorzano CC, Nader MC, et al. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery. 2003;134(6):973–979. doi:10.1016/j.surg.2003.06.001. PMID 14668730 (Carneiro 2003)
  69. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144(7):768–773. doi:10.1016/0002-9378(82)90349-0. PMID 7148898
  70. Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments of 1988 (CLIA) proficiency testing regulations related to analytes and acceptable performance. Final rule. Fed Regist. 2022;87:41194; proficiency testing amendments effective July 11, 2024. https://www.federalregister.gov/documents/2022/07/11/2022-14513 (accessed 2026-11-17) (CMS 2022)
  71. Chan K, Guo Y, Zhang S, et al. Clinical and genetic characteristics of rare congenital adrenal hyperplasia: a retrospective analysis in a Chinese population. Front Genet. 2026;17:1709951. doi:10.3389/fgene.2026.1709951. PMID 41709876
  72. Chiu YH, Spiegelman D, Dockery DW, et al. Secondhand smoke exposure and inflammatory markers in nonsmokers in the trucking industry. Environ Health Perspect. 2011;119(9):1294–1300. doi:10.1289/ehp.1003199. PMID 21628108
  73. Christensen SE, Nissen PH, Vestergaard P, et al. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008;69(5):713–720. doi:10.1111/j.1365-2265.2008.03259.x. PMID 18410554 (Christensen 2008)
  74. Cole LA, Laidler LL, Muller CY. USA hCG reference service, 10-year report. Clin Biochem. 2010;43(12):1013–1022. doi:10.1016/j.clinbiochem.2010.05.006. PMID 20493830 (Cole 2010b)
  75. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8:102. doi:10.1186/1477-7827-8-102. PMID 20735820 (Cole 2010a)
  76. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575. PMID 32860058 (Collet 2020)
  77. Committee on Fetus and Newborn; Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127(3):575–579. doi:10.1542/peds.2010-3851. PMID 21357346
  78. Connolly CT, Grubman O, Al-Ibraheemi Z, et al. A case of markedly elevated isolated alkaline phosphatase in the third trimester of pregnancy. Case Rep Obstet Gynecol. 2022;2022:1611304. doi:10.1155/2022/1611304. PMID 35531126
  79. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16(3):231–245. doi:10.1093/humupd/dmp048. PMID 19934213
  80. Correction to: "Approach to the patient: insulinoma". J Clin Endocrinol Metab. 2026;111(7):e1925. doi:10.1210/clinem/dgag165. PMID 42012859 (Hofland 2024 correction)
  81. Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation. 2025;151(13):e865. doi:10.1161/CIR.0000000000001328. PMID 40163565 (Rao 2025 corrections)
  82. Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation. 2025;152(19):e402. doi:10.1161/CIR.0000000000001397. PMID 41212941 (Rao 2025 corrections)
  83. Coyle M, McEvoy JW. Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction. Eur Heart J. 2025;46(29):2890–2893. doi:10.1093/eurheartj/ehaf308. PMID 40343768 (Coyle 2025)
  84. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94(3):709–728. doi:10.1210/jc.2008-1410. PMID 19088155
  85. Curnow KJ, Wilkins-Haug L, Ryan A, et al. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. Am J Obstet Gynecol. 2015;212(1):79.e1–9. doi:10.1016/j.ajog.2014.10.012. PMID 25447960
  86. D'Ambrosio P, Cipriano L, Pugliese A, et al. SCN4A channelopathies: from disease mechanisms to variant interpretation. Genes (Basel). 2026;17(9):1116. doi:10.3390/genes17091116. PMID 42793010
  87. D'Orazio P, Burnett RW, Fogh-Andersen N, et al. Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem. 2005;51(9):1573–1576. doi:10.1373/clinchem.2005.051979. PMID 16120945
  88. da Silva JSV, Seres DS, Sabino K, et al. ASPEN consensus recommendations for refeeding syndrome. Nutr Clin Pract. 2020;35(2):178–195. doi:10.1002/ncp.10474. PMID 32115791 (da Silva 2020)
  89. Dabir M, Mousavi MK, Mohamadi M, et al. Pseudohyperphosphatemia in multiple myeloma: a systematic review of case reports and case series. J Clin Lab Anal. 2026;40(15):e70281. doi:10.1002/jcla.70281. PMID 42272045 (Dabir 2026)
  90. de Bakker M, Thurston AJF, Hammarsten O, et al. Macrotroponin complexes and risk of cardiovascular events. Circulation. 2026;154(18):1777–1790. doi:10.1161/CIRCULATIONAHA.126.080483. PMID 42708217 (de Bakker 2026)
  91. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–3090. doi:10.2337/dci22-0027. PMID 36189689
  92. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65(2):20–29. doi:10.1016/j.metabol.2015.10.014. PMID 26773926
  93. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907–1947. doi:10.1210/clinem/dgae290. PMID 38828931 (Demay 2024)
  94. Desgagnés N, King JA, Kline GA, et al. Use of albumin-adjusted calcium measurements in clinical practice. JAMA Netw Open. 2025;8(1):e2455251. doi:10.1001/jamanetworkopen.2024.55251. PMID 39836424 (Desgagnés 2025)
  95. Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455. doi:10.3389/fendo.2020.00455. PMID 32793115
  96. Drummond K, Gupta N, Mac Namara E, Christopoulos S. Leucocytosis-induced artefactual hypoglycaemia in the setting of chronic neutrophilic leukaemia. BMJ Case Rep. 2025;18(3):e264459. doi:10.1136/bcr-2024-264459. PMID 40132945
  97. du Fay de Lavallaz J, Prepoudis A, Wendebourg MJ, et al. Skeletal muscle disorders: a noncardiac source of cardiac troponin T. Circulation. 2022;145(24):1764–1779. doi:10.1161/CIRCULATIONAHA.121.058489. PMID 35389756 (du Fay de Lavallaz 2022)
  98. Duewall JL, Fenves AZ, Richey DS, et al. 5-Oxoproline (pyroglutamic) acidosis associated with chronic acetaminophen use. Proc (Bayl Univ Med Cent). 2010;23(1):19–20. doi:10.1080/08998280.2010.11928574. PMID 20157498
  99. Dungan JS, Klugman S, Darilek S, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(2):100336. doi:10.1016/j.gim.2022.11.004. PMID 36524989
  100. Duška F, Krbec M, Heldeweg M, et al. A pragmatic approach to complex acid base disturbances of critical illness: the "Stewart light". Intensive Care Med. 2026;52(6):1322–1325. doi:10.1007/s00134-026-08416-3. PMID 41944868
  101. Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798–826. doi:10.1210/er.2012-1033. PMID 23671155
  102. Egan AM, Galior KD, Maus AD, et al. Pitfalls in diagnosing hypoglycemia due to exogenous insulin: validation and utility of an insulin analog assay. Mayo Clin Proc. 2022;97(11):1994–2004. doi:10.1016/j.mayocp.2022.07.021. PMID 36210202
  103. Eisenhofer G, Peitzsch M, Kaden D, et al. Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clin Chim Acta. 2019;490:46–54. doi:10.1016/j.cca.2018.12.019. PMID 30571948
  104. El-Hajj Fuleihan G, Clines GA, Hu MI, et al. Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):507–528. doi:10.1210/clinem/dgac621. PMID 36545746 (El-Hajj Fuleihan 2023)
  105. Electronic Code of Federal Regulations. 42 CFR 493.931, Routine chemistry, version as of 2024-01-01. https://www.ecfr.gov/on/2024-01-01/title-42/section-493.931 (accessed 2026-11-17) (eCFR 2024)
  106. Electronic Code of Federal Regulations. 42 CFR 493.931, Routine chemistry, version as of 2026-11-01. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493/subpart-I/subject-group-ECFR4f9b8e94b7bd61d/section-493.931 (accessed 2026-11-17) (eCFR 2026)
  107. Emmett M. Acetaminophen toxicity and 5-oxoproline (pyroglutamic acid): a tale of two cycles, one an ATP-depleting futile cycle and the other a useful cycle. Clin J Am Soc Nephrol. 2014;9(1):191–200. doi:10.2215/CJN.07730713. PMID 24235282
  108. Emmett M. Metabolic alkalosis: a brief pathophysiologic review. Clin J Am Soc Nephrol. 2020;15(12):1848–1856. doi:10.2215/CJN.16041219. PMID 32586924
  109. English E, Idris I, Smith G, Dhatariya K, Kilpatrick ES, John WG. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia. 2015;58(7):1409–1421. doi:10.1007/s00125-015-3599-3. PMID 25994072
  110. Ertek S, Caglar K. Underestimated reason of hyperkalemia in diabetic patients: type IV renal tubular acidosis, mini review. Front Clin Diabetes Healthc. 2025;6:1570868. doi:10.3389/fcdhc.2025.1570868. PMID 40717832
  111. Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med. 2018;379(5):428–439. doi:10.1056/NEJMoa1803760. PMID 30067922
  112. Fenves AZ, Kirkpatrick HM 3rd, Patel VV, et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol. 2006;1(3):441–447. doi:10.2215/CJN.01411005. PMID 17699243
  113. Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med. 1998;26(11):1807–1810. doi:10.1097/00003246-199811000-00019. PMID 9824071
  114. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847–875. doi:10.1016/S2213-8587(21)00235-7. PMID 34687601
  115. Fliers E, Bianco AC, Langouche L, et al. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015;3(10):816–825. doi:10.1016/S2213-8587(15)00225-9. PMID 26071885
  116. Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021;44(8):1597–1607. doi:10.1007/s40618-020-01482-4. PMID 33320308
  117. Fong JMN, Tang GXJ, See KC. The anion gap: basic chemistry, powerful clinical implications. Singapore Med J. 2026;67(3):132–134. doi:10.4103/SINGAPOREMEDJ.SMJ-2026-101. PMID 41877411
  118. Freitas PAC, Ehlert LR, Camargo JL. Glycated albumin: a potential biomarker in diabetes. Arch Endocrinol Metab. 2017;61(3):296–304. doi:10.1590/2359-3997000000272. PMID 28699985
  119. Frias JP, Lim CG, Ellison JM, Montandon CM. Review of adverse events associated with false glucose readings measured by GDH-PQQ-based glucose test strips in the presence of interfering sugars. Diabetes Care. 2010;33(4):728–729. doi:10.2337/dc09-1822. PMID 20351227
  120. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. PMID 4337382
  121. Fujimaru T, Shuo T, Nagahama M, et al. Assessing urine ammonium concentration by urine osmolal gap in chronic kidney disease. Nephrology (Carlton). 2021;26(10):809–813. doi:10.1111/nep.13937. PMID 34288275
  122. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916. doi:10.1210/jc.2015-4061. PMID 26934393
  123. Gan T, Liao B, Xu G. The clinical usefulness of glycated albumin in patients with diabetes and chronic kidney disease: progress and challenges. J Diabetes Complications. 2018;32(9):876–884. doi:10.1016/j.jdiacomp.2018.07.004. PMID 30049445
  124. Garcia JM, Biller BMK, Korbonits M, et al. Macimorelin as a diagnostic test for adult GH deficiency. J Clin Endocrinol Metab. 2018;103(8):3083–3093. doi:10.1210/jc.2018-00665. PMID 29860473
  125. Garrett RE, Wagner B, Sam R, et al. Hypotonic hyponatremia: diagnosis and management. J Clin Med. 2026;15(20):8056. doi:10.3390/jcm15208056. PMID 42941569
  126. Garwicz D, Karlman M. Early recognition of reverse pseudohyperkalemia in heparin plasma samples during leukemic hyperleukocytosis can prevent iatrogenic hypokalemia. Clin Biochem. 2012;45(18):1700–1702. doi:10.1016/j.clinbiochem.2012.07.104. PMID 22877885
  127. Gasco V, Bioletto F, Lucisano D, et al. Morning cortisol and central adrenal insufficiency: new thresholds from low-dose ACTH test and second-generation assay. J Endocrinol Invest. 2026;49(6):1271–1284. doi:10.1007/s40618-026-02807-5. PMID 41619159
  128. Giustina A, Biermasz N, Casanueva FF, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7–22. doi:10.1007/s11102-023-01360-1. PMID 37923946
  129. Gorvin CM, Cranston T, Hannan FM, et al. A G-protein subunit-α11 loss-of-function mutation, Thr54Met, causes familial hypocalciuric hypercalcemia type 2 (FHH2). J Bone Miner Res. 2016;31(6):1200–1206. doi:10.1002/jbmr.2778. PMID 26729423 (Gorvin 2016)
  130. Grati FR, Bajaj K, Zanatta V, et al. Implications of fetoplacental mosaicism on cell-free DNA testing for sex chromosome aneuploidies. Prenat Diagn. 2017;37(10):1017–1027. doi:10.1002/pd.5138. PMID 28801976
  131. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056–1065. doi:10.1038/gim.2016.97. PMID 27467454
  132. Grenache DG, Gronowski AM. Fetal lung maturity. Clin Biochem. 2006;39(1):1–10. doi:10.1016/j.clinbiochem.2005.10.008. PMID 16303123
  133. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625. PMID 30586774
  134. Guibourdenche J, Leguy MC, Pidoux G, et al. Biochemical screening for fetal trisomy 21: pathophysiology of maternal serum markers and involvement of the placenta. Int J Mol Sci. 2023;24(8):7669. doi:10.3390/ijms24087669. PMID 37108840
  135. Haber LA, Dhaliwal G, Lo L, et al. Evaluating a low anion gap: a practical approach. Cleve Clin J Med. 2023;90(10):619–623. doi:10.3949/ccjm.90a.23035. PMID 37783490
  136. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992;327(9):588–593. doi:10.1056/NEJM199208273270902. PMID 1379344
  137. Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435–455. doi:10.1038/s41581-019-0152-5. PMID 31068690 (Haffner 2019)
  138. Hammarsten O, Becker C, Engberg AE. Methods for analyzing positive cardiac troponin assay interference. Clin Biochem. 2023;116:24–30. doi:10.1016/j.clinbiochem.2023.03.004. PMID 36889375 (Hammarsten 2023)
  139. Hamrahian AH, Yuen KC, Gordon MB, et al. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. Pituitary. 2016;19(3):332–341. doi:10.1007/s11102-016-0712-7. PMID 26897383
  140. HAPO Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991–2002. doi:10.1056/NEJMoa0707943. PMID 18463375 (HAPO 2008)
  141. Harel Z, McArthur E, Hladunewich M, et al. Serum Creatinine Levels Before, During, and After Pregnancy. JAMA. 2019;321(2):205–207. doi:10.1001/jama.2018.17948. PMID 30644975
  142. Harley K, Bissonnette S, Inzitari R, et al. Independent and combined effects of biotin and hemolysis on high-sensitivity cardiac troponin assays. Clin Chem Lab Med. 2021;59(8):1431–1443. doi:10.1515/cclm-2021-0124. PMID 33761581 (Harley 2021)
  143. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168. doi:10.1210/jc.2011-3362. PMID 22344196
  144. Hashmi SB, Ahmed S, Hashmi S, et al. Choosing the right equation for calculating indirect LDL-cholesterol (LDL-C) in adult Pakistani population: evaluation of seven equations using big data analytics. Pract Lab Med. 2024;41:e00418. doi:10.1016/j.plabm.2024.e00418. PMID 39119471
  145. Heidemann BE, Koopal C, Baass A, et al. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene. Clin Genet. 2022;102(4):253–261. doi:10.1111/cge.14185. PMID 35781703
  146. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063. PMID 35363499 (Heidenreich 2022)
  147. Heng YJ, Liong S, Permezel M, et al. Human cervicovaginal fluid biomarkers to predict term and preterm labor. Front Physiol. 2015;6:151. doi:10.3389/fphys.2015.00151. PMID 26029118
  148. Herr RD, Swanson T. Pseudometabolic acidosis caused by underfill of Vacutainer tubes. Ann Emerg Med. 1992;21(2):177–180. doi:10.1016/s0196-0644(05)80161-1. PMID 1739211
  149. Higgins V, Nichols M, Gao H, et al. Defining blood gas analysis stability limits across five sample types. Clin Biochem. 2023;115:107–111. doi:10.1016/j.clinbiochem.2022.09.006. PMID 36126745
  150. Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106(4):399–403. doi:10.1016/s0002-9343(99)00055-8. PMID 10225241
  151. Hira S, Özcan Ö, İpcioğlu OM, et al. Analytical performance of an alternative wavelength in the O-CPC calcium assay. EJIFCC. 2026;37(4):659–666. PMID 42730034 (Hira 2026)
  152. Hirai K, Minato S, Kaneko S, et al. Approximation of bicarbonate concentration using serum total carbon dioxide concentration in patients with non-dialysis chronic kidney disease. Kidney Res Clin Pract. 2019;38(3):326–335. doi:10.23876/j.krcp.19.027. PMID 31378012
  153. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004;50(1):166–174. doi:10.1373/clinchem.2003.024802. PMID 14709644
  154. Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the patient: insulinoma. J Clin Endocrinol Metab. 2024;109(4):1109–1118. doi:10.1210/clinem/dgad641. PMID 37925662
  155. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930. doi:10.1210/jc.2011-0385. PMID 21646368 (Holick 2011)
  156. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288(16):2015–2022. doi:10.1001/jama.288.16.2015. PMID 12387654
  157. Honest H, Bachmann LM, Gupta JK, et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ. 2002;325(7359):301. doi:10.1136/bmj.325.7359.301. PMID 12169504
  158. Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34(Suppl 3):iii2–iii11. doi:10.1093/ndt/gfz206. PMID 31800080
  159. Iglesias P. An update on advances in hypopituitarism: etiology, diagnosis, and current management. J Clin Med. 2024;13(20):6161. doi:10.3390/jcm13206161. PMID 39458112
  160. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–1974. doi:10.2337/dc15-1419. PMID 26404926
  161. International Federation of Clinical Chemistry and Laboratory Medicine, Committee on Clinical Applications of Cardiac Bio-Markers (C-CB). Biomarkers reference tables (high-sensitivity cardiac troponin I and T assay analytical characteristics v072026; troponin and natriuretic peptide interference tables). https://ifcc.org/ifcc-education-division/emd-committees/committee-on-clinical-applications-of-cardiac-bio-markers-c-cb/biomarkers-reference-tables/ (accessed 2026-11-17) (IFCC C-CB 2026)
  162. Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg. 2004;28(12):1287–1292. doi:10.1007/s00268-004-7708-6. PMID 15517474 (Irvin 2004)
  163. Jan de Beur SM, Minisola S, Xia WB, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. 2023;293(3):309–328. doi:10.1111/joim.13593. PMID 36511653 (Jan de Beur 2023)
  164. Januzzi JL Jr, Chen-Tournoux AA, Christenson RH, et al. N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study. J Am Coll Cardiol. 2018;71(11):1191–1200. doi:10.1016/j.jacc.2018.01.021. PMID 29544601 (Januzzi 2018)
  165. Javorsky BR, Raff H, Carroll TB, et al. New cutoffs for the biochemical diagnosis of adrenal insufficiency after ACTH stimulation using specific cortisol assays. J Endocr Soc. 2021;5(4):bvab022. doi:10.1210/jendso/bvab022. PMID 33768189
  166. Jensen RT, Cadiot G, Brandi ML, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98–119. doi:10.1159/000335591. PMID 22261919
  167. Jha V, Rouniyar R, Rao SD, et al. An outbreak of vitamin D toxicity in a family: report of 3 cases from unregulated fortification. JCEM Case Rep. 2025;3(12):luaf230. doi:10.1210/jcemcr/luaf230. PMID 41179273 (Jha 2025)
  168. Johannessen TR, Ruud SE, Larstorp ACK, et al. Rapid rule-out of acute myocardial infarction using the 0/1-hour algorithm for cardiac troponins in emergency primary care: the OUT-ACS implementation study. BMC Prim Care. 2025;26(1):34. doi:10.1186/s12875-025-02723-2. PMID 39930354 (Johannessen 2025)
  169. Johannessen TR, Vallersnes OM, Larstorp ACK, et al. One-hour troponin using a high-sensitivity point-of-care assay in emergency primary care: the OUT-POC pilot study. Cardiology. 2026;151(2):168–180. doi:10.1159/000545127. PMID 40058362 (Johannessen 2026)
  170. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803–817. doi:10.1111/dme.12159. PMID 23413806
  171. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751. doi:10.1089/thy.2014.0028. PMID 25266247
  172. Kageyama K, Sato K, Tasso M, Nakada Y. Thyrotroph pituitary neuroendocrine tumors: molecular pathology, diagnostic challenges, and receptor-targeted therapeutic strategies. Cancers (Basel). 2026;18(5):838. doi:10.3390/cancers18050838. PMID 41827771
  173. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186. doi:10.1159/000490384. PMID 30283735
  174. Kamel KS, Halperin ML. Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications. Curr Opin Nephrol Hypertens. 2011;20(5):547–554. doi:10.1097/MNH.0b013e328349b8f9. PMID 21788894
  175. Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical update. Endocr Connect. 2018;7(4):R135–R146. doi:10.1530/EC-18-0109. PMID 29540487
  176. Katrangi W, Baumann NA, Nett RC, et al. Prevalence of clinically significant differences in sodium measurements due to abnormal protein concentrations using an indirect ion-selective electrode method. J Appl Lab Med. 2019;4(3):427–432. doi:10.1373/jalm.2018.028720. PMID 31659081
  177. Kavsak PA, Hoard B, Mackett K, et al. Detection of macrotroponin in patients receiving treatment for breast cancer. CJC Open. 2023;5(8):658–660. doi:10.1016/j.cjco.2023.05.010. PMID 37720180 (Kavsak 2023)
  178. Khalil H, Borai A, Dakhakhni M, et al. Stability and validity of intact parathyroid hormone levels in different sample types and storage conditions. J Clin Lab Anal. 2021;35(6):e23771. doi:10.1002/jcla.23771. PMID 33792964 (Khalil 2021)
  179. Khan AA, Ali DS, Bilezikian JP, et al. Best practice recommendations for the diagnosis and management of hypoparathyroidism. Metabolism. 2025;171:156335. doi:10.1016/j.metabol.2025.156335. PMID 40581321 (Khan 2025)
  180. Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the Second International Workshop. J Bone Miner Res. 2022;37(12):2568–2585. doi:10.1002/jbmr.4691. PMID 36054621 (Khan 2022)
  181. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59. doi:10.1016/j.kisu.2017.04.001. PMID 30675420 (KDIGO 2017)
  182. Kim WJ, Park CY, Lee KB, et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care. 2012;35(2):281–286. doi:10.2337/dc11-1462. PMID 22210564
  183. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–1343. doi:10.2337/dc09-9032. PMID 19564476
  184. Koch CD, Vera MA, Messina J, et al. Preventing pseudohyponatremia: Intralipid-based lipemia cutoffs for sodium are inappropriate. Clin Chim Acta. 2021;520:63–66. doi:10.1016/j.cca.2021.05.032. PMID 34077753
  185. Koechlin L, Boeddinghaus J, Lopez-Ayala P, et al. Impact of Food and Drug Administration regulations on the performance of guideline-recommended pathways with an approved point-of-care high-sensitivity cardiac troponin I assay. J Am Heart Assoc. 2025;14(6):e039164. doi:10.1161/JAHA.124.039164. PMID 40079304 (Koechlin 2025)
  186. Köner Ö, Utku T, Demirağ K, et al. Base excess and beyond: evolving concepts in acid-base analysis. Turk J Anaesthesiol Reanim. 2026;54(1):9–14. doi:10.4274/TJAR.2025.252127. PMID 41496655
  187. Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int. 2021;99(2):324–335. doi:10.1016/j.kint.2020.10.035. PMID 33509356
  188. Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. Thyroid. 2026;36(5):481–544. doi:10.1177/10507256261445624. PMID 42219800
  189. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308–e319. doi:10.1016/j.jacl.2024.03.001. PMID 38565461
  190. Koulouri O, Moran C, Halsall D, et al. Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab. 2013;27(6):745–762. doi:10.1016/j.beem.2013.10.003. PMID 24275187
  191. Krahn J, Khajuria A. Osmolality gaps: diagnostic accuracy and long-term variability. Clin Chem. 2006;52(4):737–739. doi:10.1373/clinchem.2005.057695. PMID 16455871
  192. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2(1):162–174. doi:10.2215/CJN.03020906. PMID 17699401
  193. Kristensen JH, Hasselbalch RB, Strandkjær N, et al. Half-life and clearance of cardiac troponin I and troponin T in humans. Circulation. 2024;150(15):1187–1198. doi:10.1161/CIRCULATIONAHA.123.066565. PMID 39253802 (Kristensen 2024)
  194. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946. doi:10.1093/eurheartj/ehac361. PMID 36036785
  195. Kudu E, Kucukardali AE, Altun M, et al. The diagnostic accuracy of the ESC 0/1-hour algorithm in non-ST-segment elevation myocardial infarction in a crowded emergency department. BMC Emerg Med. 2025;25(1):129. doi:10.1186/s12873-025-01289-7. PMID 40670967 (Kudu 2025)
  196. Kur DK, Hillig T, Hansen SI, et al. Evaluation of a new automated routine measurement for serum adjusted ionized calcium (at pH 7.4) in patients suspected of calcium metabolic disease. J Appl Lab Med. 2020;5(4):704–715. doi:10.1093/jalm/jfaa006. PMID 32603436 (Kur 2020)
  197. Labcorp. Test menu: 004309 follicle-stimulating hormone (FSH), 004283 luteinizing hormone (LH), 004515 estradiol and 004317 progesterone. https://labcorp.com/tests/004309/follicle-stimulating-hormone-fsh (accessed 2026-11-17)
  198. Lam L, Aspin L, Heron RC, et al. Discrepancy between cardiac troponin assays due to endogenous antibodies. Clin Chem. 2020;66(3):445–454. doi:10.1093/clinchem/hvz032. PMID 32031592 (Lam 2020)
  199. Lam L, Tse R, Gladding P, et al. Effect of macrotroponin in a cohort of community patients with elevated cardiac troponin. Clin Chem. 2022;68(10):1261–1271. doi:10.1093/clinchem/hvac118. PMID 35929566 (Lam 2022)
  200. Lam V, Dhaliwal SS, Mamo JC. Adjustment of ionized calcium concentration for serum pH is not a valid marker of calcium homeostasis: implications for identifying individuals at risk of calcium metabolic disorders. Ann Clin Biochem. 2013;50(Pt 3):224–229. doi:10.1177/0004563212473747. PMID 23615406 (Lam 2013)
  201. Laugaudin G, Kuster N, Petiton A, et al. Kinetics of high-sensitivity cardiac troponin T and I differ in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention. Eur Heart J Acute Cardiovasc Care. 2016;5(4):354–363. doi:10.1177/2048872615585518. PMID 25943557 (Laugaudin 2016)
  202. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049–2102. doi:10.1007/s00198-021-05900-y. PMID 35478046 (LeBoff 2022)
  203. Lee Y, Kim M, Lee YJ, et al. Clinical characteristics and outcomes of Korean patients with lipoid congenital adrenal hyperplasia: an analysis of data from the OUTSPREAD cohort study. Endocrinol Metab (Seoul). 2026;41(4):566–578. doi:10.3803/EnM.2025.2611. PMID 42190700
  204. Lee Y, Yoo KD, Baek SH, et al. Korean Society of Nephrology 2022 recommendations on controversial issues in diagnosis and management of hyponatremia. Kidney Res Clin Pract. 2022;41(4):393–411. doi:10.23876/j.krcp.33.555. PMID 35919925
  205. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942. doi:10.1210/jc.2014-1498. PMID 24893135
  206. Levine MA. Diagnosis and management of vitamin D dependent rickets. Front Pediatr. 2020;8:315. doi:10.3389/fped.2020.00315. PMID 32596195 (Levine 2020)
  207. Li J, Hatten-Beck M, Lee JKY, Hoofnagle AN. Insights into insulin analog cross-reactivity: a comparative study of Siemens Atellica and LC-MS/MS. Endocrine. 2025;87(1):79–84. doi:10.1007/s12020-024-03970-6. PMID 39030378
  208. Li J, Ma H, Lei Y, et al. Diagnostic value of parameters from a spot urine sample for renal potassium loss in hypokalemia. Clin Chim Acta. 2020;511:221–226. doi:10.1016/j.cca.2020.10.024. PMID 33096028
  209. Liang S, Wang X, Tao C, et al. Lipoprotein X as a source of analytical and interpretative interference in routine laboratory testing. Clin Chem Lab Med. 2026. doi:10.1515/cclm-2026-0950. PMID 42598798
  210. Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med. 2004;164(14):1561–1566. doi:10.1001/archinte.164.14.1561. PMID 15277290
  211. Lin Y, Zhan H, Wang S, et al. A multicenter prospective study on the ESC algorithm for the early diagnosis of non-ST-elevation myocardial infarction. iScience. 2024;27(9):110643. doi:10.1016/j.isci.2024.110643. PMID 39262795 (Lin 2024)
  212. Lindner G, Burdmann EA, Clase CM, et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. Eur J Emerg Med. 2020;27(5):329–337. doi:10.1097/MEJ.0000000000000691. PMID 32852924
  213. Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3(3):446–451. doi:10.1177/193229680900300307. PMID 20144281
  214. Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med. 1991;325(10):669–674. doi:10.1056/NEJM199109053251001. PMID 1870640
  215. Long B, Lentz S, Gottlieb M. Alcoholic ketoacidosis: etiologies, evaluation, and management. J Emerg Med. 2021;61(6):658–665. doi:10.1016/j.jemermed.2021.09.007. PMID 34711442
  216. Lu WL, Ma XY, Zhang J, et al. Clinical and molecular characterization of 10 Chinese children with congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. World J Pediatr. 2024;20(4):422–433. doi:10.1007/s12519-023-00739-1. PMID 37486441
  217. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455. PMID 31504418 (Mach 2019)
  218. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359–4378. doi:10.1093/eurheartj/ehaf190. PMID 40878289 (Mach 2025)
  219. Mahler K, Kerlin R, Jones J, et al. Heparin concentration in evacuated tubes and its effect on pH, ionized calcium, lactate, and potassium in venous blood gas analysis. Lab Med. 2023;54(5):e157–e160. doi:10.1093/labmed/lmad022. PMID 37095624 (Mahler 2023)
  220. Mair J. The pathophysiology of cardiac troponin release and the various circulating cardiac troponin forms: potential clinical implications. J Clin Med. 2025;14(12):4241. doi:10.3390/jcm14124241. PMID 40565986 (Mair 2025)
  221. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167. doi:10.1056/NEJMoa020233. PMID 12124404 (Maisel 2002)
  222. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005;353(19):2001–2011. doi:10.1056/NEJMoa043693. PMID 16282175
  223. Mantovani G, Bastepe M, Monk D, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement. Nat Rev Endocrinol. 2018;14(8):476–500. doi:10.1038/s41574-018-0042-0. PMID 29959430 (Mantovani 2018)
  224. Marcovina SM, Albers JJ, Kennedy H, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994;40(4):586–592. PMID 8149615
  225. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061–2068. doi:10.1001/jama.2013.280532. PMID 24240933 (Martin 2013a)
  226. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62(8):732–739. doi:10.1016/j.jacc.2013.01.079. PMID 23524048 (Martin 2013b)
  227. Martinello F, Luiz da Silva E. Mechanism of ascorbic acid interference in biochemical tests that use peroxide and peroxidase to generate chromophore. Clin Chim Acta. 2006;373(1–2):108–116. doi:10.1016/j.cca.2006.05.012. PMID 16806141
  228. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368. PMID 34447992 (McDonagh 2021)
  229. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288. doi:10.1210/jc.2010-1692. PMID 21296991
  230. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev. 1989;10(3):232–274. doi:10.1210/edrv-10-3-232. PMID 2673754
  231. Meng QH, Wagar EA. Pseudohyperkalemia: a new twist on an old phenomenon. Crit Rev Clin Lab Sci. 2015;52(2):45–55. doi:10.3109/10408363.2014.966898. PMID 25319088
  232. Miida T. Global standardization of lipid/lipoprotein testing. Juntendo Iji Zasshi. 2024;70(5):324–331. doi:10.14789/jmj.JMJ24-0019-P. PMID 39545227
  233. Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010;56(6):977–986. doi:10.1373/clinchem.2009.142810. PMID 20378768
  234. Mirsafaie M, Moghaddam-Banaem L, Kheirollahi M. The relationship between screening markers in the first trimester of pregnancy and chromosome aberrations. Int J Prev Med. 2022;13:81. doi:10.4103/ijpvm.IJPVM_572_20. PMID 35706851
  235. Mohammed M, Fiseha M, Belay G, et al. Reference intervals for common renal and liver function clinical chemistry parameters among apparently healthy pregnant and non-pregnant women in South Wollo Zone, Amhara National Regional State, Northeast Ethiopia. Int J Gen Med. 2022;15:5145–5157. doi:10.2147/IJGM.S363129. PMID 35637704
  236. Morikawa MJ, Ganesh PR. Acid-base interpretation: a practical approach. Am Fam Physician. 2025;111(2):148–155. PMID 39964926
  237. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018;275:265–272. doi:10.1016/j.atherosclerosis.2018.06.814. PMID 29980054
  238. Mudde AH, van den Berg H, Boshuis PG, et al. Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer. 1987;59(9):1543–1546. PMID 3493837 (Mudde 1987)
  239. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731. doi:10.1002/ejhf.1494. PMID 31222929 (Mueller 2019)
  240. Myers GL, Kimberly MM, Waymack PP, et al. A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem. 2000;46(11):1762–1772. PMID 11067811
  241. Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73(11):1264–1272. doi:10.1016/j.jacc.2019.01.018. PMID 30846338 (Myhre 2019)
  242. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–1478. doi:10.2337/dc08-0545. PMID 18540046
  243. National Glycohemoglobin Standardization Program. Factors that interfere with HbA1c test results (updated 10/23/2026). https://ngsp.org/factors.asp (accessed 2026-11-17) (NGSP factors page)
  244. National Glycohemoglobin Standardization Program. HbA1c assay interferences: effects of hemoglobin variants and elevated fetal hemoglobin (updated October 2026). https://ngsp.org/interf.asp (accessed 2026-11-17) (NGSP interference table)
  245. National Glycohemoglobin Standardization Program. IFCC standardization of HbA1c: the IFCC and NGSP. https://ngsp.org/ifccngsp.asp (accessed 2026-11-17) (NGSP IFCC page)
  246. Neerhof MG, Dohnal JC, Ashwood ER, et al. Lamellar body counts: a consensus on protocol. Obstet Gynecol. 2001;97(2):318–320. doi:10.1016/s0029-7844(00)01134-0. PMID 11165603 (Neerhof 2001a)
  247. Neerhof MG, Haney EI, Silver RK, et al. Lamellar body counts compared with traditional phospholipid analysis as an assay for evaluating fetal lung maturity. Obstet Gynecol. 2001;97(2):305–309. doi:10.1016/s0029-7844(00)01133-9. PMID 11165600 (Neerhof 2001b)
  248. Nerenz RD, Song H, Gronowski AM. Screening method to evaluate point-of-care human chorionic gonadotropin (hCG) devices for susceptibility to the hook effect by hCG β core fragment: evaluation of 11 devices. Clin Chem. 2014;60(4):667–674. doi:10.1373/clinchem.2013.217661. PMID 24463559
  249. Nesbit MA, Hannan FM, Howles SA, et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet. 2013;45(1):93–97. doi:10.1038/ng.2492. PMID 23222959 (Nesbit 2013)
  250. Ng JL, Lim EM, Zhang R, et al. Serum 21-deoxycortisol for diagnosis of nonclassic congenital adrenal hyperplasia in women with androgen excess. J Clin Endocrinol Metab. 2023;108(12):e1560–e1570. doi:10.1210/clinem/dgad377. PMID 37358001
  251. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care. 2010;33(11):2310–2313. doi:10.2337/dc10-0917. PMID 20798337
  252. Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynaecol Obstet. 2025;171(Suppl 1):78–86. doi:10.1002/ijgo.70275. PMID 40631439
  253. Ngan HYS, Seckl MJ, Horowitz N, et al. FIGO staging for gestational trophoblastic neoplasia: 2026. Int J Gynaecol Obstet. 2026;174(3):1172–1180. doi:10.1002/ijgo.71229. PMID 42473063
  254. Nicola AG, Carsote M, Gheorghe AM, et al. Approach of heterogeneous spectrum involving 3beta-hydroxysteroid dehydrogenase 2 deficiency. Diagnostics (Basel). 2022;12(9):2168. doi:10.3390/diagnostics12092168. PMID 36140569
  255. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–1540. doi:10.1210/jc.2008-0125. PMID 18334580
  256. Nishioka H, Yamamotoya T, Itoda Y, et al. Artifactual hypoglycemia caused by Raynaud's phenomenon: a case report with literature review. Front Endocrinol (Lausanne). 2025;16:1695633. doi:10.3389/fendo.2025.1695633. PMID 41367919
  257. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490a. doi:10.1093/eurheartj/eht273. PMID 23956253 (Nordestgaard 2013)
  258. Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61. doi:10.1016/j.atherosclerosis.2019.12.005. PMID 31928713 (Nordestgaard 2020)
  259. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944–1958. doi:10.1093/eurheartj/ehw152. PMID 27122601 (Nordestgaard 2016)
  260. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372(17):1589–1597. doi:10.1056/NEJMoa1407349. PMID 25830321
  261. O'Brien T, O'Brien PC, Service FJ. Insulin surrogates in insulinoma. J Clin Endocrinol Metab. 1993;77(2):448–451. doi:10.1210/jcem.77.2.8345050. PMID 8345050
  262. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4):e362–e425. doi:10.1161/CIR.0b013e3182742cf6. PMID 23247304 (O'Gara 2013)
  263. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991;325(13):897–905. doi:10.1056/NEJM199109263251301. PMID 1652686
  264. Osinga JAJ, Derakhshan A, Palomaki GE, et al. TSH and FT4 reference intervals in pregnancy: a systematic review and individual participant data meta-analysis. J Clin Endocrinol Metab. 2022;107(10):2925–2933. doi:10.1210/clinem/dgac425. PMID 35861700
  265. Overgaard-Steensen C, Ring T. Clinical review: practical approach to hyponatraemia and hypernatraemia in critically ill patients. Crit Care. 2013;17(1):206. doi:10.1186/cc11805. PMID 23672688
  266. Pappa T, Ferrara AM, Refetoff S. Inherited defects of thyroxine-binding proteins. Best Pract Res Clin Endocrinol Metab. 2015;29(5):735–747. doi:10.1016/j.beem.2015.09.002. PMID 26522458
  267. Park KE, Latack KR, Vestal NL, et al. Association of hCG level with ultrasound visualization of the gestational sac in early viable pregnancies. Reprod Sci. 2023;30(12):3623–3628. doi:10.1007/s43032-023-01308-7. PMID 37563479
  268. Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4(5893):643–646. doi:10.1136/bmj.4.5893.643. PMID 4758544 (Payne 1973)
  269. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215–228. doi:10.1159/000356507. PMID 24783053
  270. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511. doi:10.1161/01.cir.0000052939.59093.45. PMID 12551878 (cited through Chiu 2011; full text not opened)
  271. Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176(12):1834–1842. doi:10.1001/jamainternmed.2016.6875. PMID 27820614
  272. Persani L, Brabant G, Dattani M, et al. 2018 European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism. Eur Thyroid J. 2018;7(5):225–237. doi:10.1159/000491388. PMID 30374425
  273. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693. doi:10.2337/dc15-0843. PMID 26078479
  274. Pickering JW, Than MP, Cullen L, et al. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: a collaborative meta-analysis. Ann Intern Med. 2017;166(10):715–724. doi:10.7326/M16-2562. PMID 28418520 (Pickering 2017)
  275. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151–1157. doi:10.1016/j.fertnstert.2020.09.134. PMID 33280722 (ASRM 2020)
  276. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29(2):388–394. doi:10.1007/s11606-013-2595-x. PMID 24002631
  277. Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. J Bone Miner Res. 2019;34(4):579–604. doi:10.1002/jbmr.3657. PMID 30803025 (Ralston 2019)
  278. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation. 2025;151(13):e771–e862. doi:10.1161/CIR.0000000000001309. PMID 40014670 (Rao 2025)
  279. Rastegar A. Use of the ΔAG/ΔHCO3− ratio in the diagnosis of mixed acid-base disorders. J Am Soc Nephrol. 2007;18(9):2429–2431. doi:10.1681/ASN.2006121408. PMID 17656477
  280. Refardt J, Atila C, Chifu I, et al. Arginine or hypertonic saline-stimulated copeptin to diagnose AVP deficiency. N Engl J Med. 2023;389(20):1877–1887. doi:10.1056/NEJMoa2306263. PMID 37966286
  281. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646. PMID 18997196
  282. Rohlfing CL, Connolly SM, England JD, et al. The effect of elevated fetal hemoglobin on hemoglobin A1c results: five common hemoglobin A1c methods compared with the IFCC reference method. Am J Clin Pathol. 2008;129(5):811–814. doi:10.1309/YFVTUD0GHJF7D16H. PMID 18426743
  283. Roizen JD, Li D, O'Lear L, et al. CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest. 2018;128(5):1913–1918. doi:10.1172/JCI98680. PMID 29461981 (Roizen 2018)
  284. Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405–413. doi:10.1210/jc.2006-1864. PMID 17090633
  285. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi:10.1016/j.fertnstert.2003.10.004. PMID 14711538 (Rotterdam 2003)
  286. Sabouret P, Mafrica D, Giamundo DM, et al. The 2026 ACC/AHA dyslipidemia guideline: a critical and transatlantic perspective on personalized lipid management. Life (Basel). 2026;16(9):1470. doi:10.3390/life16091470. PMID 42795336
  287. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2023;69(8):808–868. doi:10.1093/clinchem/hvad080. PMID 37473453
  288. Salehi M, Vella A, McLaughlin T, Patti ME. Hypoglycemia after gastric bypass surgery: current concepts and controversies. J Clin Endocrinol Metab. 2018;103(8):2815–2826. doi:10.1210/jc.2018-00528. PMID 30101281
  289. Sampson M, Ling C, Sun Q, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540–548. doi:10.1001/jamacardio.2020.0013. PMID 32101259 (Sampson 2020)
  290. Sampson M, Wolska A, Meeusen JW, et al. Identification of dysbetalipoproteinemia by an enhanced Sampson-NIH equation for very low-density lipoprotein-cholesterol. Front Genet. 2022;13:935257. doi:10.3389/fgene.2022.935257. PMID 35910208 (Sampson 2022)
  291. Sanders GT, Huijgen HJ, Sanders R. Magnesium in disease: a review with special emphasis on the serum ionized magnesium. Clin Chem Lab Med. 1999;37(11-12):1011–1033. doi:10.1515/CCLM.1999.151. PMID 10726809 (Sanders 1999)
  292. Santiago B, de Sousa GM, Felippe V, et al. Saturation gap during anesthesia in glucose-6-phosphate dehydrogenase deficiency and methemoglobinemia: a case report and review of perioperative management. Cureus. 2026;18(4):e107030. doi:10.7759/cureus.107030. PMID 41988351
  293. Savas M, Mehta S, Agrawal N, et al. Approach to the patient: diagnosis of Cushing syndrome. J Clin Endocrinol Metab. 2022;107(11):3162–3174. doi:10.1210/clinem/dgac492. PMID 36036941
  294. Severinghaus JW, Astrup PB. History of blood gas analysis. III. Carbon dioxide tension. J Clin Monit. 1986;2(1):60–73. doi:10.1007/BF01619178. PMID 3086509 (Severinghaus 1986a)
  295. Severinghaus JW, Astrup PB. History of blood gas analysis. IV. Leland Clark's oxygen electrode. J Clin Monit. 1986;2(2):125–139. doi:10.1007/BF01637680. PMID 3519875 (Severinghaus 1986b)
  296. Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol. 2011;26(10):1789–1802. doi:10.1007/s00467-011-1871-4. PMID 21503667
  297. Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386(10012):2481–2488. doi:10.1016/S0140-6736(15)00391-8. PMID 26454362 (Shah 2015)
  298. Sharlip ID, Belker AM, Honig S, et al. Vasectomy: AUA guideline. J Urol. 2012;188(6 Suppl):2482–2491. doi:10.1016/j.juro.2012.09.080. PMID 23098786
  299. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103(5 Pt 1):981–991. doi:10.1097/01.AOG.0000126245.35811.2a. PMID 15121574
  300. Singh RJ, Taylor RL, Reddy GS, et al. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab. 2006;91(8):3055–3061. doi:10.1210/jc.2006-0710. PMID 16720650 (Singh 2006)
  301. Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial bias in pulse oximetry measurement. N Engl J Med. 2020;383(25):2477–2478. doi:10.1056/NEJMc2029240. PMID 33326721
  302. Snyder MW, Simmons LE, Kitzman JO, et al. Copy-number variation and false positive prenatal aneuploidy screening results. N Engl J Med. 2015;372(17):1639–1645. doi:10.1056/NEJMoa1408408. PMID 25830323
  303. Society for Maternal-Fetal Medicine; Rink BD, Dugoff L, Kuller JA. Society for Maternal-Fetal Medicine Consult Series #74: cell-free DNA screening for aneuploidies: updated guidance. Pregnancy (Hoboken). 2025;1(6):e70139. doi:10.1002/pmf2.70139. PMID 42597105 (SMFM 2025)
  304. Soliman AR, Ahmed RM, El Meligi AAH, et al. Non-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD). Cardiovasc Diabetol Endocrinol Rep. 2025;11(1):22. doi:10.1186/s40842-025-00234-8. PMID 41047420
  305. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–47. doi:10.1530/EJE-13-1020. PMID 24569125
  306. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043–4088. doi:10.1210/jc.2018-01865. PMID 30272171
  307. Stettler C, Stahl M, Allemann S, et al. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care. 2008;31(8):1534–1535. doi:10.2337/dc08-0385. PMID 18426859
  308. Stevenson HP, Archbold GP, Johnston P, et al. Misleading serum free thyroxine results during low molecular weight heparin treatment. Clin Chem. 1998;44(5):1002–1007. PMID 9590373
  309. Stevic I, Bolsover J, Moore R, et al. Long term stability of lactate in uncentrifuged sodium fluoride/potassium oxalate blood collection tubes. Ann Clin Biochem. 2024;61(3):204–209. doi:10.1177/00045632231213746. PMID 37903217
  310. Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol. 1983;61(12):1444–1461. doi:10.1139/y83-207. PMID 6423247
  311. Strenger V, Kerbl R, Dornbusch HJ, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer. 2007;48(5):504–509. doi:10.1002/pbc.20888. PMID 16732582
  312. Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018;72(6):662–680. doi:10.1016/j.jacc.2018.05.044. PMID 30071997
  313. Su HW, Yi YC, Wei TY, et al. Detection of ovulation, a review of currently available methods. Bioeng Transl Med. 2017;2(3):238–246. doi:10.1002/btm2.10058. PMID 29313033
  314. Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017;28(9):2541–2556. doi:10.1007/s00198-017-4082-4. PMID 28631236 (Szulc 2017)
  315. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463. PMID 37580314
  316. Thadhani R, Lemoine E, Rana S, et al. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2022;1(12):EVIDoa2200161. doi:10.1056/EVIDoa2200161. PMID 38319832
  317. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. doi:10.1210/jc.2012-1230. PMID 22723327
  318. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167(2):238–245. doi:10.1016/j.jpeds.2015.03.057. PMID 25957977
  319. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618–e651. doi:10.1161/CIR.0000000000000617. PMID 30571511 (Thygesen 2018)
  320. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020–2035. doi:10.1161/CIR.0b013e31826e1058. PMID 22923432 (Thygesen 2012)
  321. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161–1173. doi:10.1210/jc.2016-2935. PMID 28324103
  322. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia. 2024;67(8):1455–1479. doi:10.1007/s00125-024-06183-8. PMID 38907161
  323. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257–1275. doi:10.2337/dci24-0032. PMID 39052901
  324. Valbuena VSM, Seelye S, Sjoding MW, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013–19: multicenter, retrospective cohort study. BMJ. 2022;378:e069775. doi:10.1136/bmj-2021-069775. PMID 35793817
  325. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. doi:10.1007/s00198-010-1501-1. PMID 21184054 (Vasikaran 2011)
  326. Vasuyattakul S, Lertpattanasuwan N, Vareesangthip K, et al. A negative anion gap as a clue to diagnose bromide intoxication. Nephron. 1995;69(3):311–313. doi:10.1159/000188476. PMID 7753265
  327. Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119(4):296–301. doi:10.7326/0003-4819-119-4-199308150-00008. PMID 8328738
  328. Verly IR, van Kuilenburg AB, Abeling NG, et al. Catecholamines profiles at diagnosis: increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. Eur J Cancer. 2017;72:235–243. doi:10.1016/j.ejca.2016.12.002. PMID 28061374
  329. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672. doi:10.1210/jcem.84.10.6079. PMID 10523012
  330. Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007;157(1):75–83. doi:10.1530/EJE-07-0109. PMID 17609405
  331. Violin A, Enard E, Blin J, et al. Insulin: know what your immunoassay detects. Evaluation of two new immunoassays. Clin Chim Acta. 2023;548:117516. doi:10.1016/j.cca.2023.117516. PMID 37598742
  332. Vreman HJ, Ronquillo RB, Ariagno RL, et al. Interference of fetal hemoglobin with the spectrophotometric measurement of carboxyhemoglobin. Clin Chem. 1988;34(5):975–977. PMID 2453310
  333. Wald NJ, Cuckle H, Brock JH, et al. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet. 1977;1(8026):1323–1332. PMID 69055 (UK Collaborative Study 1977)
  334. Walsh MN, Kober L, Sliwa K, et al. AHA/ACC/ESC/WHF expert consensus document: Second Universal Definition of Heart Failure (2026). Circulation. 2026;154(7):e279–e293. doi:10.1161/CIR.0000000000001455. PMID 42366997 (Walsh 2026)
  335. Wang S, McDonnell EH, Sedor FA, et al. pH effects on measurements of ionized calcium and ionized magnesium in blood. Arch Pathol Lab Med. 2002;126(8):947–950. doi:10.5858/2002-126-0947-PEOMOI. PMID 12171493 (Wang 2002)
  336. Wang T, Li C, Han C, et al. Clinical and genetic spectrum of cytochrome P450 oxidoreductase deficiency in Chinese patients. Endocr Connect. 2026;15(9):e260247. doi:10.1530/EC-26-0247. PMID 42615253
  337. Warner JV, Marshall GA. High incidence of macrotroponin I with a high-sensitivity troponin I assay. Clin Chem Lab Med. 2016;54(11):1821–1829. doi:10.1515/cclm-2015-1276. PMID 27092651 (Warner 2016)
  338. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem. 2001;47(9):1579–1596. PMID 11514391
  339. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. doi:10.1089/thy.2014.0335. PMID 25810047
  340. Willemsen AL, Torpy DJ, De Sousa SMC, et al. 17α-Hydroxylase/17,20-lyase deficiency (17-OHD): a meta-analysis of reported cases. J Clin Endocrinol Metab. 2025;110(4):e1261–e1271. doi:10.1210/clinem/dgae773. PMID 39500362
  341. Williams KA, Blumenthal RS. Keeping it simple: top 10 things to know about the 2026 dyslipidemia guideline. American College of Cardiology, April 28, 2026. https://www.acc.org/Latest-in-Cardiology/Articles/2026/04/27/19/07/accel-lite-28apr2026 (accessed 2026-11-17) (Williams 2026)
  342. Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–392. doi:10.1016/j.jacl.2019.04.010. PMID 31147269
  343. Winzeler B, Cesana-Nigro N, Refardt J, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019;394(10198):587–595. doi:10.1016/S0140-6736(19)31255-3. PMID 31303316
  344. Wise SA, Camara JE, Sempos CT, et al. Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias. J Steroid Biochem Mol Biol. 2021;212:105917. doi:10.1016/j.jsbmb.2021.105917. PMID 34010687 (Wise 2021)
  345. Witteveen JE, van Thiel S, Romijn JA, et al. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45–R53. doi:10.1530/EJE-12-0528. PMID 23152439 (Witteveen 2013)
  346. Won H, Bae JH, Lim H, et al. 2024 KSoLA consensus on secondary dyslipidemia. J Lipid Atheroscler. 2024;13(3):215–231. doi:10.12997/jla.2024.13.3.215. PMID 39355405
  347. Wrenn K. The delta (Δ) gap: an approach to mixed acid-base disorders. Ann Emerg Med. 1990;19(11):1310–1313. doi:10.1016/s0196-0644(05)82292-9. PMID 2240729
  348. Wu AHB, Christenson RH, Greene DN, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the IFCC. Clin Chem. 2018;64(4):645–655. doi:10.1373/clinchem.2017.277186. PMID 29343532 (Wu 2018)
  349. Wu L, Wu Q, Li Q, et al. Consecutive reference intervals for biochemical indices related to serum lipid levels and renal function during normal pregnancy. BMC Pregnancy Childbirth. 2022;22(1):642. doi:10.1186/s12884-022-04960-0. PMID 35971117
  350. Xu H, Tang Q, Chen Q. 1,5-Anhydroglucitol: from short-term glycemic monitoring to risk stratification of diabetes complications. Diabetes Metab Syndr Obes. 2026;19:596620. doi:10.2147/DMSO.S596620. PMID 42158844
  351. Yan R, Tarr H, McNally M, et al. Interference of gadolinium-based contrast agents on colorimetric calcium assays. Clin Biochem. 2014;47(7-8):648–653. doi:10.1016/j.clinbiochem.2013.12.012. PMID 24365398 (Yan 2014)
  352. Yeganeh BS, Soleimani N, Zare S, et al. The effect of hemolysis on biochemical tests: determining interference cutoffs and managing hemolytic samples. J Anal Methods Chem. 2026;2026:9307894. doi:10.1155/jamc/9307894. PMID 41767878 (Yeganeh 2026)
  353. Yildirim M, Salbach C, Mueller-Hennessen M, et al. Comparative analysis of single- and dual-marker strategies for rapid non-ST-segment-elevation myocardial infarction rule-out using cardiac myosin-binding protein C, copeptin, and high-sensitivity cardiac troponin T in the emergency department. J Am Heart Assoc. 2025;14(10):e039379. doi:10.1161/JAHA.124.039379. PMID 40357668 (Yildirim 2025)
  354. Yoshida K, Kuwabara Y, Tanaka T, et al. Dimeric inhibin A as a fourth marker for Down's syndrome maternal serum screening in native Japanese women. J Obstet Gynaecol Res. 2000;26(3):171–174. doi:10.1111/j.1447-0756.2000.tb01306.x. PMID 10932977 (Yoshida 2000)
  355. Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191–1232. doi:10.4158/GL-2019-0405. PMID 31760824
  356. Zand Irani A, Almuwais A, Gibbons H. Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use. BMJ Case Rep. 2020;13(4):e233306. doi:10.1136/bcr-2019-233306. PMID 32273269
  357. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13–22. doi:10.1056/NEJMoa1414838. PMID 26735990
  358. Zhang B, Zhan Z, Xi S, et al. Alkaline phosphatase of late pregnancy promotes the prediction of adverse birth outcomes. J Glob Health. 2025;15:04028. doi:10.7189/jogh.15.04028. PMID 39849974 (Zhang B 2025)
  359. Zhang L, Qiu Y, Ainiwan D, et al. The associations of maternal liver biomarkers in different trimesters with birth weight outcomes. Sci Rep. 2026;16(1):5575. doi:10.1038/s41598-026-36050-y. PMID 41545683 (Zhang L 2026)
  360. Zhang L, Shen Y, Wu K, et al. Establishing trimester-specific reference intervals for coagulation parameters in pregnant women in China. BMC Pregnancy Childbirth. 2026;26(1). doi:10.1186/s12884-026-09296-7. PMID 42151871 (Zhang 2026)
  361. Zhang Y, Chen Z, Sun L, et al. An overview of hypopituitarism's causes. Front Endocrinol (Lausanne). 2025;16:1695833. doi:10.3389/fendo.2025.1695833. PMID 41573202
  362. Zhao Q, Zhao Z, Leung-Pineda V, et al. Predicting respiratory distress syndrome using gestational age and lamellar body count. Clin Biochem. 2013;46(13-14):1228–1232. doi:10.1016/j.clinbiochem.2013.03.020. PMID 23570861